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Summary
Within a tumor, a subpopulation of cells, namely the cancer stem cells (CSCs), can self-renew,
generate more differentiated progeny, and replicate the tumor of origin in vivo, thereby sustain-
ing and promoting tumor growth. Importantly, these cells are often quiescent and resistant to
treatment, so that efforts should be put into finding novel ways to target CSCs to improve patient
survival. While genetic mutations participate in creating a CSC phenotype, epigenetic mecha-
nisms play an equally important role in transformation. Among these, microRNAs (miRNAs)
and long non-coding RNAs (lncRNAs) modulate the expression of a large network of genes.
Let-7 miRNAs induce differentiation, but are often repressed in cancer. Here, we attempted
to enhance miRNA maturation and restore their function in glioblastoma (GBM), a highly ag-
gressive primary brain malignancy with an exceedingly poor prognosis, using the small molecule
enoxacin, which has been shown to stimulate miRNA maturation in other settings. We injected
primary patient-derived GBM cells in mice and treated them with enoxacin and temozolomide
(an alkylating agent used in GBM treatment), alone or in combination. Enoxacin did not impair
tumor formation, suggesting that miRNA maturation cannot be further stimulated in GBM.
Subsequently, we looked at lncRNAs expressed in GBM that may be involved in CSC mainte-
nance and focused on H19. Expression of H19 correlated with poor patient outcome, and H19
binds IMP2, an RNA-binding protein (RBP) essential for CSC maintenance in GBM. Although
we could not reach clear conclusions as to its role in GBM due to technical issues, we believe
that H19 may be involved in GBM tumorigenesis, and its function requires further investigation.
In addition to non-coding RNAs, RBPs are essential regulators of gene expression, as they
are involved in every step of mRNA life. Among RBPs involved in cancer, LIN28B, an oncofetal
RBP that inhibits let-7 maturation, is necessary for CSC survival in a subset of highly aggressive
Ewing sarcomas (EwS). EwS is the second most common primary bone cancer in children and
adolescents, and harbors the t(11;22) translocation leading to the chimeric transcription factor
EWS-FLI1. Of note, LIN28B stabillizes EWS-FLI1 transcripts, and mediates CSC maintenance.
We explored the biological relevance of IMPs for EwS CSCs. IMPs are RBPs known to inhibit the
let-7 pathway. However, silencing IMP paralogs failed to affect CSC tumorigenicity. Therefore,
our results further support the role of LIN28B for CSC maintenance. Because LIN28B affects
translation of targets, we will further investigate the role of LIN28B in EwS by comparing whole
5
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RNA and proteomic data of LIN28B+ EwS. In doing so, we will identify pathways regulated by
LIN28B independently of let-7 and EWS-FLI1, that increase the aggressiveness of a subset of
EwS. Moreover, these pathways may be applicable to other LIN28B+ childhood cancers driven
by a fusion protein.
Résumé
Dans une tumeur, les cellules souches cancéreuses (CSC) sont capables de se renouveler, générer
des cellules plus différenciées, et répliquer la tumeur d’origine in vivo. Ces cellules sont notam-
ment souvent quiescentes et résistantes aux traitements, faisant d’une priorité l’identification de
nouvelles méthodes pour cibler les CSC afin d’augmenter la survie du patient. Alors que les
mutations génétiques favorisent l’acquisition d’un phénotype de CSC, les mécanismes épigéné-
tiques jouent un rôle tout aussi prépondérant dans la transformation tumorale. Parmi eux,
les microARN (miRNA) et longs ARN non-codants (long non-coding RNAs, lncRNA) peuvent
influencer l’expression d’un vaste réseau de gènes.
Les miRNA let-7 sont exprimés dans les cellules différenciées mais sont souvent réprimés
dans les cancers. Ici, nous avons tenté d’accroître leur expression et rétablir leurs fonctions
dans le glioblastome (GBM), une tumeur primaire cérébrale hautement aggressive, en utilisant
la molécule d’enoxacine qui stimule la maturation de miRNA. Nous avons injecté des organoïdes
de GBM dérivés de tumeurs de patients dans des souris que nous avons traitées avec l’enoxacine
et/ou du temozolomide (l’agent de chimiothérapie couramment utilisé pour le traitement des
GBM), seuls ou en combinaison. L’enoxacine n’a pas diminué la formation de tumeurs, suggérant
que la maturation de miRNA ne peut pas être stimulée dans les GBM. Nous avons donc cherché
les lncRNA exprimés dans les GBM qui pourraient être impliqués dans le maintien des CSC.
Nous avons identifié H19, dont l’expression corrèle avec un mauvais pronostic. H19 peut se lier à
IMP2, une protéine liant les ARN (RNA-binding proteins, RBP) essentielle au maintien des CSC
dans les GBM. Bien que nous n’ayons pas pu atteindre de conclusions en raison de difficultés
techniques, il semble que H19 soit impliqué dans la tumorigénèse des GBM, et sa fonction dans
ce contexte mérite d’être explorée.
Les RBP sont des régulateurs essentiels de l’expression génique, car impliqués dans chaque
étape de la vie de l’ARNmessager. LIN28B, une RBP oncofoetale capable d’inhiber la maturation
des miRNA let-7, est requise pour la survie des CSC dans une partie des sarcomes d’Ewing (SE),
le deuxième cancer primaire de l’os le plus fréquent chez les enfants et adolescents, caractérisé
par la translocation t(11;22), formant la protéine de fusion EWS-FLI1. Nous avons étudié le rôle
de la famille de RBP IMP, comprenant trois paralogues partiellement redondants et capables
de réprimer la cascade de signalisation des let-7. Le knockdown de chacun des trois IMPs n’a
7
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pas réduit la tumorigenicité des CSC. Nos résultats renforcent donc la position de LIN28B pour
le maintien des CSC. Sachant que LIN28B affecte la traduction d’ARN cibles, nous souhaitons
investiguer son rôle dans le SE en comparant les données des ARN et du protéome totaux des
SE LIN28B+. Ainsi, nous pourrons identifier des circuits régulés par LIN28B indépendamment
des let-7 et d’EWS-FLI1 qui contribuent au phenotype agressif d’une partie des SE. De plus,
ces circuits pourraient être impliqués dans d’autre cancers pédiatriques LIN28B+ présentant une
protéine de fusion.
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Chapter 1
Introduction
Cancer is currently the second most common cause of death worldwide, and has recently replaced
cardiovascular diseases as the first cause of death in high-income countries. The same is predicted
to occur in middle- and low-income countries, as cancer may progressively become the leading
cause of mortality worldwide during the next decades (Dagenais et al., 2019). Importantly,
despite multimodal therapeutic approaches, considerable advances in patient management and
the never-ending efforts in the field of research, cancer still bears a somber prognosis. Drastic
improvement in patient survival for some forms of cancer over the last half-century remains
overshadowed by other cancer types that invariably represent a death sentence for the patient at
the moment of diagnosis. Thus, as the global cancer burden is increasing, much research is still
warranted to better understand tumors, so that they can be better prevented, identified earlier,
and treated more efficiently by adopting more specific and personalised therapeutic approaches.
Major advancements in cellular profiling during the last decades have provided extensive in-
sight into the individual particularities of the cells composing the tumor bulk, and have shed light
onto the extensive cellular plasticity within the tumor, as well as onto the role of cellular permis-
siveness for malignant transformation. Thus, increasing effort is being put into characterizing
the regulatory pathways that shape the cell tumorigenicity.
In this context, the goal of my work was to identify, characterize, dissect and target the
mechanisms that shape the cancerous cell to maintain and promote its malignant behavior.
17
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The main body of this manuscript is divided into four chapters:
1) General introduction: first, we start by defining cancer and look into the different post-
transcriptional epigenetic regulation mechanisms that are of particular interest in this work.
2) Part 1: here, we focus on Glioblastoma Multiforme (GBM), in which we introduce key
aspects of this aggressive tumor and present the results and discussions from two projects
that I worked on, focusing on targeting a key regulatory pathway in malignant cells, and
on identifying a potential actor responsible for malignant transformation.
3) Part 2: this part focuses on Ewing sarcoma (EwS), after introducing some key points to
consider in pediatric malignancies. The molecular pathology of this subclass of sarcomas
is presented, followed by the results from the main project of this thesis, which is still
ongoing, where I explored the roles of two families of RNA binding proteins in promoting
and preserving cancer stem cells in EwS.
4) Conclusion: we finish by putting our findings in perspective and discussing future axes,
based on the results from the previous chapters.
1.1 Cancer: definition and hallmarks
Cancer encompasses over a hundred highly complex and dynamic diseases that are unified by
common denominative features. Indeed, a tumor can arise in most tissues, from virtually any
cell type, and at any stage of life. This variable constellation of conditions will grant the tumor
with particular traits, specific degrees of differentiation and a singular behavior based on when,
where and how it develops. Accordingly, cell transformation in the epithelium, mesenchyme or
bone marrow will lead to the development of carcinoma, sarcoma or hematologic malignancies,
respectively.
Despite a large degree of heterogeneity, cancers display shared characteristics. The principle
unifying cancer is rather straightforward and can be succinctly described as a cell escaping home-
ostatic regulation and developing in an uncontrolled manner. Following a succession of genetic
alterations and epigenetic modifications, the transformed cell acquires proliferative advantage
over neighboring cells, leading to the formation of a tumor mass that disrupts the societal rules
of cells. The features developed by cancer cells to sustain tumor growth were first defined in
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Figure 1.1: The Hallmarks of Cancer. Adapted from Hanahan and Weinberg (2011).
2000 and listed as the hallmarks of cancer (Hanahan and Weinberg, 2000), later expanded with
the addition of two supplementary properties (Hanahan and Weinberg, 2011) (Figure 1.1).
Properties of cancer cells include: 1) sustaining proliferative growth; 2) evading growth sup-
pressors; 3) avoiding immune destruction; 4) enabling replicative immortality; 5) stimulating
tumor promoting inflammation; 6) activating invasion and metastasis; 7) inducing angiogenesis;
8) genome instability; 9) resisting cell death; 10) deregulating cellular genetics.
Taken together, these hallmarks define cancer as a unique entity capable of using the mi-
croenvironment to its advantage and constantly adapting to increase its chances of survival and
propagation. Therefore, each of the hallmarks of cancer must be explored so that we become
more familiar with the enemy and identify potential weaknesses in this complex system, requiring
a detailed understanding of the crucial mechanisms behind tumor growth and maintenance of
its driving force.
My research focused on identifying and understanding some of the regulators essential for
cellular proliferation and survival, with the goal to find ways of targeting such mechanisms.
More specifically, I concentrated my work on exploring ways of targeting the main driving force
of the tumor, namely the cancer stem cells (CSCs). In the experimental applications presented,
20 CHAPTER 1. INTRODUCTION
I focused on some of the fundamental biological properties of CSCs: their proliferative potential,
their capacity to form tumors in vivo, expression of stemness markers, and the role of epigenetic
regulators that mediate CSC plasticity.
1.2 Tumor heterogeneity
1.2.1 The stochastic and cancer stem cell models
At first, tumors were thought to be made out of uniform and undifferentiated cells. However,
about a century ago, it was noted that tumor histology is not homogeneous. Cells that consti-
tute the tumor bulk are heterogeneous, and can be distinguished as diverse subpopulations with
distinct proliferation kinetics, cell markers, genetic anomalies, therapeutic response and tumori-
genic potential (Kreso and Dick, 2014). This led to the notion that one of the subpopulations
may provide the driving force of the tumor and possibly give rise to the other subpopulations.
Two models have since been suggested to explain the heterogeneity observed within a tumor.
First, the stochastic model proposes that an initial tumor cell can give rise to a progeny after
a first oncogenic event. This event creates genetic instability, resulting in the accumulation of
additional mutations over time. Some mutations may provide no survival advantage, causing
the cells to die, while others may confer cells with selective advantage. As a result, this cell
subpopulation takes over and becomes the dominant clone within the tumor. This leads to
the development of a bulk of heterogeneously mutated cells, some of which become increasingly
aggressive and preserve tumor initiating capacity (Nowell, 1976). Intrinsic (genetic instability
and epigenetic changes) as well as extrinsic (immune and environmental) factors all contribute
to ongoing stochastic cellular changes, thereby erasing any possible hierarchical structure within
the tumor (Figure 1.2A, left panel).
However, this concept was challenged a little over 20 years ago with the emergence of the CSC
theory, first evidenced in leukemias (Bonnet and Dick, 1997) and subsequently in solid tumors,
including breast (Al-Hajj et al., 2003), brain (Singh et al., 2003), colon (O’Brien et al., 2007)
and sarcoma (Wu et al., 2007; Suvà et al., 2009), among others. New evidence supported the
notion that a tumor initiating cell acquires self-renewal capacity through genetic mutations and
epigenetic modifications, which provide it with the ability to maintain the tumor source indef-
initely (Figure 1.2A, right panel). Similar to normal embryonic stem cells that self-renew and
generate a differentiated progeny within a normal tissue through asymmetrical division, CSCs
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Figure 1.2: Tumor heterogeneity and CSCs. (A) Left, the stochastic model: each cell within the tumor bulk can
reproduce a tumor following genomic instability and random mutations. Right, the CSC model: the tumor bulk consists of
heterogeneous subpopulations of cells, of which the CSCs are the only ones that maintain a tumorigenic potential and repro-
duce the tumor of origin following successful isolation. (B) Mechanisms that regulate CSCs state. Key intrinsic regulators
include genetic, epigenetic, and metabolic processes, and extrinsic regulators include interactions with the microenviron-
ment, including niche factors and the immune system. Adapted from Lathia et al. (2015). (C) Some key characteristics of
CSCs.
behave as drivers of tumor growth and progression, ensuring indefinite self-renewal and fuelling
the bulk with heterogeneous tumor progenitor cells and more differentiated subpopulations ex-
hibiting limited proliferative potential. This creates a hierarchical model, at the apex of which
is a small population of CSCs. Isolation of a small proportion of cells that express restricted,
although not specific, cell surface markers, notably CD133 and CD44 (Visvader and Lindeman,
2008), provided evidence to support the CSC model. Upon xenotransplantation, isolated CSCs
successfully reproduced the initial tumor phenotype, thereby giving birth to heterogeneous cell
subpopulations, composed of CSCs and more differentiated progeny, most of which lack tumori-
genic potential. CSCs are regulated by both intrinsic (genetic, epigenetic and metabolic) and
extrinsic (microenvironmental, immune and niche) factors (Figure 1.2B). Some of these aspects,
such as epigenetic events and niche cues, are discussed hereafter.
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The question remains open as to the nature of the cell of origin of CSCs. Care must be
taken not to misinterpret the name “cancer stem cell”, as it does not imply that CSCs necessarily
arise from a normal stem cell. Instead, the name merely refers to the CSCs sharing many
common properties with normal stem cells, such as self-renewal and the ability to generate a
more differentiated progeny (Figure 1.2C). Also, much like normal stem cells, CSCs typically
remain in a quiescent state with slow proliferative kinetics, which, among other mechanisms,
protects them from conventional chemotherapy targeted at actively dividing cells (Kreso et al.,
2013). The question regarding the cell of origin of CSCs remains a highly debated topic and
the answer varies depending on the cancer type. This will be discussed in more details later,
specifically for GBM and EwS.
Tumors harbor an average of 4.6 driver mutations in protein-coding genes or, less frequently,
in non-coding genes, that mainly affect three essential processes: cell fate, cell survival and
genome maintenance (Vogelstein et al., 2013; Campbell et al., 2020; Rheinbay et al., 2020).
Moreover, genome sequencing of a variety of tumors has revealed an additional level of complex-
ity: within one tumor type, a multitude of driver mutations have been described, while the same
single driver mutation can be found in multiple cancer types (Alexandrov et al., 2013; Campbell
et al., 2020). Indeed, cancer progression follows an evolutionary multistage process consisting of
acquisition of mutations and subsequent selection, and each subclone can behave differently to
those mutations (Burrell et al., 2013).
Extensive intratumoral heterogeneity (ITH) has been reported in a variety of solid and hema-
tologic neoplasms (Rosenthal et al., 2017). Numerous parameters collectively act on the tumor
bulk and mediate the resulting heterogeneity. The trigger driver mutations may initially appear
slowly (Merlo et al., 2006), or result from catastrophic events (chromothripsis, chromoplexy or
kataegis) that may directly shift the cell to an aggressive phenotype (Campbell et al., 2010).
Subsequently, mutations produce fitter subclones that expand under the selective pressures from
microenvironmental, immune or therapeutic cues (Rosenthal et al., 2017), and it is possible for
multiple CSC populations to coexist (Anderson et al., 2011). In addition, clone populations
may compete for substrates (Marusyk and Polyak, 2010), while some subclones may provide a
crosstalk with the dominant population and further support its growth (Calbo et al., 2011). In
parallel, neutral evolution also occurs during tumor progression, resulting in the existence of
passenger mutations, which do not necessarily confer advantage to the cells but are maintained
as the clonal population grows (Hess et al., 2019). In line with this, the order in which mutations
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are acquired can affect transformation and response to therapy (Ortmann et al., 2015), suggest-
ing that a permissive environment may provide proliferative advantage and an optimal context
to further support malignant progression following additional mutations. Consistent with this
notion, premalignant leukemic precursor cells are detected in the blood of healthy individuals,
but may either disappear, remain quiescent, or further transform into overt leukemic cells years
later as a result of intrinsic or extrinsic factors (Rodríguez-Hernández et al., 2017). Thus, acqui-
sition of mutations and/or genomic aberrations combined with selective pressure lead to ITH,
contributing to tumor progression following a complex hierarchy.
Importantly, tumors with high ITH, in which higher numbers of distinct clonal populations
are detected, have been linked to poorer outcome (Mroz et al., 2015; Morris et al., 2016; Andor
et al., 2016), and could potentially predict the metastatic potential and clinical course of the
tumor (Iacobuzio-Donahue et al., 2020). Moreover, the clinical significance of ITH translates
into additional challenges for CSC targeting. Particularly, therapy of the initial tumor using
cytotoxic agents can select or even generate resistant clones and ease their outgrowth, which
provides an explanation as to why the molecular profile of recurrent tumors may differ from that
of the original lesion (Sharma et al., 2010).
Taken together, adult cancers result from a multistage process, and a single mutation is
rather unlikely to constitute the defining trait of a single tumor type, and each tumor may
respond differently to this mutational event. In childhood cancers, in contrast, a single mutation
may suffice to trigger transformation. Nonetheless, cancer cells behave differently as a result of
additional mutations or epigenetic changes, as we will discuss later. Furthermore, as distinct
driver and passenger mutations may coexist in cell clones, whether a genomic alteration has
biological relevance must be tested and functionally confirmed. Thus, with so many degrees of
heterogeneity, each tumor requires detailed characterization to obtain a precise landscape of its
cellular profiles. This has become possible in recent years with high-throughput sequencing and
single-cell profiling on cells within various tumor types (Garraway and Lander, 2013), and has
highlighted the ability of tumors to adapt and change over time via cellular plasticity.
1.2.2 CSC plasticity
The CSC theory does not completely abrogate the stochastic model. These two apparently
separate notions can be unified by observing cellular plasticity. Indeed, random mutations,
gene expression deregulation and a certain degree of genomic instability are required for initial
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CSC emergence. More precisely, there are two accepted principles behind this process: 1) a
normal stem cell becomes a CSC following transforming genetic mutations; and 2) accumulated
mutations and epigenetic changes reprogram cells to create a permissive environment for them
to revert from their differentiated state into stem-like pluripotent cells (Reya et al., 2001; Frank
and Nowak, 2003). This creates a conundrum, in which we may eradicate CSCs but as long as
there may still be a subset of plastic cells with the ability to dedifferentiate, in the light of clonal
evolution and selective pressure, they may recreate a new subpopulation of CSCs. Inflammation
is also believed to participate in emergence of CSCs (Iliopoulos et al., 2011). Furthermore, the
effects of a stochastic event will cause variable responses depending on the cell undergoing this
change (Kreso and Dick, 2014).
For carcinomas to be able to metastasize, cancerous epithelial cells need to acquire mobility.
This is rendered possible by the epithelial-to-mesenchymal transition (EMT) process. EMT is
a physiological process in the context of development and wound healing. Upon environmental
cues, such as hypoxia and secretion of transforming growth factor beta (TGF-β), or internal
mutations, an epithelial cell loses cell-to-cell adhesion and apical-basal polarity, thereby acquir-
ing a mesenchymal-like phenotype (Lamouille et al., 2014). Importantly, the EMT process is
not strictly dichotomous with either pure epithelial or mesenchymal phenotypes. Rather, EMT
includes the intermediate spectrum ranging between these two extremes, as the current termi-
nology “transition” instead of “transformation” adequately implies. Hence, partial EMT refers
to the particular magnitude of phenotypic changes acquired by the cell toward a mesenchymal-
like state. In cancer, de novo expression of stemness genes grants invasion and motility to a
transformed cell, a first step toward metastasis. The cell escapes the primary tumor in order
to join the blood or lymphatic circulation and reach distal organs (Nieto et al., 2016). Despite
some data challenging the central role of EMT in metastasis, EMT should not be ruled out
as a key process in tumor invasion, as partial activation of EMT associated traits are widely
found in carcinoma and CSCs, at least to a certain degree, and facilitates their dissemination as
single cells or in clusters (Nieto et al., 2016; Batlle and Clevers, 2017; Derynck and Weinberg,
2019). Moreover, EMT is believed to be reversible, with cells reacquiring an epithelial phenotype
during this mesenchymal-to-epithelial transition (MET), a process that could be involved in the
metastatic process as the cells settle in a distant site after migration (Thiery, 2002; Yang and
Weinberg, 2008; Mani et al., 2008).
The plasticity observed in non-tumor initiating cells further fueled the idea of engineering
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induced pluripotent stem cells (iPSCs) by reprogramming differentiated cells to acquire stem-
like properties. Succeeding in doing so would provide sensitive information to identify the key
molecular players in the transformation and maintenance of CSCs. By combining the expres-
sion of a panel of stem-cell associated transcription factors (TFs), a panel of four TFs, namely
OCT3/4, SOX2, c-MYC and KLF4, permitted to obtain iPSCs from differentiated fibroblasts
(Takahashi and Yamanaka, 2006). Shortly thereafter, another group identified another set of four
TFs capable of reprogramming human fibroblasts: OCT4, SOX2, NANOG and LIN28 (Yu et al.,
2007). Similarly, four core TFs necessary for tumor propagation were identified in GBM cells,
that include POU3F2, SOX2, SALL2, and OLIG2, allowing to reprogram differentiated glioma
cells back into a CSC-like state (Suvà et al., 2014). Identifying TFs essential for pluripotency is
a key step toward better understanding the mechanisms behind tumor initiation.
The hierarchy of normal stem cells has been shown to be more plastic than previously ex-
pected, as findings reported that pluripotent cells, and even lineage-committed cells, can re-enter
a stem-like state in a specific environment (Tata et al., 2013; Batlle and Clevers, 2017). This
phenomenon was also observed in breast cancer, where particular environmental stimuli could
cause cells from various phenotypes to acquire tumorigenic properties (Gupta et al., 2011). This
observation suggests that the hierarchy may not always be so rigid and that the cancer environ-
ment is yet another critical determinant of cellular plasticity in the tumor. Based on this, efforts
to target CSCs should be combined with therapies that target the more differentiated progeny to
increase the chances of completely eradicating the tumor by preventing the reversible transition
of differentiated cells to CSCs.
1.2.3 The role of the CSC niche
Tumors cannot be simplified as closed-up organisms acting independently of their surround-
ings. Rather, tumors are constantly exchanging information and acting upon their environment
through a bidirectional regulation (Quail and Joyce, 2013). Normal stem cells proliferate and
sustain their population within a specific microenvironment called a niche. These niches consist
of stromal cells, comprising mesenchymal and immune cells, vascular endothelial cells, soluble
factors secreted by the different actors, and components of the extracellular matrix, that are
exploited toward promoting cancer progression by providing CSCs with the most favorable con-
ditions for growth. Indeed, the niche can drive the stem state of the tumor cells and sustain their
stemness features (Scadden, 2014). Niches have been thoroughly studied and particularly well
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described in colorectal cancer, underlining their role in sustaining local inflammation and tumor
progression (Borovski et al., 2011). Gliomas offer another good example of the importance of
the niche for tumor growth, as CSCs rely tightly on the surrounding vasculature and the signals
from the endothelial cells for tumor maintenance (Borovski et al., 2011).
Interestingly, different tumor types have the propensity to follow specific organ-selectivity
and kinetics for metastatic spread. For instance, prostate cancer tends to metastasize mainly
to the bones following a prolonged latency, whereas lung adenocarcinoma will generally present
with multi-organ metastasis after a shorter latency period (Nguyen et al., 2009). This is in part
due to the organ specific barrier, which will be more or less permissive for cell extravasation. As a
result, a cell is more likely to colonize an organ with a more complex barrier, such as the brain, if
it is already equipped with the necessary tools and properties to successfully invade locally. Such
functions may be intrinsically acquired at the initial site through random mutations, or result
from the influence of the CSC niche (Obenauf and Massagué, 2015). In addition, an adequate
environment is essential for the malignant cells to proliferate at the metastatic destination.
Indeed, only about 0.01% of circulating tumor cells successfully home and colonize an organ and
eventually produce visible metastases (Chambers et al., 2002). According to the “seed and soil”
paradigm, the development of a metastasis strongly depends on an appropriate microenvironment
that sustains the tumor growth, in a comparable manner as in the primary site (Valastyan and
Weinberg, 2011).
Furthermore, niches can also create a protective environment for tumor cells at a secondary
site, such as in the bone marrow, and constitutes one of the many pathways behind CSC resistance
to therapy (Nguyen et al., 2009; Obenauf and Massagué, 2015).
1.2.4 CSC resistance to therapy
Most chemotherapies and radiotherapies developed in the last century focus on targeting the fast-
dividing non-CSCs by inducing DNA damage in actively replicating cells. As mentioned before,
CSCs are often dormant and therefore may escape conventional therapies (Chen et al., 2012; Qin
et al., 2012; Vanner et al., 2014). Reduced sensitivity of CSCs compared to non-CSCs has been
extensively described in many tumors, and implicate various mechanisms, ranging from activation
of DNA repair pathways (Bao et al., 2006) to remodeling of the chromatin (Sharma et al., 2010;
Liau et al., 2017). Additionally, cytotoxic agents used in chemotherapies can induce mutations
in the cells. Depending on the mutation caused in surviving cells, this process stochastically
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confers the cells increased fitness and may be a vector of selection for CSCs with improved
survival (Greaves and Maley, 2012). Regardless of the mechanism, the CSC model explains why
relapse can occur despite the virtual disappearance of cancer cells after therapy, and underlines
the need for targeted approaches specifically designed for dormant CSCs.
Unfortunately, some new treatments targeted at the CSCs that show encouraging initial re-
sponse can be later followed by relapse as a result of newly acquired resistance of CSCs (Dagogo-
Jack and Shaw, 2018). Detection of fusion genes as the main mutational drivers for a variety
of cancers, including leukemia or EwS, bore major promises. Rightfully so, it seemed plausible
that targeting the fusion protein would single handedly stop tumor progression and ensure CSCs
eradication. The t(9;22)(q34;q11) translocation in a hematopoietic stem cell has been identi-
fied as the principal initiating event for chronic myeloid leukemia (CML) in more than 95% of
patients, and leads to the formation of the constitutively activated BCR-ABL tyrosine kinase
(Goldman and Melo, 2003). Significant effort was put into finding a functional tyrosine kinase
inhibitor and clinical trials quickly started after identification of imatinib (Gleevec) as a poten-
tial candidate, with very encouraging results (Druker, 2002). However, the system is not perfect
and analysis of refractory patients revealed various mechanisms responsible for drug resistance:
1) imatinib may fail to inhibit BCR-ABL following oncogene amplification or reduced binding
capacity resulting from amino acid changes (target-dependent resistance); 2) the cell may have
already adapted and acquired additional pathways, making BCR-ABL less essential for survival
(target-independent resistance); 3) expression of drug efflux pumps such as ATP binding cas-
settes (ABCs) increase the efflux of imatinib from the cell, decreasing its intracellular availability
(drug-dependent resistance) (Henkes et al., 2008). CML and the use of imatinib illustrate well
the challenges encountered while developing CSC targeted therapies, and each of the resistance
strategies listed above have been described in other tumor types (Gottesman et al., 2002). Over-
all, targeting of many promising candidate pathways eventually show rather mixed results upon
clinical testing and fail to significantly improve patient survival (Adorno-Cruz et al., 2015).
Identification of pathways and distinct signatures proper to CSCs, and understanding the
mechanisms behind drug resistance could help predict how these cells can be targeted to enhance
patient outcome. Currently, much effort is being put into building systems to efficiently predict
patient response based on the patient’s tumor characteristics, linking clinical and genomic data.
GBM represents a sadly excellent example of a particularly challenging and complex refractory
tumor, as a result of extensive inter- and intratumoral heterogeneity and cellular plasticity.
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Localized sampling is therefore rarely representative of the extent of the tumor mass and cells
are largely prone to adapting to the treatment by off-target alterations (Eder and Kalman, 2014).
The genetic profile of GBM has been extensively well defined, with considerable data regarding
its mutational landscape. As we will review in Chapter 2, although some molecular subtypes
are associated with better prognosis, much effort is still warranted to identify a specific pathway
whose targeting will prove truly beneficial for GBM patients in the long-term.
1.3 Epigenetic regulation of cellular plasticity
Epigenetics refer to all the various heritable processes that lead to changes in the transcriptome
without altering the primary DNA sequence. Indeed, all the cells in an organism carry the same
genetic information encoded in their DNA. Yet, organs, tissues, as well as cells within a given
tissue, can vary considerably in morphology, function and behavior. Tight regulation of cell fate
is critical to ensure homeostasis of the body, and is controlled by dynamic epigenetic modulation,
which permits the orchestration of the expression of specific genes through various mechanisms.
The most common and best characterized epigenetic alterations include:
1) DNA methylation, which can repress gene transcription at the promoter site;
2) histone modifications that underlie chromatin remodeling and modulate access to DNA for
transcription;
3) post-transcriptional changes of gene expression via non-coding RNAs (ncRNAs) that con-
stitute the main focus of this work.
Although cancer is basically a genetic disease, it is becoming increasingly apparent that
epigenetic modifications play an equally important and sometimes even dominant role in car-
cinogenesis compared to genetic events (Kreso and Dick, 2014). A single oncogenic event, such
as a point mutation, may initiate transformation. However, in the majority of adult cancers, this
single event is not sufficient to generate the series of following events leading to proliferation and
tumorigenesis. This suggests that a first event leads to a permissive cell state that may allow
other events to occur, which could in their turn cause the cell to acquire tumorigenicity. To
support this, efficiency of cellular reprogramming into iPSCs varies considerably based on the
initial differentiation state of the manipulated cell. Thus, compared to fibroblasts, mouse-derived
neural stem cells can be reprogrammed more efficiently and require induction of only two TFs,
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namely in combination with KLF4 or c-MYC (Kim et al., 2008). Furthermore, epigenetics is also
involved in response to therapy. For example, various cancer cells displayed modified chromatin
conformation following exposure to drug, rendering them resistant to treatment (Sharma et al.,
2010). Therefore, exploring the epigenetic landscape of CSCs, including the impact of ncRNAs
on post-transcriptional gene expression regulation, can provide key elements to identify thera-
peutic approaches that augment patient remission and, in at least some tumor types, possibly
lead to cure (Baylin and Jones, 2011).
The former approach to biology long focused on a clear sequence of events initiated by DNA
transcription into an RNA strand, subsequently translated into a protein that permits the ul-
timate expression of the genetic information into a specific phenotype. According to this view,
RNA serves merely as an intermediary messenger for protein expression. This principle has pro-
gressively been challenged, as new types of RNA were identified, such as ribosomal RNA (rRNA)
and transfer RNA (tRNA), both involved in protein translation. Finally, with the development
of whole genome sequencing technologies 20 to 30 years ago, it could be demonstrated that about
70% of the genome is transcribed, while only 2% of the transcriptomic output encodes proteins
(Dunham et al., 2012). Deep-sequencing of the genome revealed pervasive DNA transcription
that produces stable RNAs of various lengths and lacking any protein-coding potential (Carninci
et al., 2005; Kapranov et al., 2007). While these transcripts were first viewed as random noise, it
became clearer that this “dark matter” required further investigation, as the number of identified
non-coding transcripts kept on growing, and it remained to be established whether they were
inert or had functional biological relevance (Johnson et al., 2005). When looking at a typical
eukaryotic cell, rRNAs, tRNAs and mRNAs represent up to 99% of the total RNA mass, with
up to 107 copies in total. In contrast, other ncRNAs compose less than 1% of the RNA mass
and their molecules are much less abundant, by two to three orders of magnitude (Palazzo and
Lee, 2015). If these ncRNAs are so scarce in the cell in comparison to mRNA and the translation
machinery, it can be assumed that their function can only be very limited. However, findings
demonstrating the presence of binding sites around protein-coding and non-protein coding genes
suggest otherwise, showing that ncRNA expression can be regulated by transcription factors, im-
plying a function that needs to be neatly monitored for cellular homeostasis (Cawley et al., 2004).
Furthermore, comparison of the murine and human genomes underscores high sequence conser-
vation outside coding-frames on chromosome 21, further supporting a potentially important role
of non-coding elements in the genome (Dermitzakis et al., 2002).
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Altogether, these observations reinforce the notion that epigenetic events and regulatory
elements may play an increasingly important role in regulation of both normal cell fate and
tumorigenesis. Studying the biogenesis and functions of ncRNAs may provide essential insight
into potentially targetable epigenetic pathways maintained in CSCs. The ncRNAs involved in
epigenetic regulation include microRNAs (miRNAs), long non-coding RNAs (lncRNAs), short in-
terfering RNAs (siRNAs), and piwi-interacting RNAs (piRNAs). Here, we will focus on miRNAs
and lncRNAs.
1.3.1 MicroRNAs
miRNAs were initially discovered in 1993 in C. elegans, where the gene LIN-14 had to be
downregulated for normal larval development by lin-4, a short RNA sequence that did not encode
a protein (Lee et al., 1993). Remarkably, many other short ncRNAs were later found to be
highly conserved across species, including the let-7 family (Pasquinelli et al., 2000), highlighting
a potentially essential role of these short transcripts in cell development and control of gene
expression.
miRNAs are short ncRNA sequences, generally 22 nucleotide-long, and act mainly as post-
transcriptional gene repressors by binding the 3’-UTR of target mRNAs and repressing their
translation or targeting them for degradation (Melo and Esteller, 2011), thereby promoting
cell differentiation (Bartel, 2009; Martinez and Gregory, 2010), proliferation (Brennecke et al.,
2003; Hatfield et al., 2005) and apoptosis (Xu et al., 2003). In embryonic stem cells, a limited
repertoire of miRNAs is expressed, that is absent or expressed at very low levels in differentiated
cells. Therefore, miRNA clusters are differentially involved and tightly regulated depending on
their effect on promoting or repressing the cell cycle (Martinez and Gregory, 2010).
Expression of the mature forms of miRNAs follows a specific pattern, highly dependent on the
tissue and cell state, and is under the control of tissue-, developmental- and cell-specific signalling
(Kim et al., 2009b). About half of the miRNAs are found in clusters and are transcribed from a
common promoter. They can be localized at protein-coding loci, most often in intronic regions,
or in non-protein coding areas. Transcription of miRNA genes is regulated by the recruitment
of transcription factors, including p53 and c-MYC, and can also be epigenetically modulated,
for instance as a result of changes in the DNA methylation state and histone marks (Kim et al.,
2009b; Peng and Croce, 2016).
The canonical biogenesis of miRNAs begins in the nucleus with transcription of the DNA
1.3. EPIGENETIC REGULATION OF CELLULAR PLASTICITY 31
sequence into a primary-miRNA (pri-miRNA), which is then cleaved by DROSHA in association
with dsRNA-binding protein DGCR8 (DiGeorge syndrome critical region gene 8), into a hairpin
RNA, namely the premature-miRNA (pre-miRNA) (step 1 in Figure 1.3). Following exportation
from the nucleus into the cytoplasm, mediated by XPO5 (Exportin 5) in association with the
GTPase Ran (step 2 in Figure 1.3), the pre-miRNA strand is converted into a mature duplex
by the RNase III endonuclease DICER1, and cleaved into the miRNA/miRNA* duplex (step
3 in Figure 1.3), consisting of the passenger strand destined for degradation (miRNA*) and
the leading strand (miRNA) (step 4 in Figure 1.3). Trans-activation responsive RNA-binding
protein 2 (TRBP2) functions as a guide to determine which of the RNA strands constitutes the
leading miRNA strand to be further processed and loaded on an Argonaute RNase (AGO1-4).
Together, DICER1, Argonaute, TRBP2 and the leading miRNA strand form the RNA-induced
silencing complex (RISC), also known as miRNA loading complex (miRLC). Finally, RISC binds
the 3’-UTR of target mRNA transcripts for translation inhibition or mRNA degradation (step
5 in Figure 1.3) (Melo and Esteller, 2011). In addition, direct pathway activation by miRNAs
acting as ligands of Toll-like receptors (TLR) has been described (Fabbri et al., 2012; Fabbri,
2012). Alternatively, some miRNAs follow the non-canonical pathway, which involves splicing
of their mRNA precursor. In this case, the hairpin sequence, called mirton, bypasses DROSHA
to be processed by a spliceosome instead, and is available for export from the nucleus to the
cytoplasm where it undergoes the subsequent steps of maturation (Winter et al., 2009).
The main mechanism for miRNA binding involves the nucleotides in positions 2 to 7 at the
5’-end of the mature miRNA strand, referred to as the seed region (Lewis et al., 2003, 2005),
and follows simple Watson-Crick base pairing. This sequence is essential for target recognition
at the canonical sites, which are conserved binding sites found across a broad range of mRNA
transcripts (Agarwal et al., 2015), leading to significant changes in the proteome (Selbach et al.,
2008). With each miRNA capable of targeting hundreds of mRNA, miRNAs have the power to
affect large molecular networks (Thomas et al., 2010).
Shortly after miRNAs were discovered and their presence confirmed in mammalian cells
(Lagos-Quintana et al., 2001), scientists postulated and investigated miRNA implication in cel-
lular deregulation and cancer pathways. This was first clearly demonstrated in adult chronic
lymphoblastic leukemia (CLL), in which loss of the chromosomal region 13q14 had already been
described but was not associated with the loss of a key gene in this context. By more accurately
identifying the critical lost chromosomal region, miR-15a and miR-16-1 were found to be signifi-
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Figure 1.3: The canonical miRNA biogenesis pathway. Adapted from Melo and Esteller (2011).
cantly downregulated in a majority of CLL patients (Calin et al., 2002). Several studies followed
showing that miRNAs can act either as tumor suppressors or as oncogenes (Kent and Mendell,
2006; Ventura and Jacks, 2009).
Therefore, the perturbed miRNA signature found in cancerous cells is the result of a dysreg-
ulation of miRNA expression and can occur at several levels (Peng and Croce, 2016):
− chromosomal aberration may lead to duplication or loss of genomic region containing
miRNA loci;
− miRNA transcription may be modulated by changes in DNA methylation and histone
marks, or affected by the expression of specific transcription factors that activate miRNA
transcription;
− miRNA maturation may be impaired at various levels, based on the activity or expression
of proteins implicated in the biogenesis pathway. Indeed, expression of certain miRNAs in
tumors remain low, although the levels of pre- and pri-miRNA are maintained, suggesting
impaired miRNA maturation as a key component in oncogenesis (Thomson et al., 2006);
− post-transcriptionally, miRNAs can be bound by proteins or other RNAs that repress
miRNA function, as is the case of LIN28B, which we discuss later.
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The let-7 family of highly conserved miRNA, consisting of 13 members that are partially func-
tionally redundant, is absent in embryonic stages, but strongly expressed in differentiated cells,
and its downregulation is known to promote transformation (Kumar et al., 2007). Furthermore,
decreased expression levels of let-7 have been seen in various malignant tumors, including lung,
hepatocellular, skin, breast, ovarian and urothelial cancers, as well as hematopoietic malignancies
(Viswanathan et al., 2009; Croce, 2009). Their repressed target genes include the oncogene c-
MYC (Kim et al., 2009a), the cell cycle regulator Cyclin D1 (Li et al., 2012), HMGA2, involved in
motility and self-renewal (Lee and Dutta, 2007), IMP2, involved in CSC metabolism (Degrauwe
et al., 2016a), and RRM2, involved in DNA synthesis in dividing cells (Bhutia et al., 2013),
among others. The let-7 miRNAs are usually repressed in embryonic stem cells and CSCs by
the RNA binding protein (RBP) LIN28B, thus contributing to maintenance of cell pluripotency
(Viswanathan and Daley, 2010).
1.3.2 Long non-coding RNAs
While smaller ncRNAs have been thoroughly investigated, lncRNAs represent a subgroup of
transcripts that remain largely enigmatic. lncRNAs are defined as transcripts that are greater
than 200 nucleotides long, have no clear open reading frames (ORFs) and lack protein-coding
potential (Angrand et al., 2015). Like mRNAs, lncRNAs are transcribed by RNA Polymerase
II and can undergo splicing and polyadenylation (Quinn and Chang, 2016). However, they
display poor cross-species conservation (Derrien et al., 2012). Whereas they were first believed
to represent junk RNA, subsequent findings progressively demonstrated their diverse roles in the
cell (Figure 1.4). Some data show that several lncRNAs can actually give rise to small functional
peptides, for instance in the skeletal muscle (Anderson et al., 2015), but ribosome profiling
confirms lncRNAs as mainly untranslated transcripts (Guttman et al., 2013). They now appear
to be significant regulators of various processes, including cell pluripotency and tumorigenesis,
either as tumor suppressors or as oncogenes, by interactions with other molecules (Fatica and
Bozzoni, 2014; Wapinski and Chang, 2011; Yan et al., 2015; Schmitt and Chang, 2016).
The first reported lncRNA, H19, was identified in mouse embryogenesis (Pachnis et al., 1988)
and consists of a 2.3 kbp-long transcript. Further investigation confirmed that the H19 transcript
undergoes splicing and polyadenylation but is not translated into a protein (Brannan et al.,
1990). Since then, thousands of lncRNAs have been reported, but biological activity has been
defined in only about a handful of them (Ponting et al., 2009). LncRNAs can be subdivided
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in five categories that define their genomic organization, based on their position relative to a
neighboring protein-coding gene:
1) Sense: the lncRNA locus overlaps one or more exons of another transcript;
2) Antisense: the lncRNA locus overlaps one or more exons of another transcript in the
opposite direction;
3) Bidirectional or divergent: the lncRNA is under the control of a promoter that also initiates
transcription of a coding gene in the opposite direction;
4) Intronic: the lncRNA corresponds to the intron of another transcript;
5) Intergenic: the lncRNA is produced from a transcription unit located between two protein
coding genes.
This classification, however, is based solely on the lncRNA sequence location in the genome,
and does not necessarily correlate with their expression or function. As mentioned earlier,
lncRNA expression is largely dependent on the cell type and state, and will vary in the context
of disease. Regulation of lncRNA transcription thus relies on the control of highly conserved
promoters. However, it is unclear if lncRNA activation is the cause or the result of its expression
in certain cellular contexts. Transcription of lncRNAs require an open chromatin with promoters
enriched in active histone modifications. Some studies, however, have shown that lncRNAs may
be regulated not individually, but rather as a class, as their global expression is significantly
downregulated upon knockdown of DICER1 and depends on c-MYC expression (Zheng et al.,
2014). Furthermore, as listed above, many lncRNAs result from the antisense transcription of
a protein-coding gene under the control of a bidirectional promoter. This phenomenon, called
divergent transcription, suggests that antisense transcripts may be under specific regulation in-
dependent of their mRNA counterparts (Quinn and Chang, 2016).
Understanding the mechanisms underlying lncRNA function is required to determine their
putative utility in cancer treatment. Due to their length, lncRNA transcripts can fold and con-
tain several binding sites for other molecules, so that the secondary structure is an important
factor for their function. Whether located in the nucleus or in the cytoplasm, lncRNAs can
regulate gene expression through various mechanisms, based on interactions with different cel-
lular macromolecules: 1) direct binding of lncRNAs to chromatin, changing its conformation or
recruiting other regulatory molecules to specific loci, 2) binding of lncRNA to proteins, leading
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Figure 1.4: Representation of various functions of lncRNAs. Inside the nucleus, lncRNAs can recruit chromatin
remodelling proteins to change chromatin conformation, and positively or negatively regulate gene transcription by binding
TFs. In the cytoplasm, lncRNAs can act as sponges and sequestrate miRNAs and regulate translational activity, splicing,
as well as RNA degradation. By binding several partners, lncRNAs can act as scaffolds.
to formation of protein complexes or inhibiting protein-protein interactions, 3) interaction with
mRNA causing recruitment of proteins and affecting splicing, stability or translation, or interac-
tion with miRNAs leading to their sequestration and loss of function (Wang and Chang, 2011;
Angrand et al., 2015; Bergmann and Spector, 2014).
Furthermore, lncRNAs can affect both proximal (cis-acting) and distal (trans-acting) genes
(Kopp and Mendell, 2018). On a cis-acting level, a lncRNA can regulate the transcription of a
neighboring gene by recruiting the necessary transcriptional machinery for regulated transcrip-
tion. This mechanism is employed by Xist to silence almost all of the inactivated X chromosome,
by extensively repressing chromatin. Alternatively, DNA regulatory elements found within the
lncRNA locus may impact transcription of the neighboring protein-coding gene. Another mech-
anism of action is independent of the mature lncRNA sequence but relies on transcription of the
antisense lncRNA to interfere with transcription of the protein-coding gene. Similarly, splicing
of a nearby lncRNA locus can affect gene transcription (Kopp and Mendell, 2018). Functions of
lncRNAs in trans include chromatin state reprogramming, as exemplified by HOTAIR, whose
expression is increased in breast cancer and is associated with an invasive phenotype, as a result
of Polycomb repressive complex 2 (PRC2) redistribution across the genome (Gupta et al., 2010).
Other lncRNAs may reorganize nuclear structure, by acting as scaffolds linking distal areas of
actively transcribed DNA together. Additionally, lncRNAs may bind specific RBPs or sequester
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other RNAs, thereby limiting their availability in the cell (Kopp and Mendell, 2018). Lastly,
lncRNAs may be precursors of miRNAs, as evidenced by H19. Indeed, miR-675 is found within
the first intron of H19. Interestingly, expression levels of H19 and miR-675 are neither equal
nor stable across tissues, suggesting that processing into miRNA may be regulated based on the
local function of the lncRNA (Dey et al., 2014).
Altogether, the term lncRNA as used to define a single subclass is rather elusive, as it
currently encompasses largely heterogeneous transcripts that can exert a broad spectrum of
relevant cellular functions. Further characterization of these long transcripts is warranted to
better subdivide them based on their biological properties. As their expression pattern varies
in a tissue and cancer specific manner, lncRNAs are interesting candidate biomarkers to predict
tumor prognosis and response to therapy (Schmitt and Chang, 2016).
1.4 RNA binding proteins
Investigations on the post-transcriptional fate of mRNA have brought to light a wide range of
regulatory processes implicated in all levels of mRNA metabolism, from the birth of a nascent
mRNA to its decay (Figure 1.5). Indeed, transcripts do not circulate inside the cells as naked
nucleotide strands. Rather, they form messenger ribonucleoparticles (mRNPs) in combination
with a dynamic assembly of proteins bound to the transcript, involved in all steps of mRNA
fate, including transcription, splicing, 3’-end and 5’-end processing, transportation, translation,
as well as mRNA stability and decay (Glisovic et al., 2008). RBPs are involved as much in
transport and localization as in maturation of mRNA, either directly or by recruiting additional
proteins. It is believed that each RBP can individually target hundreds of transcripts, which can
in turn bind a multitude RBPs, thus creating a complexly entangled network (Müller-McNicoll
and Neugebauer, 2013). The identification of more than a thousand RBPs (Sundararaman et al.,
2016; Trendel et al., 2019), as well as their striking conservation across species (Gerstberger et al.,
2014), indicate that post-transcriptional regulation is an essential component of gene expression.
In addition to mRNAs, RBPs can also synergize with or antagonize ncRNAs to affect gene
expression, either by competitive binding to target mRNAs, recruitment of RISC, or facilitating
miRNA binding through changes of mRNA conformation (Mitchell and Parker, 2014; Degrauwe
et al., 2016b).
Thus, RBPs increase the diversity of the regulatory network that controls cell fate. Indeed,
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Figure 1.5: RBPs are involved in mRNA fate. RNA transcripts are bound by changing complexes of multiple RBPs,
which are involved in maturation, modification, splicing, export of mRNAs and transport to specific sites. Following delivery
to site, mRNA is either translated or stocked in P-bodies until further processing or degradation. AAn, polyadenylation;
hnRNPs, heterogeneous nuclear ribonucleoproteins; P-bodies, processing-bodies. Adapted from Marchese et al. (2016).
post-transcriptional regulation provides a faster response in comparison to transcriptional con-
trol. Also, it gives a chance for the environment to directly influence the transcriptome through
signalling cues from the cellular niche. By having an effect independently of the gene expression
levels, an additional regulatory dimension allows more precise fine-tuning of the cell identity.
With the development of more stringent and selective technologies, such as photoactivatable
ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) (Hafner et al., 2010)
and enhanced RNA interactome capture (eRIC) (Perez-Perri et al., 2018), studies have started
unmasking the identity and function of RBPs with more precision. These technologies have also
started shedding light onto the so-called “enigmRBPs”, a group of proteins without previously
recognized RNA binding domains, identified as RBPs in yeast and human proteomes (Beckmann
et al., 2015). Moreover, while a panel of protein-RNA binding motifs have been described,
38 CHAPTER 1. INTRODUCTION
such as the RNA recognition motif (RRM) and the K-homology (KH), more non-canonical sites
are progressively being uncovered thanks to these new methods, highlighting the complexity of
RNA-protein interactions (Castello et al., 2012, 2016).
Alterations in the correct assembly of mRNPs and impaired function of such regulatory
pathways can negatively impact the cellular balance and trigger a large panel of diseases, ranging
from degenerative disorders to cancer (Ramaswami et al., 2013; Lukong et al., 2008). Among the
RBPs that have been associated with cancer, the LIN28 paralogs are involved in the let-7 miRNA
maturation pathway and normally expressed during embryogenesis (Viswanathan et al., 2009).
Additionally, the IMP family of highly conserved oncofetal RBPs, also termed IGF2 mRNA
binding proteins (IGF2BPs), is known to be highly expressed in developing tissues, important
for cell growth and cell migration during embryogenesis (Mueller-Pillasch et al., 1999), and is
believed to be a key player in the process of stemness maintenance.
1.4.1 The LIN28 paralogs
LIN28 was first described in C. elegans, where its differential regulation at early larval stages
is critical for developmental timing (Ambros and Horvitz, 1984). Later, LIN28 was found to
be highly conserved across species and expressed exclusively during development (Moss and
Tang, 2003). In mammals, two paralogs have been identified, LIN28A and LIN28B (here, we
use “LIN28” to refer to the two paralogs together). Both paralogs share 73% amino acid iden-
tity across a unique combination of two RNA binding regions, namely one cold shock domain
(CSD) and one zinc knuckle domain (ZKD), composed of two CCHC zinc fingers (Figure 1.6A).
Interestingly, phylogenetic studies found that LIN28A and LIN28B are more closely related in-
dividually across species than to one another within the same species. Furthermore, LIN28 in C.
elegans is similarly related to both paralogs (Figure 1.6B). This suggests that LIN28B may have
resulted from a duplication event in an ancestral gene, and that LIN28A/B may possess distinct
properties (Guo et al., 2006). Indeed, LIN28B contains a nuclear and a nucleolar localization
signal (Figure 1.6A), causing LIN28B to be recruited to the nucleus, while LIN28A is primarily
located in the cytoplasm (Piskounova et al., 2011)
LIN28 paralogs are typically expressed during normal embryogenesis, where they control the
critical balance between pluripotency and differentiation, and regulate the stem cell metabolism
(Zhang et al., 2016a). Notably, LIN28B participates in cellular dedifferentiation and repro-
gramming of somatic cells (Yu et al., 2007). The potential role of LIN28 in tumorigenesis was
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uncovered by using NIH3T3 cells, in which overexpression of LIN28 was sufficient for tumors
to form in vivo (Viswanathan et al., 2009). Furthermore, reactivation of LIN28B has been re-
ported in various tumor types, where it is linked to malignant transformation and correlates with
cancer aggressiveness, leading to its classifciation as an oncofetal protein (Viswanathan et al.,
2009; Balzeau et al., 2017). Most interestingly, among all tumors that express LIN28, 25% are
childhood malignancies (Carmel-Gross et al., 2015), and include various cancer types, such as
Wilms tumor (Urbach et al., 2014), neuroblastoma (Hennchen et al., 2015; Powers et al., 2016)
and primitive neuro-ectodermal brain tumors (Choi et al., 2016; Picard et al., 2012).
Most of the work on LIN28 has focused on the interactions between the LIN28 paralogs and
the let-7 miRNAs. Early on, LIN28 was early found to be negatively regulated by let-7 during
nematode development, as the 3’-UTR of LIN28 contains several let-7 binding sites (Pasquinelli
et al., 2000). Later, observations demonstrated that LIN28 can repress let-7 biogenesis. Indeed,
disparities observed respectively high and low levels of precursor and mature let-7 transcripts
during development helped uncover mechanisms of post-transcriptional regulation of ncRNAs.
Among these, LIN28 was shown to bind the GGAG loop in let-7 miRNAs and affect their matu-
ration process (Heo et al., 2008; Viswanathan et al., 2008). As a result of the different locations
of the LIN28 paralogs, distinct mechanisms participate in let-7 miRNA silencing. LIN28A, pri-
marily located in the cytoplasm, binds a conserved let-7 loop and recruits the TUTase Zcchc11
(TUT4), which uridylates the 3’-end of let-7 precursors, leading to transcript degradation by the
nuclease DIS3L2 (Heo et al., 2008). In contrast, LIN28B, found in the nucleus, blocks let-7 mat-
uration by recruiting precursor transcripts to nucleoli devoid of the microprocessor machinery
and preventing further maturation (Piskounova et al., 2011) (Figure 1.6C). Given that LIN28 is
expressed during early development, whereas let-7 miRNAs appear at later stages, this negative
feedback loop is central in maintaining the balance between stem and differentiated cell states
(Figure 1.6D). As a result, aberrant reactivation of LIN28 negatively regulates let-7 expression,
reverses the cell to a stem-like state, and hence participates in tumorigenesis. To further ap-
preciate the impact of LIN28 expression, a recent study demonstrated that depletion of mature
let-7 frees Argonaute proteins from let-7 miRNAs, and RISC complexes become more available
to bind other miRNAs, thus shifting the miRNome and the resulting transcriptome (Tan et al.,
2019).
Nevertheless, there is increasing evidence that LIN28 function is not limited to let-7 downreg-
ulation. Transgenic mouse experiments showed that varying levels of LIN28 affect glucose uptake
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Figure 1.6: LIN28 structure and mechanisms of action. (A) Schematic representation of the human LIN28 paralogs
structure with their domains. CSD, cold shock domain; CCHC, Cys-Cys-His-Cys zinc finger; ZKD, zinc knuckle domain;
NoLS, nucleolar localization signal; NLS, nuclear localization signal. Adapted from Thornton and Gregory (2012). (B)
Phylogenetic tree representing sequence alignments of the LIN28 paralogs. The number in parentheses after the gene
name correspond to the calculated evolutionary distance. Hs, Homo sapiens; Mm, Mus musculus; XI, Xenopus laevis;
Dm, Drosophila melanogaster ; Ce, Caenorhabditis elegans. Adapted from Guo et al. (2006). (C) LIN28A/B regulation
of let-7 maturation. In the nucleus, LIN28B binds and sequestrates pri-let-7 to nucleoli and prevents maturation by the
microprocessor DGCR8/DROSHA. In the cytoplasm, LIN28A binds pre-let-7 transcripts and recruits TUT4, which adds
a short polyU tail to pre-let-7, which is no longer a DICER1 substrate, resulting in degradation of pre-let-7 by DIS3L2.
(D) Biological consequence of the LIN28-let-7 balance. High LIN28 expression in undifferentiated cells blocks biogenesis
of let-7 miRNAs. As differentiation progresses, LIN28 expression is lost, resulting in production of mature let-7 that can
negatively regulate LIN28. In the generation of iPSCs and in tumorigenesis, LIN28 helps drive pluripotency, self-renewal,
de-differentiation, and/or cellular transformation to a malignant phenotype. Adapted from Balzeau et al. (2017). (E)
Distribution of LIN28B binding sites in conservative sequence clusters to non-coding RNAs and different transcript regions
(5’-UTR, CDS and 3’-UTR) of protein-coding genes. Adapted from Graf et al. (2013).
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and insulin sensitivity whereas mature let-7 transcripts remain stable (Zhu et al., 2011). More-
over, LIN28 promotes proliferation of embryonic stem cells by binding to mRNAs encoding cell
cycle regulators and enhancing their translation into the final protein product, suggesting a role in
post-transcriptional gene regulation independent of let-7 miRNAs (Peng et al., 2011). Recently,
UV crosslinking and immunoprecipitation sequencing (CLIP-seq) and PAR-CLIP analyses have
identified thousands of transcripts bound by LIN28A and LIN28B at a loop motif containing
GGAGA and RGGSWG sequences, respectively, and have shown that targets consist mainly of
3’-UTR and protein-coding sequences in addition to the let-7 precursors (Figure 1.6E). Some
identified transcripts bound to LIN28B include IGF2 (Polesskaya et al., 2007), (Qiu et al., 2009),
Cyclins and CDK4 (Xu et al., 2009a), HMGA1 (Peng et al., 2011), and LIN28B itself (Graf et al.,
2013; Hafner et al., 2013). Notably, most binding transcripts encoded RNA transcriptional regu-
lators, as well as RNA processing and splicing factors, and are positively regulated when bound
to LIN28 (Wilbert et al., 2012; Graf et al., 2013; Hafner et al., 2013). Furthermore, LIN28 inter-
action with RNA helicase A (RHA) supports a function in translational regulation in association
with ribosomes (Balzer and Moss, 2007; Peng et al., 2011; Jin et al., 2011). As a result, LIN28
paralogs can bind a plethora of targets and affect their abundance and translation, and it may be
expected that the binding partners involved in transformation are specific to the cellular context
in which LIN28 is expressed.
Based on these studies, it appears that the role of the RBPs LIN28 in tumorigenesis is
not limited to their interaction with let-7 miRNA precursors and further investigation of their
implication in cancer requires the inclusion of the post-transcriptional effects of the paralogs on
bound protein-coding transcripts.
1.4.2 The IMP family of RBPs
The IMP family of RBPs is composed of three members, namely IMP1, IMP2 and IMP3. All
three IMPs share a similar structure, composed of two RRM domains at the N-terminal end and
four KH domains in the C-terminal region, a similarity that is translated into shared functions
of these three RBPs (Nielsen et al., 1999). IMP1 and IMP3 share the highest homology in the
family, with 73% amino acid sequence identity. KH3/4 seem to regulate mRNA recognition,
whereas KH1/2 and the RRM domains contribute to stabilize mRNA binding (Bell et al., 2013).
In addition, the presence of repeated KH binding sites increases binding affinity and specificity, as
the KH domains allow recognition of only short segments of mRNA (Chao et al., 2010). Recently,
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KH domains in IMPs were reported to identify the N6-methyladenosine (m6A) modification in
mRNA, one of the most abundant post-transcriptional mRNA modifications (Huang et al., 2018).
The prolonged half-life of IMP-mRNA complexes reflects important binding affinity and sta-
bility, and suggests an essential role of IMPs in stocking or long-distance transport of target
transcripts (Nielsen et al., 2004). Despite a similar structure, KH3/4 domains in IMPs recognize
and bind distinct RNA consensus sequences (Schneider et al., 2019; Biswas et al., 2019). Never-
theless, enhanced CLIP analyses showed overlap in identified IMP targets (Conway et al., 2016).
Moreover, knockdown of IMP1 in this study did not show dramatic changes of the transcriptional
profile, suggesting a redundancy between IMPs. Altogether, IMPs appear to be involved in the
regulation of many steps of mRNA maturation by forming mRNPs that control mRNA stability,
export and fate and the large repertoire of targets places IMPs in the control of a large and
complex mRNA network.
IMP1 is known to be strongly involved in localization of transcripts and regulates neural
stem cell (NSC) differentiation and function (Nishino et al., 2013). In human pluripotent stem
cells, IMP1 promotes cell survival and adhesion (Conway et al., 2016). Furthermore, IMP1 ap-
pears to be involved in metabolism and stem cell maintenance, as IMP1-deficient mice are smaller
than normal littermates and display significantly impaired and delayed gut development (Hansen
et al., 2004). Mechanistically, IMP1 can prevent miRNA silencing by sequestrating target mR-
NAs in RISC-free granules, thus protecting transcripts from miRNA-mediated degradation, and
participates in the transport of transcripts to their appropriate destination for translation initi-
ation (Weidensdorfer et al., 2009; Müller et al., 2018). By preventing miRNA silencing of target
transcripts, IMP1 may participate in the maintenance of an undifferentiated cell state.
IMP2 has been less deeply investigated than the other two paralogs, probably due to the fact
that it is still detected in adult tissues, making its reexpression less likely to cause transformation.
However, recent work has revealed that IMP2 may also function as an oncogene. Whereas
IMP2 is involved in muscle cell motility (Boudoukha et al., 2010) and in brain development,
where it is essential for the neural progenitor cell population (Degrauwe et al., 2016a), it is also
required for CSC maintenance in GBM, where it regulates key metabolic pathways (Janiszewska
et al., 2012). Implication of IMP2 in cellular metabolism is further supported by observations
of IMP2-deficient mice. Homozygous deletion of IMP2 leads to a smaller phenotype, a decrease
in adipocyte precursors, and resistance to obesity (Dai et al., 2015). Importantly, IMP2 binds
to miRNA recognition elements (MREs) and consequently protects a wide range of transcripts
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Figure 1.7: IMPs structure and mechanisms of action. (A) Schematic representation of the human IMP paralogs
structure with two RRM domains followed by two pairs of KH domains. In IMP2, a splice variant where exon 10 is skipped
generates an isoform named p62. The affected area is shown in green. Adapted from Bell et al. (2013). (B) Phylogenetic
tree representing sequence homology of the IMP paralogs across species. Human IMP1 and IMP3 are most closely related,
whereas no ortholog has been described for IMP2. Hs, Homo sapiens; Mm, Mus musculus; XI, Xenopus laevis; Dm,
Drosophila melanogaster ; Gl, Gallus gallus. Adapted from Christiansen et al. (2009). (C) Schematic representation of
mechanisms of action of IMPs. IMP1 and IMP3 can recruit target transcripts inside RISC-free mRNPs, whereas IMP2 can
competitively bind the let-7 miRNA recognition elements (MRE) in the 3’-UTR of target transcripts. Both mechanisms
prevent let-7-mediated target degradation. LIN28A/B are included in the image, as they also regulate the let-7 pathway
by inhibiting the let-7 maturation process. (D) Biological consequence of the IMP-let-7 balance. High IMP expression
in undifferentiated cells prevents let-7-mediated decay, thereby conserving the expression of target transcripts, such as
LIN28. As differentiation progresses, loss of IMPs restores let-7 activity, resulting in downregulation of IMPs and its
targets, including LIN28 and HMGA2. In tumorigenesis, IMPs participate in driving cellular transformation to a malignant
phenotype.
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from let-7 mediated decay (Degrauwe et al., 2016a). Thus, IMP2 uses diverse mechanisms to
promote and maintain a stem-like cell state.
In contrast, IMP3 has been widely studied in cancer (Bell et al., 2013). Similarly to IMP1,
IMP3 was shown to sequester mRNA targets in RISC-free mRNP granules, thereby safeguarding
mRNAs from degradation (Jønson et al., 2014). Evidence strongly suggests that IMP3 is impli-
cated in increased tumor aggressiveness across many malignancies, including pancreatic, renal,
urothelial, colorectal and hepatic cancers (Jeng et al., 2008; Schaeffer et al., 2010; Gong et al.,
2014; Lederer et al., 2014). Consistent with this notion, IMP3 synergized with IMP1 to promote
mesenchymal features and increase cell invasion (Lederer et al., 2014).
In physiological conditions, IMP1 and IMP3 are expressed exclusively in embryonic tissues. In
contrast, IMP2 expression levels are high during development and further maintained into adult-
hood in some tissues (Degrauwe et al., 2016b). Despite distinct targets, all IMPs are involved
in the control of mRNA turnover and transport. The implication of IMPs in the promotion
of a stemness phenotype was proven in various malignancies, including breast, colorectal and
hepatic carcinomas, as well as GBM (Degrauwe et al., 2016b) and is strongly supported by their
ability to interfere with normal miRNA-mediated silencing. Particularly, IMPs protect their
own transcripts from let-7 degradation, thereby forming a positive feedback loop that further
potentiates IMP expression. While it is not yet clear if IMPs act coordinately or individually,
their reactivation may underlie a key pathway essential for CSC maintenance.
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1.5 Aim of the study
Our laboratory recently found that IMP2 preserves CSCs in GBM by protecting transcripts
from let-7 degradation (Degrauwe et al., 2016a). To further explore the roles of IMP2 and let-7
pathways in GBM, I first attempted to reverse the CSC phenotype by re-establishing proper
let-7 function. Additionally, PAR-CLIP data on CSC provided an extensive landscape of IMP2
targets. From this, we identified the lncRNA H19 as a potential candidate and we attempted
to define its functional role in CSC maintenance. Lastly, given that LIN28 is often re-expressed
in childhood cancers, that LIN28 and IMPs are commonly expressed together in tumor cells,
and that both RBP families converge to regulate the let-7 miRNA pathway, I assessed possible
redundancy between these various players in the pediatric context of EwS, in which dysregulation
of let-7 miRNAs has been previously described and effectively targeted (De Vito et al., 2011,
2012; Cornaz-Buros et al., 2014).

Chapter 2
Glioblastoma
2.1 Introduction
2.1.1 Characteristics of GBM
Glioblastoma Multiforme (GBM) is the most common form of primary brain malignancy in
adults, with an incidence of about 3 newly diagnosed cases per 100’000 per year and discrete
male predominance. Prognosis for GBM is particularly dismal, as the median survival is 15
months with treatment and 3 months if left untreated, with a 5-year survival rate below 5%
(Thakkar et al., 2014). Most cases of GBM occur between the ages 45 and 70. Typically, GBM
patients present with neurological signs, including local neurological deficits, headache, and/or
seizures, depending on the location and size of the tumor. Symptoms develop rather rapidly,
appearing over a couple of days to a few weeks before diagnosis (Gladson et al., 2010). The clinical
presentation of GBM is similar to that of any brain tumor or brain metastasis, prompting the
patient to undergo brain magnetic resonance imaging (MRI) to identify the underlying lesion,
followed by definite diagnosis based on analysis of tumor tissue obtained during surgical resection,
or from localized brain biopsy (Figure 2.1).
The current standard of care includes maximal safe surgical resection as the first step in
the management of high-grade gliomas. At this stage, brain MRI should be repeated to assess
the extent of the resection, as GBM is a notoriously invasive tumor. Subsequently, the patient
receives radiation therapy and chemotherapy, most commonly with temozolomide (TMZ), an
alkylating agent that readily crosses the blood brain barrier (BBB). However, despite advances
in treatment strategies and maintenance protocols, virtually all cases of GBM relapse, making
this cancer largely incurable to this date. This is due to its strong invasive proclivity into the
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Figure 2.1: Macroscopic and microscopic morphology of GBM. (A) Gross appearance of GBM showing a hem-
orrhagic, necrotic and infiltrating mass. Image adapted from Wikimedia Commons under a CC BY-SA 4.0 license. (B)
T1 MRI of the brain with contrast, showing a tumor in the right hemisphere with right lateral ventricle involvement, later
confirmed as GBM by histopathology. From left to right: axial, coronal and sagittal views. Image adapted from Wikimedia
Commons under a CC BY-SA 3.0 license. (C) Micrographs of gliomas grades II to IV. Increased mitotic activity is found in
WHO Grade III gliomas (insert) and WHO grade IV/GBM tumors display pseudopalisading necrosis, the signature feature
of GBM (arrows). Magnification x 40. Adapted from Huse et al. (2013).
brain tissue, extensive ITH, and persistence of tumor-initiating cells (Auffinger et al., 2015).
GBM is the most aggressive form of astrocytoma, a family of tumors subdivided into four
WHO grades, based on histological features, with increasing degrees of malignancy: grade I,
pilocytic astrocytoma; grade II, diffuse astrocytoma; grade III, anaplastic astrocytoma; grade
IV, GBM. In most cases (90-95%), GBM arises de novo, typically in patients aged 60 or more,
and is therefore called primary GBM. Alternatively, in around 5% of cases, GBM can result
from pre-existing grade II/III gliomas that transform into a more aggressive phenotype, and is
thus termed secondary GBM, mainly in younger patients (Gladson et al., 2010). Although the
age-adjusted prognosis is similar in primary and secondary onset GBM, this distinction bears
considerable clinical significance for therapy, as it implies that different mechanisms govern GBM
development, and, as a result, primary and secondary GBM display distinct molecular profiles
(Ohgaki and Kleihues, 2005). The majority of GBMs involve the brain hemispheres, and, less
commonly, secondary GBM can be found in the brain stem or the spinal cord.
Grade I gliomas are most common in children and bear a good prognosis due to their benign
nature. Grade II gliomas are associated with a median survival of 5 to 8 years and display
increased cellularity with nuclear atypia. Grade III gliomas display higher hypercellularity and
atypia, increased mitosis, and bear a worse prognosis, with a 3-year median survival. The major
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hallmarks that distinguish Grade IV GBM from lower-grade gliomas include the presence of ex-
tensive pseudopalisading necrosis within the tumor tissue and/or marked endothelial proliferation
(Gladson et al., 2010) (Figure 2.1C).
2.1.2 Glioma stem cells
The genetic heterogeneity of GBM has been long established (Shapiro et al., 1981), and the
identification of a subpopulation of tumor-initiating cells in leukemia launched the quest for such
cells in solid tumors, including the highly heterogeneous GBM. In 2003, Singh et al. identified a
small subset of cells in pediatric brain tumors that shared some of the expected characteristics of
CSCs, in that they mimicked the NSC phenotype, expressed stemness markers, namely CD133
and nestin, and were crucial for proliferation of the tumor in vitro. Final confirmation of the
CSC model in brain tumors shortly followed, as the same group later confirmed reproduction of
the tumor in vivo upon xenotransplantation of as few as 100 CD133+ cells, whereas as many as
105 injected CD133– cells failed to form a tumor (Singh et al., 2004). In parallel, another study
further characterized tumor-initiating cells isolated from primary GBM samples and confirmed
their ability to differentiate, proliferate and reproduce the tumor of origin after serial xenotrans-
plantation (Galli et al., 2004). In GBM, the cells displaying CSC features are termed glioma
stem cells (GSCs).
Successful identification of GSCs allows to better understand and determine potential key
pathways that govern their emergence and maintenance, and that could potentially be targeted.
Indeed, GSCs are known to be involved in the various processes that lead to therapeutic resistance
and the resulting poor GBM prognosis: GSCs promote resistance to radiation (Bao et al., 2006)
as well as chemoresistance and recurrence (Chen et al., 2012), in addition to neovascularization
(Cheng et al., 2013) and invasion (Wakimoto et al., 2009). Thus, eradication of GSCs appears as
an inevitable strategy toward achieving GBM cure. Efforts to better identify and permit robust
isolation of GSCs to study these cells have been challenged by the lack of a unique cell surface
marker specific for GSCs. Thus, using a combination of several surface markers to isolate GSCs
seems to be the only alternative. This panel now includes CD133, SSEA1 and CD44 (Singh
et al., 2004; Son et al., 2009; Anido et al., 2010), although their expression is heterogeneous
among patients and can change as a result of microenvironmental cues (Dirkse et al., 2019). In
addition to surface markers, detection of intracellular proteins offers a supplementary means to
identify GSCs, as they express stemness genes such as SOX2, OLIG2 and nestin, many of which
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are also expressed in normal NSCs (Gimple et al., 2019).
In situ, GSCs have been identified in specialized GBM niches, all highly dependent on spe-
cific vascularization patterns. Brain tumor niches can present in three different constellations.
First, the perivascular niches stimulate CSC proliferation around abnormal capillaries in the
brain, where specific angiogenic signals are produced by CSCs, mainly VEGF, and survival
factors are in turn produced by endothelial cell, thus promoting CSCs propagation (Calabrese
et al., 2007). Furthermore, increased capillary leakiness facilitates entry of immune cells, in-
cluding tumor-infiltrating macrophages, monocytes, and neutrophils, that globally participate in
immune-suppressive functions and facilitate tumor propagation (Hambardzumyan and Bergers,
2015). Second, GSCs also reside in hypoxic niches. Indeed, poor perfusion is a characteristic trait
of GBM and confers supplementary stemness traits to GSCs, via induction of hypoxia inducible
factors (HIFs) (Heddleston et al., 2009; Auffinger et al., 2015). These areas of hypoxia further
develop into necrotic regions surrounded by pseudopalisading tumor cells, the signature histolog-
ical feature of GBM. These cells migrate, resulting in extension of necrosis and of inflammation.
Third, the invasive niche implicates a dialog between GSCs and the available surrounding as-
trocytes and microglia to actively invade the normal brain parenchyma along normal vascular
highways, with activation of the EMT-like program within the GSCs (Hambardzumyan and Berg-
ers, 2015). These observations reveal the multiplicity and divergence on which GSCs can rely
for their survival and progression. Moreover, the tumor environment can substantially reshape
the cells and is also responsible for GSC heterogeneity and plasticity (Dirkse et al., 2019).
2.1.3 GBM heterogeneity
As the name “Glioblastoma Multiforme” implies, Bailey and Cushing (1926) noticed early on
already that this aggressive brain tumor can take various shapes. That this heterogeneity is in
addition extensively encountered at the molecular level could not have been predicted, and has
been largely reported since. Precisely characterising and understanding the mutational landscape
of GBM increases the likelihood of finding culprit pathways crucial for GSC maintenance, and
whose targeting may represent efficient therapeutic strategies. Thanks to large-scale DNA and
RNA analyses, many recurrent genetic alterations, such as point mutations, genomic copy num-
ber alterations, epigenetic modifications, as well as commonly disrupted pathways, have been
identified in GBM during the last two decades. Particularly, highly prevalent mutations or copy
number alterations of TP53, PTEN, RB1, EGFR and PI3K, among others, helped highlight three
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main pathways that are deregulated in virtually all GBM cases, namely the RTK/RAS/PI3K
pathway, alongside the p53 and the Rb tumor suppressors pathways (The Cancer Genome Atlas
Research Network et al., 2008; Parsons et al., 2008) (Figure 2.2A).
Moreover, distinct sets of mutations are found in primary GBM and secondary GBM, based
on the knowledge collected from sequencing of lower-grade gliomas. Indeed, although they likely
originate from the same progenitor cell, a NSC, their transformation processes follow different
pathways (Figure 2.2B). By sequencing a greater number of genes in a smaller pool of GBM
samples, Parsons et al. (2008) found recurrent mutations in IDH1, a gene involved in isocitrate
oxidation. Whereas approximately 10% of primary GBM harbor mutated IDH1, a striking
majority of secondary GBM carry a IDH1 mutant. This is also the case in many grade II and III
gliomas (Dunn et al., 2012), and survival analysis revealed that mutated IDH1 is associated with
improved prognosis (Parsons et al., 2008; Yan et al., 2009). Consequentely, GBM is characterized
as either IDH1 -wild-type or IDH1 -mutant, a feature now included in the routine diagnostic
evaluation of GBM (Louis et al., 2016).
Among epigenetic alterations found in a subset of GBM, the methylation status of O6-
methylguanine-DNA methyltransferase (MGMT), which encodes a DNA repair enzyme that
removes alkyl groups from guanine bases in DNA, constitutes an essential prognostic factor.
TMZ is a widely used alkylating agent in GBM chemotherapy that causes DNA damage leading
to apoptosis. Methylation of the MGMT promoter, found in about half of GBM patients, re-
presses MGMT transcription, thereby preventing the target cell from removing TMZ-established
alkyl groups and repairing DNA. This ultimately leads to apoptotic cell death, as DNA repair
is hindered, and improves patient response to treatment. The methylation status of the MGMT
promoter has therefore become a key prediction marker for patient response to alkylating agents.
As a result, a methylated status identifies the patients who benefit most from TMZ therapy reg-
imens and correlates with better survival rates (Hegi et al., 2005).
The accumulated data from comprehensive tumor profiling has prompted researchers to im-
plement a new taxonomy to subdivide GBM, that integrates the nature and frequency of genetic
alterations across samples. In a pivotal paper, using information from 200 sequenced tumors
taken from The Cancer Genome Atlas (TCGA) database, Verhaak et al. (2010) proposed four
new categories based on the mutational profiles of GBM samples and named in accordance
with previously identified transcriptional signatures (Phillips et al., 2006): classical, mesenchy-
mal, proneural and neural. This subclassification was strengthened with further support from
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Figure 2.2: Genomic alterations underlying glioblastoma tumorigenesis. (A) Critical alterated pathways in
GBM and the frequency of mutation or amplification. Adapted from The Cancer Genome Atlas Research Network et al.
(2008). (B) Common alterations found in primary or secondary onset GBM. Primary onset GBM is mainly associated
with a IDH1 wild-type phenotype, and poorer prognosis (95% of cases). On the other hand, secondary GBM develops from
lower grade GBM, either from grade II progressing to grade III glioma, or directly from grade II glioma, with accumulation
of genetic aberrations. It is associated with mutated IDH1 and bears a better prognosis (5% of cases). Adapted from Dunn
et al. (2012).
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Figure 2.3: Gene expression and genomic alterations across the four glioblastoma subtypes. Gene expression
data (202 samples) and mutation and copy number data (116 samples) from the TCGA dataset for frequently mutated
genes. ge, gene expression; cn, copy numbers; mut, mutations. Reproduced from Verhaak et al. (2010).
publicly available independent GBM datasets. Each subtype harbors specific signature genetic
alterations (Figure 2.3), and correlates with patient survival: proneural tumors have the best
prognosis, with an expression profile that resembles that of normal brain cells and differentiating
neurons, as opposed to the mesenchymal subtype, which displays similarities to mesenchymal
tissue and is associated with a more severe prognosis.
Recently, single-cell sequencing has revealed additional heterogeneity within the tumor itself,
as subpopulations of cells with different expression profiles can co-exist within the tumor bulk
(Patel et al., 2014). GSCs, particularly, primarily cluster to the proneural and mesenchymal
subtypes. Interestingly, the majority of recurrent GBM cases display a change in phenotype
with a shift toward a mesenchymal signature (Phillips et al., 2006; Verhaak et al., 2010), which
is supported by the identification of C/EBPb and STAT3 transcription factors as major mediators
of the mesenchymal phenotype and of tumor aggressiveness (Carro et al., 2010). In line with this,
proneural GSCs have a propensity to shift toward a mesenchymal signature, and subsequently
gain resistance and other aggressive features (Bhat et al., 2013; Minata et al., 2019). Moreover,
analysis of initial and recurrent GBM showed that the tumors are not closely related, but share a
rather distant ancestor: relapsed tumors display a distinct set of mutations (Wang et al., 2016),
and initial TMZ treatment may set the grounds for clonal evolution, by inducing new mutations
and applying selective pressure on GSCs (Johnson et al., 2014).
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Still, deeper single-cell approaches noted that GBM cells share four main transcriptional
signatures and can transition from one signature to the other, under the influence of some of
the mutated genes shown in Figure 2.3 (Neftel et al., 2019). Another study showed that in
spite of distinct inter- and intratumoral mutational profiles among GBM cells, the infiltrating
cells on the tumor front share the expression of common signature genes (Darmanis et al.,
2017). Thus, while the complexity of GBM relies on extensively heterogeneous cell populations,
profiling and clustering of cells has revealed additional signatures in the most aggressive cells.
Hypothetically, because such signatures appear in the most invasive cells following exhaustive
treatment attempts, they may reflect the ideal profile acquired by an optimally aggressive cell
under the strongest selective pressures, to which malignant GBM cells may ultimately converge,
as hypothesized and modelled in breast cancer (Lloyd et al., 2016).
2.1.4 The GBM cell of origin
Debate surrounding the cell of origin of GBM long opposed the notions of GBM arising from
deregulated NSCs or from a transformed dedifferentiated astrocyte. In the last decade, a sig-
nificant body of evidence has advocated NSCs as the cell of origin of GBM, mainly based on
observations from engineered mouse models. Indeed, the various known GBM genetic mutations
successfully produced GBM-like tumors in vivo when expressed in neural progenitor cells, but
not in mesenchymal cells (Gimple et al., 2019). More compellingly, in about half of the patients,
NSCs situated in the subventricular zone (SVZ) of GBM patients share common mutations with
the matching tumor tissue, thus providing strong support for NSCs as the GBM cell of origin
(Lee et al., 2018).
2.1.5 In vivo models of GBM
Since the identification of GSCs, various approaches have been used to study these cells, both in
vitro and in vivo. Three types of in vivo models have been developed for neuro-oncology research:
chemically induced, genetically engineered, including via viral induction, and xenograft models.
Chemically induced models, mainly in rats, rely on administration of a carcinogen locally into
the brain, intravenously, orally, or through the placenta of pregnant rats. However, this approach
may seem too artificial, as human cases of GBM are generally not associated with exposure to
chemical agents. Another drawback is the inconsistency of tumor production in different species,
suggesting host-dependent tumor initiation. Additionally, the lack of molecular data and the
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uncontrolled genetic base causing transformation in these tumors questions the ability of the
chemically induced model to reliably mimic the events leading to generation and evolution of
GBM (Huszthy et al., 2012).
Several genetically engineered mouse models have been developed based on the various ge-
netic alterations repeatedly found in GBM. Mouse strains bearing one or a combination of GBM
mutations can effectively mimic the genetic alterations found in human tumors within the ap-
propriate brain location and at the appropriate timepoint, avoiding early developmental stages.
Such mouse models offer an efficient approach to study tumor initiation, and allow to include the
appropriate environment for tumor growth, which helps investigate the role of the microenviron-
ment in GBM progression. Moreover, recent application of the CRISPR-Cas9 genome editing
system in mouse models has favored the introduction of specific genetic alterations in NSCs
located in the SVZ, using nestin and GFAP promoters, which are activated in GSCs and as-
trocytes, respectively (Oldrini et al., 2018). Nevertheless, apart from the obvious time and cost
limitations, murine tumors also have the disadvantage of failing to fully replicate the complexity
of human GBM and the extent of spontaneous ITH found in humans.
Xenotransplantation of established GBM cell lines, either in the brain or in flanks of mice, al-
lows easy and straightforward assessment of changes in tumorigenicity or response to treatment.
However, as cell lines may have been extensively passaged in vitro, robustness of observations
may be dubious on the account of potential genetic drift. Thus, using primary samples is key to
maintaining tumor heterogeneity in study models, both between and within samples, based on
the knowledge that GSCs adequately replicate the tumor of origin upon injection in vivo. Indeed,
orthotopic injection of GSCs from patient-derived xenograft (PDX) into immunodeficient mice
produces fast growing invasive tumors and accurately replicates the ITH observed in patients.
PDX also offers a better approach compared to primary in vitro organoid sphere culture, taking
into account the BBB, which mimics possible challenges for drug delivery, and the physiological
environment in the brain, which provides a suitable microenvironment for GSC preservation.
Moreover, it facilitates drug testing in different samples, as possible disparate responses between
samples can be addressed as needed by further characterization of the samples to identify spe-
cific factors that may influence drug response. Therefore, as our lab has access to many well
characterized patient-derived GBM samples, we favored the orthotopic PDX approach for the
different in vivo studies presented later in this chapter.
56 CHAPTER 2. GLIOBLASTOMA
2.1.6 Non-coding RNAs in GBM
Following tumor dissociation and surface marker selection, GSCs can be grown and expanded as
organoid spheres, and their CSC properties must be confirmed. Importantly, there is compelling
evidence highlighting the role of epigenetic pathways for the maintenance of the tumorigenic
properties of GSCs, suggesting that the superimposed effects of genetic alterations and epige-
netic modulation work together to support GSC aggressiveness (Stricker et al., 2013; Rheinbay
et al., 2013; Suvà et al., 2014; Flavahan et al., 2016). Indeed, GSCs require specific serum-free
culture conditions and the presence of distinct growth factors to proliferate and maintain their
properties (Lee et al., 2006). Upon exposure to serum in the culture medium, GSCs lose their
tumorigenic potential and mimic the more differentiated tumor bulk, thus profoundly changing
the cell identity (Degrauwe et al., 2016a). It is currently unknown why exposure to serum leads to
such profound changes in the cell behavior and expression profile, but this undeniably reiterates
the notion that epigenetic changes are a key component of cell plasticity and maintenance of the
stem cell phenotype in GSCs. Identifying the epigenetic pathways involved in stemness main-
tenance could thereby help find interesting approaches to eradicate the tumor effectively. The
central role of ncRNAs as regulators of broad gene expression networks places these transcripts
under the spotlight as potentially important mediators of the identity of GSCs.
As mentioned previously, the involvement of miRNAs in oncogenesis is now widely recognized.
In GBM particularly, miRNA microarrays have uncovered patterns of miRNA expression that are
specific to GSCs, with both tumor-initiating and tumor suppressive miRNAs. Indeed, several
common up-regulated miRNAs can target transcripts involved in the p53 tumor suppressive
pathway, thereby appearing to function as oncomiRs. Conversely, identified down-regulated
miRNAs mainly target transcripts of proteins involved in the IGF signaling pathway, involved in
cellular growth and proliferation (Lang et al., 2012) (Figure 2.4). In all these studies, Targetscan
has provided a valuable tool in bringing light into the pathways downstream of miRNAs. Indeed,
this database regroups the seed region of miRNAs and identifies possible binding sites in the
3’UTR of target mRNAs, allowing to further test this interaction in the cancer model of interest
(Agarwal et al., 2015). For example, miR-10b, which is strongly over-expressed in GSCs, was
found to repress several targets in cell cycle and apoptotic regulating pathways in GBM and its
inhibition can block tumor growth in vivo (Gabriely et al., 2011). Similarly, miR-21 was found
to downregulate IGFBP3, thereby stimulating the IGF pathway and promoting GBM growth
(Yang et al., 2014). On the other hand, miR-340 is down-regulated in GSCs and its reactivation
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Figure 2.4: Dysregulated miRNAs and targeted pathways in GBM. (A) Up-regulated miRNAs targeting the p53
signaling cascade, thereby down-regulating key factors involved in inhibition of angiogenesis and metastasis, apoptosis and
DNA repair pathways. (B) Down-regulated miRNAs targeting the IGF pathway. Failure to inhibit this cascade promotes
survival, growth and migration. Adapted from Lang et al. (2012).
induces cell differentiation and decreased invasion and proliferation by restoring repression of a
serine/ threonine kinase (Huang et al., 2015).
These observations lead to a central question: what are the mechanisms contributing to the
observed changes in the miRNA repertoire and their impaired function? It was first reported
that the loci of many dysregulated miRNAs are often located at fragile sites, prone to genetic
aberrations (Calin et al., 2004). Interestingly though, the genes encoding the miRNAs whose
expression change the most in GBM are not located in such regions, suggesting epigenetic regula-
tion of their expression in tumor cells, either at the transcriptional level, or post-transcriptionally
(Ciafre et al., 2005). Little is known about the exact mechanisms responsible for shifting miRNA
expression in malignant cells, and this issue needs to be addressed to better exploit the mecha-
nisms in place that regulate the miRNA profile proper to GSCs.
As exemplified by the important impact of the MGMT promoter methylation, the DNA
methylome can strongly impact the cell machinery and significantly alter the transcriptome.
Thus, it is likely involved, at least in part, in the silencing of tumor-suppressive miRNAs. Ex-
pression of various TFs may also influence transcription of miRNAs, and impaired miRNA matu-
ration also contributes to malignant transformation (Kumar et al., 2007). In particular, function
of miRNAs of the let-7 family is disrupted post-transcriptionally in GSCs, as they are actively
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transcribed in GSCs, but their target transcripts, such as HMGA2 and IMP2, do not undergo
silencing or degradation (Degrauwe et al., 2016a). Therefore, restoring let-7 function in GSCs
could constitute a potentially attractive therapeutic approach to abrogate the stemness mecha-
nisms in place.
In the projects presented here, we first aimed to reverse the stemness phenotype of GSCs by
attempting to increase let-7 levels, which may restore their tumor suppressive function. Next,
we explored another post-transcriptional pathway involved in let-7 regulation, by investigating
the role of H19 in GSCs, a lncRNA that can sequestrate let-7 miRNAs.
2.2 Targeting glioma stem cells using a small molecule
2.2.1 Background
Expression of let-7 miRNA family is decreased in many tumor types, and global changes in the
miRNA repertoire are widely associated with maintenance of stemness features. However, no
significant difference in let-7 expression is found between the tumorigenic neurospheres and the
more differentiated adherent GBM-derived cells. Nevertheless, levels of let-7 target mRNAs are
significantly higher in GSCs than in adherent GBM cells, despite the lack of LIN28B expression,
which is a common post-maturation repressor of let-7 miRNAs (Degrauwe et al., 2016a). Previous
work from the lab has shown that let-7 target silencing in GSCs is prevented by IMP2, an RBP
essential for GSC survival (Janiszewska et al., 2012). Indeed, IMP2 binds let-7 mRNA targets and
protects them from let-7 mediated decay, thereby contributing to GSC maintenance (Degrauwe
et al., 2016a).
In EwS, miRNA maturation was found to be disrupted through partial reversible repression
of TRBP2 activity in CSCs, causing downregulation of miRNA expression and boosting cell tu-
morigenicity (De Vito et al., 2012). Stimulation of TRBP2, an integral component of a DICER
complex involved in miRNA maturation, by the fluoroquinolone enoxacin, a well tolerated flu-
oroquinolone used in the treatment of urinary tract infections, showed significant upregulation
of miRNAs, restoring the cell miRNA repertoire (Shan et al., 2008; Melo and Esteller, 2011).
Previously, our lab showed that enoxacin in combination with doxorubicin, a chemotherapeutic
agent commonly used in current EwS treatment, could markedly reduce tumorigenicity of EwS
in xenotransplanted mice and improve their survival (Cornaz-Buros et al., 2014).
Based on the data generated with EwS, and having a drug in our hands that showed significant
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reduction of EwS tumorigenicity, we were prompted to test whether this small molecule could
also be effective in other tumors with deregulated miRNA function. As opposed to findings in
EwS, the let-7 miRNA expression levels in GSCs are similar to those in their non-tumorigenic
counterparts (Degrauwe et al., 2016a). However, increasing the activity of TRBP2 could lead to
increased expression of these miRNAs, thus overriding the regulatory effect of IMP2 in GSCs.
For this reason, GBM appears as an interesting candidate to assess the possible application of
enoxacin to other tumor types as a means to target CSCs that present a deregulated miRNA
expression profile. By increasing mature miRNA levels in GSCs, target mRNA silencing may
be restored, shifting cells to a more differentiated state and rendering them more sensitive to
therapy.
Here, we assessed the efficacy of enoxacin in primary GSCs as a means to decrease the
tumorigenic potential of these cells, both in in vitro and in vivo settings. To potentiate its efficacy,
we considered the possibility of using enoxacin in combination with TMZ in the treatment of
GBM.
2.2.2 Results
Enoxacin inhibits GSC organoid growth in vitro
We first tested sensitivity to enoxacin of five GBM samples obtained from patient tumors, namely
MGH 4, 8, 26, 28 and 31, which were isolated following tumor resection and maintained in cul-
ture in serum-free conditions as organoid sphere suspensions (Rheinbay et al., 2013; Wakimoto
et al., 2011; Patel et al., 2014; Suvà et al., 2014). To assess the effects of enoxacin on GSC cell
clonogenicity, single-cell clonogenic assays were performed in organoid culture medium supple-
mented with different concentrations of enoxacin (10 μg/mL or 40 μg/mL), and compared to a
control condition containing the maximum equivalent volume of 20mM NaOH. As MGH8S (S,
organoid spheres) was more difficult to grow and did not show any organoid growth when plated
at low density, even in control conditions, we plated cells from this sample at a higher density
of 25 cells per well. Overall, we observed a general decrease and inhibition of clonogenicity
in the presence of enoxacin, which was concentration-dependent for all samples (Figure 2.5A).
Sphere formation assays were performed with the same medium conditions and showed overall
concentration-dependent organoid growth inhibition in all primary GBM samples tested (Fig-
ure 2.5B).
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Characterization of GSC expression profile after incubation with enoxacin
Based on the fact that enoxacin increases affinity of TRBP2 for miRNAs leading to increased
miRNA maturation, we looked at the miRNA expression profile of cells after one week of exposure
to enoxacin or control medium. Specifically, we first checked whether levels of the let-7 family
members were increased using quantitative real-time PCR (qRT-PCR), as these miRNAs are
known to be key players in stemness regulation. We also looked at expression levels of miR-
143 and miR-145, as this cluster of miRNAs has been shown to be downregulated in GSCs
and represses essential transcription factors involved in embryonic stem cell maintenance (Lee
et al., 2013; Xu et al., 2009b). MGH4S tends to show an increase in miRNAs at low enoxacin
concentrations, whereas MGH8S displays an increase in miRNAs in response to enoxacin in a
concentration-dependent manner.
In order to confirm that loss of clonogenicity in cells was linked to increased miRNA levels
after enoxacin incubation, we compared the expression levels of various miRNA targets. Contrary
to what we expected, transcript levels of miRNA targets, including IMP2, HMGA paralogs and
RRM2, were not negatively regulated but instead remained stable or were increased upon drug
exposure (Figure 2.5D).
Analysis of protein expression in MGH28S following exposure to enoxacin confirmed that
TRBP2 expression was unaffected, as expected from previous work (De Vito et al., 2012). Also,
expression of the let-7 target transcript IMP2 remained unchanged. However, HMGA2 expression
was discreetly lower in cells treated with higher doses of enoxacin. Expression of stemness genes
such as and SOX2, which are downregulated in the presence of miR-145, remained unchanged
after treatment (Figure 2.5E). Thus, we need to further explore the mechanisms that cause
enoxacin to induce the reduced spherogenicity of organoid-derived cells observed in vitro.
Assessment the effect of enoxacin in vivo
Upon observing the effect of enoxacin on GSC clonogenicity in vitro, we interrogated the im-
pact of enoxacin treatment on GSC tumorigenicity in vivo. We injected 15’000 MGH4S or
10’000 MGH28S cells into the brains of NOD-SCID gamma mice and allowed the tumors to
engraft for four weeks, after which mice were divided into four groups (five mice per group), and
treated either with a control 20% DMSO solution, enoxacin alone (50mg/kg/day), TMZ alone
(40mg/kg/day), or a combination of both enoxacin and TMZ, for a total period of three weeks
with daily intraperitoneal injections (five injections per week). At the end of the treatment,
2.2. TARGETING GLIOMA STEM CELLS USING A SMALL MOLECULE 61
Figure 2.5: Effects of enoxacin on GBM organoids in vitro. (A) Clonogenic assays using single cells (MGH4S,
MGH26S, MGH28S, MGH31S) or 25 cells (MGH8S) per well. Results are shown as percentage of organoid formation
after three weeks in control medium containing NaOH 20mM (reference value), or in medium supplemented with enoxacin
(10 μg/mL or 40 μg/mL). One-way ANOVA was used for statistical analysis. (B) Sphere formation assay. Results are
shown as the total number of spheres counted in each 96-well plate after three weeks in control medium with NaOH 20mM,
or in medium supplemented with enoxacin (10 μg/mL or 40 μg/mL). One-way ANOVA was used for statistical analysis.
(C) Expression of miRNA in tumors MGH4S and MGH8S after enoxacin exposure for seven days, assessed by qRT-PCR,
normalized to control medium containing NaOH 20mM. Data are presented as mean± SD. Two-way ANOVA was used
for statistical analysis. (D) Expression of let-7 mRNA targets in tumors MGH4S and MGH8S after enoxacin exposure
for seven days, assessed by qRT-PCR, normalized to control medium containing NaOH 20mM. Data are presented as
mean± SD. Two-way ANOVA was used for statistical analysis. (E) Western blot of MGH28S in control (NaOH 20mM) or
enoxacin-containing medium after seven days. Tubulin and GAPDH were used as loading controls. *P < .05, **P < .01,
***P < .001, ****P < .0001.
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Figure 2.6: Experimental design for in vivo drug testing. Treatment was initiated four weeks following orthotopic
injection of primary GBM. Mice were separated into four groups and underwent four different treatment regimens four
three weeks: DMSO as a control, enoxacin, TMZ, or combination of enoxacin and TMZ. Following treatment, three mice
per group would be randomly chosen for tumor extraction and immediate subsequent analysis, while two other mice would
be kept for a first estimation for survival.
three mice were sacrificed. Brain tumor tissue was then extracted for histological analysis, RNA
extraction and fluorescence-activated cell sorting (FACS) analysis for detection of CD133+ cells.
The two remaining mice were left for first estimative survival data (Figure 2.6).
Mice from the control group and the enoxacin treatment group had to be sacrificed before
the end of the therapy, as they started exhibiting signs of tumor growth before the scheduled
date of euthanasia. Brain autopsy confirmed the presence of a tumor in these mice. Mice from
the TMZ and combination groups did not exhibit any symptoms at the time of sacrifice and
no tumor was visible upon brain dissection. Overall, survival of mice in the control group was
similar to that in the group treated with enoxacin. In contrast, survival of mice treated with
TMZ or combination therapy was significantly improved (Figure 2.7A).
We proceeded to tumor dissociation and used flow cytometry to assess the proportion of
CD133+ cells within the tumor bulk, and to determine whether tumors treated with enoxacin,
alone or in combination, may display a reduced proportion of CD133+ cells. Enoxacin treatment
caused an important decrease in CD133+ cells from MGH28S-derived xenografts, but displayed
no advantage when used in combination with TMZ compared to treatment with TMZ alone.
However, the absolute number of cells sorted from enoxacin-treated MGH28S xenograft was
notably lower than in other samples (data not shown). In MGH4S xenografts, control-treated
samples showed low initial numbers of CD133+ cells. The proportion of GSC-like cells was
increased in the enoxacin and/or TMZ treated samples. This result contradicted our hypothesis,
especially as TMZ-treated samples, alone or in combination, showed no visible tumor upon
dissection, so that we went on to perform analysis from brain parenchyma located near the area
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of tumor cell injection. Therefore, samples from these groups possibly consisted essentially of
mouse cells, while the antibody used was directed against human CD133 (Figure 2.7B and C).
According to the CSC paradigm and current definitions, GSCs that are isolated based on
expression of cell surface markers such as CD133 are able to recreate organoids in vitro (Singh
et al., 2003). In order to confirm our flow cytometry results, we kept a fraction of the cells
extracted from MGH4S-derived brain tumors from all four treatment conditions, to assess the
clonogenic potential of xenograft-derived cells. After 10 days of culture in neurosphere medium,
only the cells from control or enoxacin treated xenografts continued to proliferate, while those
treated with TMZ, alone or in combination, showed no signs of growth (Figure 2.7E). Thus,
whereas TMZ seemed to have successfully eradicated GSCs from the tumor, enoxacin appears
to have not impacted GSC survival and maintenance in vivo.
Exposure of organoids derived from xenografts to enoxacin after treatment
We assessed whether the effect previously seen in vitro would still be seen on organoids derived
from the xenografts, which would suggest the limited effect of enoxacin in vivo was possibly
due to the delivery method of enoxacin treatment. We repeated sphere formation assay on
cells from xenografts treated with DMSO or enoxacin alone. Surprisingly, lower concentration
of enoxacin (10 μg/mL) had no effect on organoid formation this time, whereas cell prolifera-
tion was completely suppressed upon exposure to higher concentrations of enoxacin (40 μg/mL)
(Figure 2.7D).
Testing toxicity of enoxacin on GBM-derived adherent cells
Based on our observations, enoxacin may in fact exhibit a general toxicity to cells that leads to the
inhibition of clonogenicity observed in our first set of experiments in vitro (Figure 2.5). To test
this, we compared proliferation of spheroids and GBM-derived adherent cells in the presence of
enoxacin at different concentrations. Because miRNA pathways are restored in the non-tumor-
initiating adherent GBM-derived cells, the TRBP2-mediated effect of enoxacin is expected to
have little to no effect on adherent cell proliferation. Surprisingly, while there was no decrease in
cell proliferation at lower doses, proliferation seemed to be similarly impaired in both spheroids
and adherent cells with higher levels of enoxacin, suggesting that enoxacin does not affect tumor
initiating GBM cells specifically. Therefore, the decrease of clonogenicity in organoids detected
initially may have resulted from general toxicity of the drug at higher doses (Figure 2.8).
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Figure 2.7: Effects of enoxacin on primary GBM organoids in vivo. (A) Kaplan-Meier survival curves of
mice injected with 15’000 MGH4S or 10’000 MGH28S, subsequently treated with 20% DMSO control solution, enoxacin
(50mg/kg/day), TMZ (40mg/kg/day) or combination of enoxacin and TMZ. The treatment window is indicated on the x
axis. Five mice per group; except for MGH4S 20% DMSO, four mice in group. P-values were calculated using log-rank test.
(B) FACS analysis of CD133+ cells (blue) from MGH28S tumor after dissociation of tumor xenograft from mice treated
with 20% DMSO, enoxacin, TMZ or combination therapy. (C) Percentage of CD133+ cells in the live cell population
in MGH28S and MGH4S tumors after dissociation of the tumor xenograft. CTRL, DMSO treatment; Enox, enoxacin
treatment alone; TMZ, TMZ treatment alone; Enox+TMZ, combination therapy. (D) Organoid sphere formation assay
of MGH4S cells after brain tumor dissociation from mice treated with 20% DMSO or enoxacin. Cells were incubated in
control medium with 20mM NaOH (CTRL) or re-exposed to enoxacin at 10 μg/mL or 40 μg/mL. (E) Representative images
of MGH4S cells grown in normal organoid culture conditions for 10 days after brain tumor dissociation from mice treated
with 20% DMSO, enoxacin, TMZ or combination therapy. The scale bars represent 200 μm.
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Figure 2.8: Toxicity of enoxacin in vitro in organoids versus adherent GBM-derived cells. Representative
images of organoid spheres (MGH28S, top) and their adherent counterparts (MGH28A, bottom) after exposure to control
medium or enoxacin for three days. The scale bars represent 100 μm.
2.2.3 Discussion
GSCs eradication is a central challenge in the treatment of GBM. Characterization of this tu-
morigenic subpopulation of cells revealed that, despite maintaining active expression of miRNAs,
target transcripts involved in stemness pathways are not downregulated (Degrauwe et al., 2016a).
Thus, we hypothesized that by further boosting the expression of miRNAs, we would restore
their function and repress essential tumorigenic pathways of GSCs. To do this, we tested a small
molecule, enoxacin, which can stimulate TRBP2 activity and the miRNA biogenesis pathway,
as shown previously in EwS (De Vito et al., 2012; Cornaz-Buros et al., 2014). We used exclu-
sively primary GBM samples, as they better represent the heterogeneous and complex behavior
of human tumors.
We first noted an important effect of enoxacin on organoid clonogenicity, but the mechanisms
of this change in cell behavior were not related to variations in let-7 target transcripts levels,
as shown by mRNA expression analysis and Western blotting. More importantly, no change
in tumorigenicity was seen in vivo. It can be argued that the delivery method of the drug
was not ideal. However, a paper showed intraperitoneal injections of enoxacin in rats increased
overall miRNA levels in the brain after one week of treatment, thus proving enoxacin adminis-
tered peripherally can pass the blood-brain barrier sufficiently to have a local effect (Smalheiser
et al., 2014). Furthermore, we used doses almost twice as high as in the aforementioned study,
suggesting our method of enoxacin delivery was most likely adequate.
In patients, TMZ dosage is calculated based on body surface, aiming a range of 70 to
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200mg/m2 depending on the therapy regimen. In mice, however, the dose is calculated based
on weight. Thus, in vivo drug assays use a range of 25 to 50mg/kg, which best reflect the
doses used in humans (Middlemas et al., 2000). We chose a dosage of 40mg/kg/day in our
study, which is consistent with current in vivo applications. By selecting a slightly lower dose
than the maximum 50mg/kg/day, we aimed at adjusting the experimental conditions to detect
a synergetic effect of TMZ when used in combination, in line with the general goal of reducing
chemotherapy doses in patients to lower the morbidity associated with the treatment. However,
the remarkable efficiency of TMZ in completely annihilating tumor growth in our experiments
came as a surprise. Indeed, response to TMZ largely depends on methylation of the MGMT
promoter. The MGMT promoter is unmethylated in MGH28S, as opposed to MGH4S, which
has a methylated promoter (Supplementary Table S1.1) (Wakimoto et al., 2011). Surprisingly,
both samples displayed a strong response to TMZ therapy, independently of their methylation
status. This unexpected observation highlights the limitations of in vitro and in vivo studies for
drug testing, and demonstrates the importance of translational medicine in effectively building
the bridge from bench to bedside.
Adherent cells derived from GBM lack tumorigenic potential and display a shift in their
expression profile, with the repression of several miRNA target transcripts. Thus, these cells
are theoretically insusceptible to enoxacin exposure. Nonetheless, when comparing toxicity of
enoxacin in spheroids and in non-tumorigenic GBM-derived cells, it appeared that enoxacin had
a general toxic effect at a high concentration on cells, rendering our first observations in vitro
unspecific.
Whereas enoxacin gave very promising results in EwS (Cornaz-Buros et al., 2014), our results
speak against a potential therapeutic role of this small molecule in GBM. As miRNA levels are
conserved in GBM, unlike in EwS, it may be more difficult to simply increase their expression
by increasing the affinity of TRBP2, and other mechanisms may already counteract miRNA
activity in a strong manner. Arguably, TRBP2 activity may have already reached its peak in
GSCs, as levels of let-7 miRNAs are indeed elevated in GBM, as opposed to EwS. Thus, as
enoxacin increases TRBP2 activity, but not its expression level, further TRBP2 stimulation may
not be possible. Therefore, stimulation of TRBP2 may not represent a good approach to restore
function of miRNAs in GSCs. For these reasons, we decided to not further explore the application
of enoxacin to GBM, as our observations point to inefficacy of this small molecule as a means to
eradicate GSCs. This prompted us to investigate other let-7 regulatory mechanisms in GBM.
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2.3 The role of long-non-coding RNA H19 in GBM
2.3.1 Background
The role of epigenetic alterations and mutations in non-coding genes and regulatory DNA se-
quences are being increasingly linked to oncogenic events in various cancer types, by affecting
transcription and the resulting cell phenotype. A growing body of evidence points to lncRNAs
as putative mediators of cancer development, contributing to the six initial hallmarks of cancer
(Hanahan and Weinberg, 2000), and their expression patterns have in some cases been linked to
prognosis (Schmitt and Chang, 2016).
Testing enoxacin as a means to increase levels of let-7 and other miRNAs in GSCs failed
to restore miRNA activity. Therefore, we should explore another approach to reestablish let-7
function. We previously mentioned the implication of IMP2 in GBM. While IMP2 was first
reported to maintain oxidative phosphorylation in GSCs, its function as an RBP, by binding to
let-7 target mRNA transcripts, was also determinant for GSC maintenance (Janiszewska et al.,
2012; Degrauwe et al., 2016a). From the data collected in our lab, PAR-CLIP revealed that
IMP2 binds several lncRNAs in GSCs, exclusively in organoids. Among these lncRNAs, H19
was the most abundant.
H19, a 2.3 kbp-long ncRNA, which undergoes splicing and adenylation, is a highly conserved
maternally expressed gene and belongs to an imprinted cluster on chromosome 11, where it is
reciprocally expressed with the paternal allele insulin-like growth factor 2 (IGF2), with which
H19 shares common enhancers. Alterations in the regulation of the chromosome 11p15.5 locus
lead to various disorders and increased risk of cancer. Loss of H19 expression and biallelic expres-
sion of IGF2 are responsible for the Beckwith-Wiedemann syndrome, associated with overgrowth
and predisposition to malignancies, whereas loss of IGF2 expression and biallelic expression of
H19 is associated with Silver-Russel syndrome, defined as restriction and retardation of growth,
with facial dysmorphia (Angrand et al., 2015). Furthermore, H19 expression tightly regulates
hematopoietic stem cell renewal (Venkatraman et al., 2013). Similar to several oncofetal pro-
teins, H19 is highly expressed in embryogenesis, is repressed after birth and remains silenced in
differentiated cells, but is often reactivated in cancers (Kallen et al., 2013).
Mechanistically, H19 may act in multiple ways. Histone modifying proteins, such as the
Polycomb histone methyltransferase EZH2, can be recruited by H19 in order to induce target
gene silencing (Luo et al., 2013). Other mechanisms of action involve binding to and inactivation
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Figure 2.9: The various mechanisms of action of H19. H19 can act both at the transcriptional level, by recruiting
PRC2 and other chromatin modifying factors, and at the post-transcriptional level, either by sequestering miRNAs, such as
let-7, by binding several proteins and affecting downstream cascades, or by repressing target transcripts trough its processing
into miR-675. Adapted from Angrand et al. (2015).
of the tumor-suppressor TP53 (Yang et al., 2012). To add to the complexity of the role of H19,
this lncRNA can be processed into a miRNA from the first exon, namely miR-675, involved in
skeletal muscle differentiation and regeneration (Dey et al., 2014). Several studies showed that
the tumor promoting function of H19 is mediated by miR-675 itself, such as in breast cancer
(Vennin et al., 2015) and GBM (Zhang et al., 2016b). Most importantly, H19 contains several
let-7 binding sites and can exert a sponge effect on let-7 miRNAs, limiting their availability in
the cell (Kallen et al., 2013).
In this study, to explore the function of H19 in GSCs, we addressed the effects of H19 depletion
in tumor-initiating cells. As the CRISPR system allows a much more specific and efficient
way to repress gene expression, it is interesting to apply this technology for lncRNA silencing.
However, because the traditional CRISPR-Cas9 method introducing local indel mutations relies
on copy frameshift or introduction of premature stop codons in protein coding sequences, it is
not suited for application to non-coding sequences, as ncRNAs may still conserve some biological
function despite point mutations. Thus, the CRISPR-intermediated interference (CRISPRi)
system can circumvent this issue (Qi et al., 2013; Gilbert et al., 2013). It uses the same guide
RNA (gRNA) strategy to recognize and bind the target of interest, but the CRISPR-associated
endonuclease 9 (Cas9) here is inactive (dCas9) and fused to a Krüppel associated box (KRAB)
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domain. Binding of the CRISPRi-KRAB complex inhibits gene transcription by recruitment
of chromatin modifying complexes and trimethylation of Lysine 9 on histone 3 (H3K9me3),
resulting in significant silencing of target transcription. Thus, in order to target H19, we used
the CRISPRi tool with a set of top-four gRNAs targeting lncRNA H19 around the transcription
start site (TSS), as chosen from the datasets from a CRISPRi Non-Coding Library (CRiNCL)
(Liu et al., 2017) and based on predicted scores following the hCRISPRi-v2.1 algorithm (Horlbeck
et al., 2016) (Supplementary Table S1.3).
Analysis of transcriptomic data from previous work reported that H19 is uniformly expressed
in GBM (Zhang et al., 2015), suggesting a possible role in GSCs. Because H19 can repress
let-7 miRNAs by acting as a sponge, and bind IMP2, which also regulates the let-7 pathways,
we hypothesized there may be a reciprocal interplay between H19 and IMP2. Therefore, we
investigated the nature and biological relevance of the interactions between IMP2 and H19 in
GSCs, using the primary GBM samples present in our lab.
2.3.2 Results
H19 expression correlates with poor patient survival
Based on RNA-sequencing data from the TCGA database, we found that elevated H19 expression
correlates with poor prognosis in GBM (Figure 2.10A). In contrast, expression of H19 does not
affect prognosis of low-grade gliomas, suggesting involvement of H19 in more aggressive tumors
only (Supplementary Figure S1.1A). Interestingly, although there is no statistical difference in
the expression levels of H19 among the four GBM subtypes (data not shown), H19 expression
is more strongly correlated with poor survival in the mesenchymal and proneural subtypes (Fig-
ure 2.10B). The other subtypes showed no statistical correlation with survival (data not shown).
This apparent contradictory observation could be explained by the fact that H19 activity is
context-dependent, and is based on its interaction with other partners, either with RBPs or
RNAs. Therefore, we looked at the genes whose expression is upregulated in tumors expressing
high levels of H19. We found that IMP2 was among the 100 most upregulated genes, and other
known let-7 targets were also found among the top 500 upregulated genes, which is consistent
with the known function of H19 as a let-7 sponge (Supplementary Table S1.2).
Characterization of primary GBM samples
We used six primary tumor samples, which can be grown either in serum-free conditions as
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organoid spheres, that maintain a tumorigenic potential, or in serum containing medium as
adherent non-tumorigenic cells. Most of the primary samples used in this study have been
previously described, namely MGH 4, 8, 11, 26, 28, and 31 (Rheinbay et al., 2013; Wakimoto
et al., 2011; Patel et al., 2014; Suvà et al., 2014), and some characteristics of most of the samples
are listed in Supplementary Table S1.1. Tumorigenicity of organoids in vivo has been well
characterized for tumors MGH4, 8, and 11, with as few as 500 spheroid-derived cells able to
form tumors, whereas as many as 100’000 adherent cells did not show tumor initiating capacity
(Degrauwe et al., 2016a). Therefore, we tested tumorigenicity of organoids and adherent cells
derived from the three other samples, namely MGH26, 28 and 31. Cells were grown as organoids
and a subset of cells was exposed to serum, which generated adherent progeny (Figure 2.10C).
After injection into immunocompromised mice, 1’000 organoid-derived cells from MGH26 and
MGH28 formed tumors within three months. In contrast, adherent cells from MGH26 did not
form tumors. Adherent cells from MGH28S organoids, however, formed a mass when injected
at high numbers, but not when injected at lower density (Figure 2.10D). Surprisingly, MGH31S
did not form any tumors, even after injection of 100’000 spheroids in the mouse brain (data
not shown). Therefore, as MGH31S cells seem to lack tumor-initiating capacity, MGH31 was
excluded from any further analysis.
Next, we looked at the overall expression levels of the IMP paralogs, as well as a known IMP2
mRNA target, namely HMGA2, and H19, in primary tumor samples, comparing organoids to
their corresponding adherent cells. Although IMP1 is more abundant in GSCs than in adherent
cells, it was generally detected at late cycles on qRT-PCR, with Ct values around 30-35 cycles.
IMP2 and IMP3 were considerably more abundant in all organoid samples than in their adherent
counterparts (Figure 2.10E). We also found that expression of IMP paralogs in cell lines U-87
and U-251 is similar to or lower than in adherent cells, but the expression of the let-7 target
HMGA2 varies substantially (Supplementary Figure S1.1B). Therefore, cell lines do not offer an
adequate representative cellular environment to investigate the function of these molecules, and
appear to behave following distinct rules compared to organoids enriched in GSCs. Based on our
observations, with relatively low expression compared to other IMPs, IMP1 is likely not essential
for tumorigenic potential in GSCs. Thus, we decided to focus on IMP2 and IMP3 in subsequent
investigations. Interestingly, H19 was virtually undetected in MGH31 (data not shown). Hence,
the failure of MGH31S to form tumors upon injection in vivo (Figure 2.10D) is in line with the
hypothesis that H19 may be a relevant player in regulating GSCs properties.
2.3. THE ROLE OF LONG-NON-CODING RNA H19 IN GBM 71
Figure 2.10: H19 is correlated with poor prognosis and is expressed in GSCs. (A) Kaplan-Meier overall survival
curves for GBM patients with low (blue) or high (red) H19 expression. Data was obtained from the TCGA database and
the curve used RNA-sequencing data from 154 primary GBM. P-value was calculated using log-rank test. (B) Kaplan-
Meier overall survival curves for the mesenchymal (Mes) and proneural (PN) GBM subtypes based on low (blue) or high
(red) H19 expression. P-values were calculated using log-rank test. (C) Representative image of tumorigenic organoids
enriched in GSCs grown in serum-free conditions (S, organoid spheres, left panel) and adherent cells growing as a monolayer
following exposure to serum (A, adherent, right panel). The scale bars represent 100 μm. (D) Kaplan-Meier survival curves
of mice following injection of organoids (S) and adherent (A) cells (100’000, 10’000 or 1’000 cells) from tumors MGH26
(upper panel) and MGH28 (lower panel). n =3 mice per group. P-values were calculated using log-rank test. (E) mRNA
expression profiles of IMPs and their mRNA target HMGA2 in organoids (S) versus adherent (A) cells in five primary GBM
samples (upper panel), and expression profile of H19 in organoids versus adherent cells in four primary GBM samples (lower
panel), measured by qRT-PCR. Values in adherent cells were used as reference. Results are shown as mean± SD. Two-way
ANOVA was used for statistical analysis. *P < .05, **P < .01, ***P < .001, ****P < .0001.
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Overexpression of H19 increases IMP2 binding and GBM clonogenicity
We next overexpressed H19, cloned into a lentiviral plasmid (pLIV), to determine whether it
might increase the tumorigenic potential of GSCs. For this, we used MGH4S, as this sample
displayed the lowest detectable expression of H19 (Figure 2.10E and Figure 2.11A, left panel).
We further confirmed successful induction of H19 in established GBM cell lines U-251 and U-
87, in which no endogenous H19 expression was detected (Supplementary Figure S1.1B and
C). Interestingly, we noticed that miR-675, the miRNA product of H19, was also significantly
overexpressed, suggesting that the exogenous H19 is intact and can be actively processed by the
cell. Based on the panel of genes that are most strongly expressed in high H19-expressing GBM
(Supplementary Table S1.2), we observed that their expression was not significantly induced by
H19 overexpression, with the marginal exception of IMP2 (Figure 2.11B, left panel). Western
blot analysis, on the other hand, did not show significant increase of IMP2, suggesting that IMP2
levels change only at the transcript level but without a change in its translation into protein.
Furthermore, the discrete changes seen in stemness genes NANOG and SOX2 do not reflect
a clearly increased stem cell profile. Although let-7 miRNAs were discretely decreased upon
H19 overexpression, this reduction was not statistically significant (Figure 2.11B, right panel).
Therefore, it seems that the overall expression profile of the cell remains stable despite a strong
induction of H19.
Intriguingly, IMP2 RNA immunoprecipitation (RIP) performed on MGH4S with or without
H19 induction shows that IMP2 binds massively more H19 transcripts upon H19 overexpression.
Moreover, IMP2 appears to bind other target transcripts more readily in the presence of H19,
as exemplified by HMGA2 (Figure 2.11C). Knowing that IMP2 protein levels are stable upon
overexpression of H19, results from the IMP2 RIP suggest that the amount of H19 transcripts
present in the cell strongly influence the relationship with its binding partner IMP2.
Finally, to address whether H19 overexpression may affect the cell phenotype, we first per-
formed single-cell clonogenic assays. Indeed, clonogenicity of MGH4S was significantly increased
upon overexpression of H19 (Figure 2.11D), promptings us to further investigate the behavior
of cells upon H19 expression.
Overexpression of H19 in vivo
To assess the effect of H19 overexpression in vivo, we injected 10’000 MGH4S cells, with or
without H19 induction, into the brains of immunosuppressed mice. Surprisingly, H19 did not
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Figure 2.11: H19 overexpression in MGH4S. (A) Overexpression of H19 and its corresponding miRNA, miR-675,
in MGH4S. Two-way ANOVA was used for statistical analysis. (B) Expression levels of a panel of genes measured by
qRT-PCR. Genes analyzed include mRNA transcripts of the IMP paralogs, a set of genes that are induced in high-H19
GBM, and two stemness genes, NANOG and SOX2 (left panel), and expression levels of miRNAs from the let-7 family,
miR-143 and miR-145 (right panel), in control (pLIV empty) and H19-induced cells (pLIV H19). The Western blot image
shows levels of IMP2 protein in control (CTRL) or H19 induced (H19) samples. Results are shown as mean± SD. Two-
way ANOVA was used for statistical analysis. (C) RNA immunoprecipitation of IMP2 shows enrichment for H19 and
HMGA2 in cells overexpressing H19 (pLIV H19) compared to control cells (pLIV empty), assessed by qRT-PCR (left
panel). Western blot images of the corresponding RIP experiment confirms isolation of IMP2 (right panel). (D) Single-
cell clonogenic assay in MGH4S control (pLIV empty) or overexpressing H19 (pLIV H19). Student’s t-test was used for
statistical analysis. (E) Kaplan-Meier survival curves of mice following orthotopic injection of 10’000 MGH4S cells (control,
pLIV empty versus H19 overexpression, pLIV H19). n =6 mice per group. P-value was calculated using log-rank test. (F)
Left panels, Representative pictures of the mouse brain at the time of sacrifice following orthotopic injection of MGH4S
control (pLIV empty, top) or overexpressing H19 (pLIV H19, bottom). The tumor is indicated with an arrowhead. Right
panels, Representative microscopic images of the tumors with H&E staining. (G) Expression levels measured by qRT-PCR
of H19 (left panel) and a panel of genes (right panel) in xenografts following tumor dissociation in control tumor (pLIV
empty) versus H19 overexpressing tumor (pLIV H19). Results are shown as mean± SD. Two-way ANOVA was used for
statistical analysis. *P < .05, **P < .01, ***P < .001, ****P < .0001. ns, not significant.
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affect the overall survival (Figure 2.11E). Upon dissection, however, although there was no
significant difference in tumor size (data not shown), tumors were much more vascularized in
the presence of H19 compared to control samples, a feature that could be expected to correlate
with a more aggressive tumor phenotype (Figure 2.11F). We confirmed that H19 overexpression
was maintained after tumor xenograft dissociation and noticed a few genes that appeared to
have been upregulated in vivo, including CCND1, HMGA2, and mainly IGF2 (Figure 2.11G),
which may translate an imbalance in the imprinting regulation between IGF2 and H19, although
post-transcriptional regulation of IGF2 by H19 has also been reported (Li et al., 1998).
In parallel, we carried out the same gain-of-function experiments with GBM cell lines, in
which endogenous H19 was undetected (Supplementary Figure S1.1B). Similar to MGH4S, or-
thotopic injection of 50’000 U-87 or U-251 cells overexpressing H19 failed to demonstrate in-
creased tumorigenicity of cells in vivo compared to control (Supplementary Figure S1.1C and
D). However, we did not see any morphological or histological difference between tumors ex-
pressing H19 or not (data not shown). Here as well, we confirmed that H19 overexpression
was maintained in vivo (Supplementary Figure S1.1E). Curiously though, U-251 showed tumor
growth only after three months, whereas mice injected with U-87 started exhibiting signs of brain
tumor progression and had to be sacrificed after a period of only three weeks, showing that these
two cell lines display very distinct tumorigenic potential.
2.3.3 Discussion
Many papers have demonstrated the role of H19 in promoting GBM proliferation and invasion,
and have well established the role of H19 as a let-7 sponge, but fewer have explored its inter-
action with RBPs. Taken together, our data suggests that H19 correlates with poor patient
survival and binds IMP2, and that overexpression of H19 enhances cell clonogenicity. This ob-
servation was however not confirmed in vivo. Our first experimental approach focused on the
effects of H19 overexpression in GSCs with low endogenous H19 (Ct values averaging 33-34).
In gain-of-function experiments, it is reasonable to assume that overexpression can only affect
the phenotype to a certain extent. The cells used here, MGH4S, already display strong stem-
ness properties and actively form tumors in vivo, which may not be stimulated further. Still,
orthotopic brain injection of fewer cells may have more readily shown changes in tumorigenicity
in vivo. Nevertheless, a strong characterization of the role of H19 at this stage would rely on
studying cell changes following depletion of H19.
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Figure 2.12: Infection efficiency in 293T and in GBM samples. Images show micrographies taken three days after
lentiviral infection with a non-silencing shRNA or a shRNA targeting H19, both containing GFP. Cells were exposed to
the same amount of virus for a period of 8 h. The lower row shows the fluorescent signal obtained from the corresponding
picture in the upper row. The scale bar indicates 100 μm.
For H19 knockdown, we planned on using the CRISPRi silencing system. The already low
endogenous level of H19 in MGH4S could not provide adequate conditions for representative
results in loss-of-function experiments. Indeed, the remainder of the work would need be per-
formed on a model with high endogenous expression of H19, as seen in MGH8S, MGH26S and
MGH28S, to achieve robust knockdown and evaluate the effect on the cell phenotype. Having
cloned several oligo sequences into the CRISPR-dCas9-KRAB plasmid, we faced major issues
upon lentiviral infection of target cells. We achieved successful infection of 293T cells and of
MGH4S, but despite using low amounts of virus, MGH26S and MGH28S stopped growing shortly
after exposure to the virus suspension, with or with addition of polybrene in the medium. We
excluded the possibility that this may be due to H19 knockdown, as the same phenomenon was
seen with the control CRISPRi vector. We questioned whether this could result from toxicity of
the CRISPRi vector itself. To address the issue, we used shRNA vectors (shRNA non-silencing
and shRNA targeting H19) that expressed to visually follow the infection efficiency. To our
surprise, even with the non-silencing control shRNA, cells stopped proliferating and died shortly
after infection (Figure 2.12). Extensive attempts to adjust infection conditions bore no fruitful
results.
Therefore, the major issue of not having a representative loss-of-function model of H19 or
IMP2 made us reconsider the feasibility and completion of the project, as we could no longer
address the various questions that remained to be answered, and that required gene editing to
provide any constructive conclusion. Consequently, we lack further evidence that H19 is essential
for GSC maintenance in our samples, and it is yet unclear why IMP2 binds to H19 transcripts.
IMP2 can bind thousands of mRNAs, with a preference for their 3’-UTRs (Conway et al., 2016).
The effects of IMP2 binding, however, are broad and depend on the binding partner. Similarly,
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H19 can interact with many proteins and transcripts, and can act through various mechanisms.
Interaction between IMP2 and H19 may contribute to either one of the binding partners. In
the first scenario, H19 binding may be important for IMP2. In this context, we can hypothesize
that H19 localizes IMP2 inside the cell. IMP2 immunohistochemistry and H19 RNA detection on
histological tumor slides would allow to see their colocalization in wild-type cells and displacement
of IMP2 in cells depleted of H19. Recently, THOR was shown to stabilize binding of IMP1
to its targets (Hosono et al., 2017). A similar mechanism between H19 and IMP2 is surely
worth investigating. Linked to previous data on the role of IMP2 in GSC maintenance, if
observations would confirm that H19 is essential for IMP2 function, it would further support
IMP2 as a key RBP in GBM and reinforce its potential for therapeutic targeting. Conversely,
in a second scenario, IMP2 binding may be necessary for H19. In light of the implication of
IMPs in controlling mRNA fate, IMP2 may participate in the stabilization and transport of
H19. Comparing levels and localization of H19 in cells depleted of IMP2 would have provided
clues as to this pathway. Transcript stabilization could easily have been tested by measuring
and comparing the half-life of H19 in wild-type GSCs and cells depleted of or lacking IMP2. If
indeed IMP2-H19 binding is essential primarily for H19, we would need to further investigate its
downstream function in our GBM samples.
We can still ask what the main mechanisms of action of H19 could be in GBM. As mentioned
previously, lncRNAs can act through various mechanisms. While H19 function was reported to
be primarily mediated by its derived miRNA miR-675 (Zhang et al., 2016b), this miRNA was
absent from our samples. Notably, this work and most studies on H19 found in the literature
mainly use established GBM cell lines, which can explain our divergent observations. Indeed,
many studies (Zhang et al., 2016b; Li et al., 2016) used the same two GBM cell lines as we did
to explore the role of H19, namely U-251 and U-87, in which we, in contrast, did not detect
any H19 expression (Supplementary Figure S1.1B). Thus, this reflects once more the limitations
of research on immortalized cell lines that often tend to display different expression profiles
following extensive subculturing, and demonstrates the importance of testing primary samples
as well to confirm findings from established cell lines.
The function of H19, in our interest, can be divided into two categories: 1) let-7-dependent
pathways, centering the role of H19 around its sponge activity for let-7 miRNAs, and 2) let-
7-independent pathways, which would require further characterization. We found that clono-
genicity of MGH4S overexpressing H19 is increased, although let-7 target transcripts, such as
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HMGA2, were unchanged. RNA profiling of cells depleted of H19 would have been able to further
confirm this, by analysis of transcriptome changes and assessing if the let-7 target mRNAs are
globally stable. At this point, we assume that increasing levels of H19 do not cause increased
sequestering of let-7 miRNAs and postulate that a let-7-independent mechanism is most likely
at play in our GBM cells.
Although H19 was initially found to be primarily located in the cytoplasm (Brannan et al.,
1990), and association with IMP1 was described to occur exclusively in the cytoplasm (Runge
et al., 2000), evidence that H19 binds to EZH2, the methyltransferase of PRC2, and is associ-
ated with increased methylation of the E-cadherin promoter suggests that H19 can additionally
localize and operate inside the nucleus (Luo et al., 2013). With increasing evidence showing
interactions of lncRNAs with chromatin, it would be of interest to perform chromatin isolation
by RNA purification sequencing (ChIRP-seq) analysis to investigate direct interactions of H19
with chromatin (Chu et al., 2015). Indeed, from the gain-of-function experiments, it can be
believed that increased levels of H19 may not significantly alter the binding sites to chromatin,
and would explain the stable phenotype observed. However, taking into account the interaction
between IMP2 and H19, we would need to suppress IMP2 in H19-expressing GSCs to observe
possible displacement of H19 along the chromatin. Another approach would require a GBM
sample that naturally lacks IMP2, which we do not have. Therefore, we again lacked a negative
model depleted of IMP2, which would have provided extensive data to compare H19 positions
on the chromatin in the presence or absence of its binding partner IMP2.
To conclude, we believe that H19 lncRNA may be a relevant player in GSCs, and further
characterization of its role using primary tumor samples can provide valuable new insight for its
role in GBM.
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2.4 Materials and Methods
Cell culture
GBM tumors were collected at Massachusetts General Hospital and have been characterized
in previous works (Supplementary Table S1.1) (Wakimoto et al., 2011; Rheinbay et al., 2013;
Suvà et al., 2014). Primary GSCs were grown as organoids in Neurobasal medium (Invitrogen)
supplemented with L-glutamine (Gibco), B27 supplement (Invitrogen), N2 supplement (Invit-
rogen), recombinant human epidermal growth factor (EGF) and basic fibroblast growth factor
(bFGF) (PROSPEC) at final concentrations of 20 ng/mL, and 1% Penicillin-Streptomycin (Pen-
Strep, Gibco). Differentiation of GSC into adherent cells was induced by culturing cells in
DMEM medium, supplemented with 10% fetal bovine serum (FBS, PAN-BIOTECH) and 1%
non-essential amino acids (NeAA, Gibco) in pre-coated plates, which were generated as follows:
a 20 μg/mL solution of poly-L-ornithine (Sigma-Aldrich) was added to plates. After 1 h incuba-
tion at 37 ◦C, the solution was removed and the plates were washed three times with PBS. A
5 μL/mL solution of laminin (Sigma-Aldrich) in PBS was added to the plates. The plates were
then incubated at 37 ◦C for three hours at least. Cells were grown as a monolayer on the coated
plates.
The GBM cell lines U-251 (RRID:CVCL_0021) and U-87 (RRID:CVCL_0022) were pur-
chased from ECACC and ATCC, respectively, and cultured in Dulbecco’s MEM (DMEM, Gibco)
supplemented with 10% FBS (PAN-BIOTECH), 1% NeAA (Gibco) and 1% PenStrep (Gibco).
The LentiX-293T cell line was purchased from Clontech (Cat#632180) and grown in DMEM
(Gibco) supplemented with 10% FBS (PAN BIOTECH), 1% NeAA (Gibco) and 1% PenStrep
(Gibco).
Cell cultures were maintained at 37 ◦C and 5% CO2 in humidified culture incubators. Cells
were regularly tested to exclude mycoplasma contamination.
Single-cell clonogenic assays
Primary gliomasphere organoids were manually dissociated into a single-cell suspension. Cells
were counted and diluted to a final concentration of 100 cells in 10mL of culture medium. Cells
were then plated at single-cell density in low-attachment 96-well plates (Corning) with 100 μL
medium per well. After one week, 100 μL of fresh medium was added to each well. After a total
incubation time of three weeks, the number of organoids was assessed by micrography imaging.
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Sphere formation assays
Primary gliomasphere organoids were manually dissociated into a single-cell suspension. Cells
were counted and 4’000 cells were added in the first well in a 96-well plate. Serial 1:2 dilutions
were performed along the first column and then along each row in the plate. Cells were incubated
in 100 μL for a week and 100 μL of fresh medium was added to each well after one week. After a
final incubation time of three weeks, the total number of organoid spheres was counted. Results
are reported as the total number of organoid spheres found in each 96-well plate. Experiments
were performed in triplicates.
Stereotactic mouse injections
NOD-SCID gamma mice were given Paracetamol one day prior to surgery. Anaesthesia was
obtained by intraperitoneal injection of a solution containing 100mg/kg Ketamine (Ketasol-100,
Graueb AG) and 16mg/kg Xylazine (Rompun 2%, Provet AG), diluted in PBS. Intracranial
injection of cells was performed using a stereotactic apparatus (Kopf Instruments) at coordi-
nates 2.2mm right lateral relative to the bregma point, and 2.5mm deep from the dura mater,
corresponding to x = −2.2mm, y = 0mm and z = −2.5mm. After surgery, treatment with Ci-
cafalte (Avène) once a day on wound and Paracetamol in water bottle was maintained for seven
days. Mice were sacrificed when showing signs of suffering, after which the brain was extracted
for further analysis. For survival data, Kaplan-Meier curves and statistical significance using
log-rank test were calculated with GraphPad Prism 8 software. Experiments were performed
under the licence number VD2488.
Drug delivery
Following stereotactic surgery, the injected tumor cells were allowed to engraft for four weeks.
Mice were subsequently treated either with a control 20% DMSO solution, enoxacin (Sigma-
Aldrich) alone (50mg/kg/day), TMZ (Sigma-Aldrich) alone (40mg/kg/day), or a combination
of both enoxacin and TMZ, with five mice per group. The treatment was given by intraperitoneal
administration for three weeks, at a rate of five injections per week. After the end of the
treatment, three mice from each group were sacrificed for immediate tissue analysis. The two
remaining mice from each group were observed for further survival data. For these mice and those
that had to be sacrificed before the end of the treatment, Kaplan-Meier curves and statistical
significance using log-rank test were calculated with GraphPad Prism 8 software. Experiments
were performed under the licence number VD2488.
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Lentiviral infection
LentiX-293T (Clontech) packaging cells were transfected using FuGENE R© 6 Transfection reagent
(Promega) for lentivirus production. The envelop and packaging vectors used were pMD2G (Ad-
dgene, plasmid #12259) and pCMVΔR8.74 (Addgene, plasmid #12263), respectively. After
72 h, the supernatant was collected, filtered (0.45 μm) and ultracentrifuged at 4 ◦C for 2 h at
26’000RPM with a SW28 rotor. The supernatant was discarded and the virus was left to
resuspend overnight at 4 ◦C. On the following day, 106 cells were incubated for 8 h with the
concentrated viral suspension from two LentiX-293T 15 cm dishes and with Polybrene at a fi-
nal concentration of 6 μg/mL. Antibiotic selection was initiated three days after infection with
puromycin at a final concentration of 2 μg/mL and maintained until the cells were used for further
experiments.
Brain tumor dissociation and flow cytometry
Tumor xenografts were dissociated using the Brain Tumor Dissociation kit (P) (Miltenyi Biotec)
according to the manufacturer’s instructions. Expression of CSC-associated cell surface marker
CD133 was analyzed by FACS with Gallios flow cytometer (Beckman Coulter) and analyzed
using FlowJo Software (FlowJo, LLC). Live cell population was selected by DAPI staining, and
then sorted using CD133/PE antibody (Miltenyi Biotec).
RNA extraction, cDNA synthesis and quantitative real-time PCR
RNA was extracted using the miRCURY RNA Isolation kit (Exiqon). For cDNA synthesis,
500 ng of RNA were reverse-transcribed using M-MLV Reverse Transcriptase (Promega). qRT-
PCR was run by QuantumStudio 5 instrument (ThermoFisher Scientific). Each PCR reaction
was performed in triplicates and fold change was calculated using the comparativeΔΔCt method.
For mRNA, PCR was performed with TaqMan Universal PCR mastermix (Applied Biosystems)
or PowerUp SYBR Green (Applied Biosystems), and specific PCR probes and primers (Supple-
mentary Table S2.3). Relative gene expression was normalized to endogenous controls GAPDH
and TBP. For miRNA, cDNA synthesis was retrotranscribed from 30 ng to 60 ng of RNA using
Universal cDNA synthesis kit (Exiqon). PCR was performed using Power SYBR Green (Ap-
plied Biosystems) and specific primers designed to recognize mature miRNA (miRNA LNA PCR
primer sets, Exiqon). Relative quantification was normalized to endogenous control Snord49A.
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Preparation of protein cell lysate and Western blot
Western blot was performed according to standard procedures. Briefly, cells were harvested,
centrifuged, washed in ice-cold PBS and lysed in SDS-RIPA buffer (150mM NaCl, 1% NP-
40, 0.5% sodium deoxycholate, 0.1% SDS, 50mM Tris pH8.0) and protease inhibitor cocktail
(Roche). The lysate was incubated on ice for 20 minutes, sonicated twice for 10 seconds at
35 kHz, and centrifuged at 4 ◦C for 10 minutes at 13’000RPM. The supernatant was used for
protein sample preparation. Protein concentration was assessed using Bradford Protein Assay
Dye (Bio-Rad). An amount of 30 to 40 μg of proteins was loaded per lane for Western Blot
and samples underwent electrophoresis through a gradient polyacrylamide gel (6%-20%) at
125mV for 2 h. Transfer was performed with a current of 250mA for 2 h onto Whatman R©
Protran R© BA83 nitrocellulose membrane. The membrane was then blocked in 5% milk in PBS
containing 0.5% tween 20 (TBST) for 1 h, washed with TBST, and hybridized with primary
antibody according to the manufacturer’s recommendations. Primary antibodies included: anti-
IMP2 (MBL International, Cat#RN008P1), anti-IMP3 (MBL International, Cat#RN009P),
anti-HMGA2 (Cell Signalling Technologies, Cat#5269), anti-TRBP2 (Abnova, Cat#MAB0811),
anti-OCT3/4 (Santa Cruz, Cat# sc-5279), anti-SOX2 (Sigma, Cat#S9072), anti-GAPDH-HRP
(Abcam, Cat#ab9482). Secondary antibodies included: HRP-conjugated sheep anti-mouse (GE
Healthcare, Cat#NA931) and goat anti-rabbit (Agilent, Cat#P0448). Bands were visualized
and analyzed using Western Bright Sirius (Wiltec AG) detection reagents, according to the
manufacturer’s instructions, with Fusion Fx software (Vilber Lourmat).
RNA-Immunoprecipitation of IMP2
RIP was performed using the RIP-Assay Kit for miRNA (MBL International) according to the
manufacturer’s instructions. Approximately 2× 107 cells were harvested, washed and lysed in
Triton-based lysis buffer. After 1 h pre-clear with Protein A agarose beads, the lysate was incu-
bated with 10 μg of anti-IMP2 antibody (MBL International) or 10 μg isotype-matched antibody
(MBL International, provided in kit) conjugated with Protein A agarose beads. Beads were then
washed with lysis buffer. 10% of beads were kept for Western blot analysis and RIP RNA was
extracted from the remaining beads. For Western blot analysis, beads were incubated in Laemmli
sample buffer and boiled for five minutes. The supernatant was collected following centrifugation
and subsequently used for Western blot. For qRT-PCR, 500 ng of RNA were retrotranscribed as
described above. RIP enrichment of targets was calculated using comparative ΔΔCt method.
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H19 overexpression
H19 cDNA was obtained from Dharmacon (Clone Id: 3449920) and verified by sequencing upon
reception. The amplified product from H19 cDNA was cloned onto pENTR/SD/D-TOPO using
pENTR Directional TOPO cloning kit (Life Technologies) and onto a Gateway receptor vector
using Gateway LR Clonase II kit (Life Technologies). The primers used to amplify cDNA of H19
were: Fwd 5’- CACCGGCAGGGGACACAGGACAG -3’ and Rev 5’-GAGTCCAGGGCTCCTG-
CTGAAG -3’.
CRISPR cloning
The CRISPRv2 plasmid was obtained from Zhang Lab (Addgene plasmid #52961) (Sanjana
et al., 2014). CRISPRv2 was digested with FastDigest Esp3I (ThermoFisher Scientific) at 37 ◦C
for 1 h. The sample was then run on an agarose gel and the 12 kb fragment was extracted using
the Monarch DNA Gel Extraction kit (NEB) according to manufacturer’s instructions. The
forward and reverse oligos were annealed by incubation for five minutes at 95 ◦C in annealing
buffer (10mM Tris pH7.5, 1mM EDTA, 50mMNaCl) and left to cool down to room temperature.
Ligation of the vector with the annealed oligos was performed with T4 DNA ligase (ThermoFisher
Scientific) at 16 ◦C for 16 h, and the enzyme was inactivated at 65 ◦C for 10 minutes. After
butanol precipitation, we electroporated STBL3 bacteria with the ligation reaction product, and
subsequently screened and sequenced the resulting clones. The gRNA sequences used in this
project were chosen based on the Broad Institute algorithm (https://portals.broadinstitute.org/
gpp/public/analysis-tools/sgrna-design). For a given gene sequence, the program browses through
all possible gRNA sequences adjacent to a protospacer-adjacent motif (PAM) sequence. We kept
the top four sequences, ranked from 1 to 4 according to specificity and limited off-target effects.
As a general rule, we ensured that our gRNA target the gene of interest between 5-66% of the
target length. The sequences used are listed in Table S1.3. For control conditions, we used a
CRISPRv2 vector without a gRNA.
For CRISPRi cloning, we used a vector containing CRISPRv2-dCas9 associated with a KRAB
domain, already available in our lab. The same protocol was applied as described above with the
oligos listed in Table S1.3, chosen from CRiNCL (Liu et al., 2017) and based on predicted scores
following the hCRISPRi-v2.1 algorithm (Horlbeck et al., 2016). For control conditions, we used
a CRISPRv2-dCas9 vector without a gRNA.
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Survival and expression correlation data
The expression data for GBM in TCGA were obtained from RNA-sequencing. These data refer
to 172 samples, of which 154 are primary tumors; for 152 of these we had overall survival
information. Dividing the patients into two groups (high- and low- H19, based on median
expression), we obtained Kaplan-Meier curves for the two groups. The survival analysis was
repeated separately for each molecular subtype (classical, mesenchymal, proneural, neural). The
same dataset was used to compute the correlation between H19 expression and the expression of
all other genes.
Statistical analyses
GraphPad Prism software 8 was used to generate graphs and to perform the corresponding
statistical tests, as indicated in the figure legends.

Chapter 3
Ewing Sarcoma
3.1 Introduction
3.1.1 Pediatric malignancies: a challenging field
Every year, an estimated 250’000 children and adolescents are diagnosed with cancer worldwide
(Steliarova-Foucher et al., 2017). Importantly, malignant diseases are the second leading cause
of death in children in Switzerland (Arndt et al., 2016). Whereas overall survival of pediatric
oncology patients has dramatically improved in the last 50 years, reaching more than 80% cure
in high-income countries (Smith et al., 2014), the prognosis is largely dependant on the tumor
type, patient age, and, for solid tumors, metastatic status at diagnosis, with metastatic spread
generally associated with dismal outcomes. Indeed, although mortality rates have continued to
decline in the last ten years, they have done so at a slower rate and appear to have reached a
plateau in the case of solid tumors, especially for high-grade gliomas and metastatic sarcomas
(Bosetti et al., 2010; Smith et al., 2014).
Interestingly, the most common sites that undergo transformation vary substantially based
on patient age, suggesting that the mechanisms underlying tumorigenesis are primarily age- and
organ-dependent (Figure 3.1A). The incidence of pediatric tumors has remained mostly stable
in the past decades. Increased incidence rates of brain tumors and acute lymphoblastic leukemia
(ALL) most likely reflect improved diagnostic and imaging techniques (Figure 3.1B). Indeed,
prevention of cancer in the pediatric population remains a major challenge, as there are limited
preventable risk factors for these diseases. The few known risk factors for childhood cancer
include syndromes resulting from inherited gene mutation (e.g. hereditary retinoblastoma, Li
Fraumeni syndrome, Down syndrome), ionizing radiation (e.g. radiation therapy, exposure of
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Figure 3.1: Epidemiological and genome-wide data of childhood cancer. (A) Distribution of cancer types by
age group from birth to 14 years in Switzerland (2008 - 2012). Area is proportional to the number of cases. Malignant
bone tumors include osteosarcoma and Ewing sarcoma. Adapted from Arndt et al. (2016). (B) Trends in incidence rates
of pediatric cancer by site for patients from birth to 19 years, between 1975 and 2010. Lines represent joinpoint fitted
trends. Benign and borderline brain tumors are not included. Malignant bone tumors include osteosarcoma and Ewing
sarcoma. Reproduced from Ward et al. (2014). (C) Genome-wide sequencing of a diverse group of pediatric (left) and adult
(right) cancers reveals strong disparity in mutational load profiles. Numbers in parentheses indicate the median number
of non-synonymous mutations per tumor. (D) Number of somatic mutations in adult and pediatric cancers. Median
number of non-synonymous mutations per tumor in a variety of adult and pediatric cancers. Horizontal bars indicate the
1st and 3rd quartiles. CNS, central nervous system; MSI, microsatellite instability; SCLC, small cell lung cancers; NSCLC,
non-small cell lung cancers; ESCC, esophageal squamous cell carcinomas; MSS, microsatellite stable; EAC, esophageal
adenocarcinomas. (C) and (D) reproduced from Vogelstein et al. (2013).
mother during pregnancy, exposure to radiation following the Chernobyl catastrophe), and age
of mother at birth (Arndt et al., 2016; Helman and Meltzer, 2003). Certain viruses may also
induce malignant transformation (e.g. Kaposi sarcoma, hepatitis, EBV). However, this hardly
defends prevention as an effective approach to reduce cancer incidence in children. Thus, the
primary goal relies on decreasing morbidity and mortality of children, essentially by developing
more targeted, less myeloablative and lower dose therapies that successfully eliminate CSCs.
While cancer is primarily recognized as a genetic disease, adult and pediatric cancers exhibit
significant disparity. Indeed, most adult tumors display a high number of mutations, partly due
to exposure to numerous stress inducers and pathogenic factors (e.g. sunlight, tobacco smoking,
infections). Pediatric cancers, in contrast, carry globally fewer genetic changes in their genome
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(Figure 3.1C and D). Nevertheless, the global expression profile of tumor cells is significantly
altered. Thus, cellular transformation may be explained in part by epigenetic events. Some
epigenetic changes may result from mutations in epigenetic regulators (Downing et al., 2012), but
may also be the consequence of epigenetic modifications resulting from non-random chromosomal
rearrangements. As epigenetic alterations can be reversed, they can contribute to explaining the
high cellular plasticity observed in tumors.
Although childhood cancers represent a significant burden of disease, their scarcity challenges
research opportunities. The small number of cases translates into reduced interest for funding in
the biopharmaceutical sector, and the limited number of available participants for phase II trials
hinders the statistical power of clinical studies. Also, pharmacological phase I trials are generally
limited in children for obvious ethical reasons, which may considerably delay potential testing
and use of novel drugs or regimens in the pediatric population. Furthermore, current drugable
targets have essentially been identified in adult cancers. Pediatric cancers, in contrast, often lack
the same genetic variations, due to their low mutational profile and distinct pathogenesis. Thus,
very few drugs used in adult contexts can be applied to pediatric malignancies, and most have
limited to no benefit for the pediatric population. Finally, while advanced-age cancer patients
may benefit from an improved survival of months to a few years, the goal in treatment of
pediatric cancer is no other than complete remission and cure, along with limiting the incidence
of secondary tumors in all long-term survivors. This sets the bar at a completely different level
for the development of new therapies.
Such challenges in pediatric cancer research highlight the primordial role of using preclini-
cal models that reliably replicate the patients’ tumors, including their heterogeneous nature, to
identify potential targets. PDX have been found to effectively reproduce the tumor of origin
in solid pediatric tumors, preserving the heterogeneous molecular profiles of the initial sample,
especially in the case of relapse (Stewart et al., 2017; Nanni et al., 2019). Working with PDX
enables drug screening with potential for translation in the clinic. Importantly, a genetic alter-
ation or an activated pathway may be identified and essential to diverse tumor types (Norris and
Adamson, 2012), suggesting that subsequent trial design and criteria for patient inclusion should
be reshaped accordingly. Genomic sequencing and individualized approach in precision oncology
may bear promising results in patient care (Allen et al., 2017; Vo et al., 2020).
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Figure 3.2: Recurrent translocations found in malignant sarcomas. Shared fusion partners are shown according
to sarcoma subtypes. The outer ring represents genomic location (as labelled), cytobands are shaded and the centromere is
in red, with curves joining fusion partners. Adapted from Taylor et al. (2011).
3.1.2 Sarcomas: a heterogeneous group of tumors
Cancers of the bones and soft tissues fall together in the category of sarcomas. They can emerge
from any mesenchymal tissue, including bone, cartilage, muscle, fat or vascular tissue, typically
with varying degrees of malignancy. Whereas these tumors are rare in adults, accounting for
only 2% of adult cancers, they represent about 20% of pediatric malignancies (Figure 3.1A).
Sarcomas can be divided into two groups based on their karyotype. One group, which comprises
70% of sarcomas, harbors complex karyotypes, linked to perturbed genomic stability, and most
commonly affects adults. As may be expected, the signaling pathways of tumor suppressors p53
and retinoblastoma-associated protein (Rb) are frequently disrupted in these sarcomas (Helman
and Meltzer, 2003). The second group, which comprises the remaining sarcomas, is characterized
by simple karyotypic alterations resulting from non-random chromosomal rearrangements, and
arise predominantly in children (Figure 3.2 and Table 3.1). The different translocations result in
the expression of an aberrant chimeric proteins that fuse a protein with a DNA binding domain
to a protein containing a potent transactivating domain, typically a TET family protein, such as
EWS, causing strong transcriptional activation of a new set of targets. Expression of the fusion
protein is believed to be the principal trigger event for transformation in a permissive cellular
environment. In some cases, the translocation can lead to the overexpression of a growth factor
(Riggi et al., 2007).
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Table 3.1: Chromosomal translocations in sarcomas.
Tumor type Translocation Fusion protein
Ewing sarcoma / ESFT t(11;22)(q24;q12) EWSR1–FLI1
t(21;22)(q22;q12) EWSR1–ERG
t(7;22)(p22;q12) EWSR1–ETV1
t(2;22)(q33;q12) EWSR1–FEV
t(17;22)(q12;q12) EWSR1–ETV4
t(16;21)(p11;q22) FUS–ERG
DSRCT t(11;22)(p13;q12) EWSR1–WT1
t(21;22)(q22;q12) EWSR1–ERG
Myxoid liposarcoma t(12;16)(q13;p11) FUS–DDIT3
t(12;22)(q13;q12) EWSR1–DDIT3
Synovial sarcoma t(X;18)(p11;q11) SS18–SSX1
t(X;18)(p11;q11) SS18–SSX2
t(X;18)(p11;q11) SS18–SSX4
t(X;20)(p11;q13) SS18L1–SSX1
Alveolar rhabdomyosarcoma t(2;13)(q35;q14) PAX3–FKHR
t(1;13)(p36;q14) PAX7–FKHR
t(2;2)(q35;p23) PAX3–NCOA1
Clear cell sarcoma t(12;22)(q13;q12) EWSR1–ATF1
Extraskeletal myxoid chondrosarcoma t(9;22)(q22;q12) EWSR1–NR4A3
t(9;17)(q22;q11) TAFII68–NR4A3
t(9;15)(q22;q21) TCF12–NR4A3
Dermatofibrosarcoma protuberans t(17;22)(q22;q13) COL1A1–PDGFB
Alveolar soft-part sarcoma t(X;17)(p11.2;q25) ASPL–TFE3
List of the non-random chromosomal translocations found in various bone and
soft tissue sarcomas. DSRCT, desmoplastic small round cell tumor. Adapted
from Riggi et al. (2007).
Most of the translocations identified in sarcomas involve Ewing sarcoma breakpoint region 1
(EWSR1) on chromosome 22, encoding the RNA binding protein EWS. Nonetheless, EWSR1 can
be found as part of a fusion protein in a variety of sarcomas, including desmoplastic small round
cell tumor (DSRCT), myxoid liposarcoma, and clear cell sarcoma of soft tissue (CCS) among
others, where the only varying factor is the fusion partner of EWSR1 (Helman and Meltzer,
2003). Generally, fusion partners of EWSR1 can be separated into two categories, based on
whether they are members of the erythroblastosis transforming virus 1 (ETS) family (such as
FLI1, found in EwS) or not. Given that the tumors resulting from translocations involving
chromosome 22 are distinct entities, it appears that the fusion partner of EWSR1 is the most
determinant factor for the tumor phenotype.
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3.1.3 Ewing sarcoma clinical presentation and diagnosis
EwS was first described as a separate entity by James Ewing a century ago, based on observations
in a patient who was first diagnosed with osteosarcoma but responded well to radiation therapy.
James Ewing later reported similar tumors in other adolescents and initially named the disease
“diffuse endothelioma of the bone”, based on the histological morphology of the tumor (Ewing,
1972). It was only 70 years later that the chromosomal translocation was detected. This led
to the definition of a new group of malignancies, the Ewing sarcoma family of tumors (ESFT),
encompassing Ewing sarcoma (EwS), Askin tumors and peripheral primitive neuroectodermal
tumor (PNET). These aggressive tumors of the bone and soft tissue quickly develop distant
metastases.
EwS is a highly aggressive sarcoma mostly seen in boys of 10 to 15 years of age, and is the
second most common primary bone malignancy in children. The overall 5-year survival rate is
around 70% but decreases significantly in the 25% of cases diagnosed with metastatic disease.
For those patients and those with relapse, even aggressive multimodal therapy comprising surgery,
chemotherapy and radiation therapy fails to increase the long-term survival above 30% (Pishas
and Lessnick, 2016). Metastatic dissemination involves mainly the lungs (75%), bones (30%)
and the bone marrow (16%) (Worch et al., 2018), and it is suspected that most patients have
subclinical metastatic disease at the time of diagnosis (Nesbit et al., 1990).
EwS most commonly presents in the diaphyses of the bone, most frequently in the distal leg
bones, and in the pelvis (Figure 3.3A), but a minority of cases primarily involve soft tissues. At
diagnosis, the child may present with localized pain or swelling at the tumor site, with a firm
mass appearing over the course of weeks to months. Minor trauma to the involved site may be the
first call for attention and reason for pediatric consult. Advanced disease may be accompanied
by systemic signs, including fever, fatigue, weight loss or anemia. Imaging of the site of lesion
shows destruction of the bone with “moth-eaten” appearance and invasion to the surrounding
soft tissues. Periostal reaction causes formation of reactive bone layers that recall onion-skin,
a visible and characteristic imaging feature on radiograms of EwS (Figure 3.3B, upper panel).
Definitive diagnosis is then obtained upon histological analysis of biopsy, which shows typical
small blue round cell morphology common to ESFT (Figure 3.3B, lower panel), detection of the
cell surface marker CD99 with immunohistochemistry, and, most importantly, identification by
fluorescent in situ hybridization (FISH) or qRT-PCR of the fusion protein that is specific for
EwS, involving EWSR1 and a member of the ETS family of TFs.
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Figure 3.3: Clinical presentation of Ewing sarcoma. (A) Frequency of primary EwS sites (Worch et al., 2018). (B)
Upper panel, radiography image of the tibia (lateral view) of a patient showing onion-skin periostal reaction of the bone
around the EwS tumor site, indicated with an arrow. Image by Michael Richardson, M.D., distributed under a CC BY-SA
3.0 license. Lower panel, Histological image of EwS showing small, poorly differentiated, blue round cells. Reproduced from
Robbins et al. (2010).
Of note, EwS is consistent with the CSC model. Indeed, a subpopulation of CD133+ cells
displays tumor-initiating capacity upon xenotransplantation, self-renews and generates CD133–
clones, and highly expresses stemness genes, including NANOG and OCT4 (Suvà et al., 2009).
3.1.4 The fusion protein EWS-FLI1
Many translocations have been associated with EwS and are all characterized by EWS fusion
to one of five members of the ETS family, namely FLI1, ERG, FEV, ETV1 or E1AF (Arvand
and Denny, 2001). About 85% of EwS tumors carry the specific translocation t(11;22)(q12;q24),
resulting in the expression of the aberrant chimeric transcription factor EWS-FLI1 responsible
for malignant transformation (Delattre et al., 1994).
EWSR1, alongside TLS/FUS and TAF15, is a member of the TET gene family, and encodes
the ubiquitously expressed protein EWS. TET proteins share a similar structure composed of
SYGQ repeats in the N-terminal region, that function as a DNA transactivation domain, and
three RGG repeats of different lengths and a 87-amino acid RRM domain at the C-terminal
end, which combined ensure binding to RNA (Paronetto, 2013) (Figure 3.4A). In particular,
92 CHAPTER 3. EWING SARCOMA
EWS can bind directly to RNA polymerase II (RNA Pol II), as well as to various transcription
activators or repressors, thereby affecting transcription (Figure 3.4C). Moreover, EWS is also
involved in mRNA splicing (Tan and Manley, 2009; Selvanathan et al., 2015) and can associate
with DROSHA for miRNA processing (Gregory et al., 2004). In studies carried in vivo, knock-
down of EWS was associated with high post-natal mortality, decreased meiosis and disrupted
B-lymphocyte maturation, as well as arrest in hematopoietic stem cell (HSC) growth and renewal
(Li et al., 2007; Paronetto, 2013). Interestingly, the transactivation domain encoded by the seven
first exons of EWSR1 is largely silent in the full length wild-type protein, but becomes strongly
activated upon translocation of the C-terminal end. Data suggest that EWS activator repression
is mediated by the RGG repeats, which is line with gain-of-function of the activator domain in
the fusion protein lacking RGG repeats (Alex and Lee, 2005).
Friend leukemia virus integration 1 transcription factor (FLI1) is a member of the ETS family
that includes at least 27 TFs. All members share a common DNA binding domain that binds a
consensus core 5’-GGAA/T -3’ motif, called the ETS binding domain (Seth and Watson, 2005;
Wei et al., 2010). In particular, FLI1 contains 3’ and 5’ ets binding domains, associated with
a helix-loop-helix secondary structure with transcriptional activity, and a FLI1 specific domain
(FLS) (Figure 3.4B). Together, the 3’ ets binding domain and FLS form the amino terminal
transactivation domain (ATA), which is much less powerful than the activation domain of EWS
and is lost after translocation, explaining the enhanced function of FLI1 in the fusion protein
compared to wild-type FLI1 (Truong and Ben-David, 2000). Moreover, after translocation, FLI1
undergoes conformational changes and activates a larger set of genes than its wild-type form,
although the DNA binding domain is conserved (Üren and Toretsky, 2005; Tan and Manley,
2009).
In adults, high FLI1 expression is maintained in hematopoietic tissues but only weak expres-
sion is found in the lungs and heart (Ben-David et al., 1991). Overexpression of FLI1 demon-
strated malignant potential by causing increased growth and self-renewal of erythroid progenitors
(Pereira et al., 1999). Moreover, FLI1 can inhibit Rb expression and promote entry into the S
phase of the cell cycle. Finally, homozygotic loss of FLI1 disrupts development of T- and B-cells
and impairs vascular endothelial differentiation, and is embryonically lethal (Spyropoulos et al.,
2000).
The breakpoint region of EWSR1 is rather small and extends over a length of 8 kb, spanning
exons 7 to 11. The majority of fusions found in EwS contain exons 1 to 7, thereby preserving
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Figure 3.4: Structural features of TET proteins and FLI1, and the EWS-FLI1 fusion protein. The structure
of members of the TET family (A) and FLI1 (B) are shown with the corresponding exons. Common breakpoints are
indicated with an arrowhead. The red arrowhead indicates the most frequent breakpoint site. The fusion protein resulting
from the t(12;22)(q22;q12) translocation is depicted in (C), upper panel, and a schematic representation of EWS-FLI1 and
its partners following DNA binding on GGAA repeats is shown in (C), lower panel, and regulates changes in target gene
expression. (D) shows the various fusion types based on exon juxtaposition. The exons are represented as numbered boxes
and the lines indicate the breakpoint sites on EWSR1 and FLI1. Adapted from Anderson et al. (2012) and Sankar and
Lessnick (2011). RRM, RNA recognition motif; ZF, zinc fingers; FLS, FLI1 specific domain; CTA, C-terminal transcription
activating domain; DBD, DNA binding domain; RHA, RNA helicase A; U1C, U1 small nuclear ribonucleoprotein C.
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the integrity of the EWS transactivation domain (Zucman-Rossi et al., 1998; Arvand and Denny,
2001; Fisher, 2014). On the other hand, the larger breakpoint region of FLI1 spans over 35 kb
(exons 4 to 9). It occurs most frequently in intron 5, leading to preservation of exons 6 to 9 in the
fused product (Zucman-Rossi et al., 1998; Arvand and Denny, 2001). As the breakpoint is quite
variable, the fusion protein is classified as type 1 fusion if EWSR1 exons 1-7 are juxtaposed to
FLI1 exons 6-9, and as type 2 fusion, less prevalent, when EWSR1 exons 1-7 are fused to FLI1
exons 5-9 (Figure 3.4D). Of note, it appears that, although some translocations include EWSR1
exon 8, this exon must be removed during splicing of the EWS-FLI1 transcript for adequate
protein expression (Grohar et al., 2016).
3.1.5 EWS-FLI1 and tumorigenesis of EwS
In about one out of five EwS cases, the chromosomal translocation responsible for EWS-FLI1
fusion is the only detected oncogenic event. Thus, EWS-FLI1 is believed to significantly modify
the transcriptomic profile of the cell to promote transformation. To understand and characterize
the implication of EWS-FLI1 in tumorigenesis, two main approaches have been privileged, one
inducing de novo expression of the fusion protein in primary cells and cell lines of various origins
and differentiation stages, and the other focusing on depleting the fusion protein in EwS primary
cells or cell lines.
Evidence that EWS-FLI1 is capable of transforming cells was first reported in NIH3T3 fi-
broblasts, where expression of the fusion protein promoted cell growth on soft agar (May et al.,
1993) and tumor formation in vivo with histological similarity to EwS (Thompson et al., 1999).
Conversely, inhibition of EWS-FLI1 using either targeted RNA silencing or dominant negative
recombinants in cell lines reduced cellular growth and tumorigenesis in mice (Kovar et al., 1996;
Tanaka et al., 1997). However, stable expression of EWS-FLI1 in mouse embryonic fibroblasts
(MEFs) and human fibroblasts was only possible with a mutated p53 regulatory pathway, allow-
ing cells to overcome growth arrest and apoptosis (Deneen and Denny, 2001). Thus, the cellular
context is critical to properly study EWS-FLI1.
To understand how EWS-FLI1 causes transformation, targets that are up- or down-regulated
were assessed for their role in oncogenesis. Indeed, EWS-FLI1 can act as both a transcriptional
activator and repressor of direct and indirect targets. Several activated genes have been reported,
including c-MYC, CCND1, ID2, EZH2, PDGFC, DAX1, SOX2 and NKX2.2, some of which
promote cell proliferation and survival. In addition, several targets are repressed with EWS-
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FLI1 expression, such as p21 and TGF-βRII, allowing the cell to escape apoptosis and growth
arrest (Ordóñez et al., 2009). Notably, EWS-FLI1 strongly induces insulin-like growth factor 1
(IGF1) expression and represses IGFBP3. Dependence of EwS and other sarcomas on the IGF1
pathway is supported by the demonstration that IGF1R blockade decreases cell proliferation
and tumorigenesis (Scotlandi and Picci, 2008). Moreover, PTPL1 induction upon EWS-FLI1
expression increases resistance to etoposide (Abaan et al., 2005), and GSTM4 expression, whose
promoter contains a GGAA microsatellite region directly bound by EWS-FLI1, also provides
resistance to chemotherapeutic drugs (Luo et al., 2009). Taken together, altered expression of
direct and indirect targets dictated by EWS-FLI1 promotes cell survival and proliferation, while
also sustaining drug resistance.
Recently, chromatin immunoprecipitation sequencing (ChIP-seq) analyses demonstrated that
EWS-FLI1 orchestrates a highly EwS-specific transcriptional program. EWS-FLI1 either re-
presses targets by displacing the regulatory machinery at single GGAA repeats, or activates
target genes by chromatin remodelling at GGAA repeats at distal regulatory elements. Binding
of EWS-FLI1 multimers is alone sufficient for activation of transcription at GGAA microsatelite
repeats at distal regulatory elements. Remarkably, targeted epigenome silencing of EWS-FLI1
bound enhancers successfully blocked gene transcription and was associated with decreased tu-
mor formation in vivo (Boulay et al., 2018). Thus, using the ChIP-seq approach has allowed
the identification of new targets activated by direct EWS-FLI1 binding to chromatin and to
attest to their importance for tumorigenesis (Riggi et al., 2014). Moreover, the SYGQ repeats in
EWS mediate recruitment of the chromatin remodeling complex BAF and enhancer activation
at GGAA repeats, a feature that is unique to the fusion protein, thus explaining the distinct
set of targets modulated by EWS-FLI1 and wild-type FLI1 (Boulay et al., 2017) (Figure 3.5A).
Taken together, these data demonstrate that EWS-FLI1 directs epigenetic changes to activate a
specific transcriptional program that induces malignant transformation.
Lastly, recent studies using a single-cell approach revealed ITH with cell-to-cell variation of
EWS-FLI1 transcriptional activity that reflects onto the cellular profile (Aynaud et al., 2019).
An optimal EWS-FLI1 activity range offers the necessary conditions for proliferation, whereas
low EWS-FLI1 activity induces a mesenchymal-like phenotype, resulting in cells with a strong
propensity to migrate and develop metastatic dissemination (Franzetti et al., 2017) (Figure 3.5B
and C). The mechanisms that modulate EWS-FLI1 activity, however, still need to be defined.
Nevertheless, these observations further support the strong propensity of EWS-FLI1 to consid-
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Figure 3.5: EWS-FLI1 modulates chromatin conformation and transcriptional profile in EwS. (A) Schematic
depiction of EWS-FLI1 binding at GGAA motifs and chromatin remodelling. Left, EWS-FLI1 multimerization permits
stable binding at GGAA repeats and recruitment of BAF complexes to enable enhancer activation, whereas wild-type FLI1
cannot stably bind at GGAA repeats and the chromatin remains at a repressed state. Right, EWS-FLI1 binds single GGAA
motifs in open chromatin and displaces endogenous ETS TFs to repress the enhancer. Adapted from Boulay et al. (2017)
and Riggi et al. (2014). (B) Intratumoral heterogeneous activity of EWS-FLI1 illustrated by SPRING representation of
the kNN graphs for an EwS PDX dataset. Transcriptional programs of EWS-FLI1 and cell cycle (G2/M and G1/S), as
well as scores for gene sets linked to oxidative phosphorylation, hypoxia and glucose metabolism, are shown. Adapted from
Aynaud et al. (2019). (C) Schematic representation of cells with low or high EWS-FLI1 transcriptional activity. Adapted
from Franzetti et al. (2017).
erably reshape the transcriptional landscape of the cell to support tumor growth, while also
showing that ITH complicates the therapeutic approach to EwS.
3.1.6 The cell of origin of EwS
As EwS is a poorly differentiated tumor that bears both mesenchymal and neuroectodermal fea-
tures, it has been long discussed whether these tumors are of mesenchymal or of neuroectodermal
origin. Moreover, because the translocations that characterize sarcomas are found almost exclu-
sively in tissues derived from the mesenchyme, it appears that the cellular state plays a major
role in allowing the tumor-initiating cell to effectively express the fusion protein. In line with
this, efforts to identify the EwS cell of origin have been long hampered by the toxicity of EWS-
FLI1 upon exogenous expression in host cells. As mentioned previously, expression of EWS-FLI1
was achieved in NIH3T3 fibroblasts, but similar attempts in primary mouse MEFs and human
3.1. INTRODUCTION 97
immortalized fibroblasts led to growth arrest and apoptosis. In human fibroblasts, EWS-FLI1
was only expressed upon loss of p53 or p19ARF, a feature that is only found in a minority of
tumors (Huang et al., 2005). A permissive environment is therefore required to enable stable
EWS-FLI1 expression.
Mesenchymal stem cells (MSCs) are particularly interesting candidates due to their pluripo-
tency and their ability to generate a wide range of differentiated tissues. Indeed, EWS-FLI1
expression induced transformation in mouse bone marrow-derived mesenchymal progenitor cells,
which generated tumors with EwS properties (Riggi et al., 2005). Subsequent studies showed
that expression of EWS-FLI1 in human MSCs resulted in a change of the transcriptome rem-
iniscent of that of EwS (Riggi et al., 2008), and that this process was even more robust upon
transformation of human pediatric mesenchymal stem cells (hpMSCs), with the generation of a
subpopulation of CD133+ CSCs displaying both mesenchymal and neural features (Riggi et al.,
2010). Furthermore, following long-term EWS-FLI1 silencing, EwS cells lines acquired a mes-
enchymal profile. In particular, neural features were generally lost upon EWS-FLI1 depletion,
suggesting that the neuroectodermal features found in EwS likely result from transcriptional
reprogramming orchestrated by the fusion protein (Tirode et al., 2007). Taken together, these
reports strongly suggest that EwS originates from MSCs, which contain the required permissive
state for expression of the fusion protein.
Of note, expression of EWS-FLI1 in hpMSCs induced cell reprogramming toward EwS but
also toward a neural crest stem cell (NCSC) phenotype (Riggi et al., 2010). Moreover, human
NCSCs have been shown to sustain EWS-FLI1 expression and recapitulate a profile similar to
EwS (von Levetzow et al., 2011). Consistent with this notion, MSCs can be derived from NCSCs
(Lee et al., 2007). Therefore, these observations may provide a unifying explanation for the
initial debate, suggesting that EwS originates from a MSC of mesenchymal or neuroectodermal
origin. Importantly, cells maintain strong plasticity following transformation, as shown by the
presence of both mesenchymal and neural features in the tumor.
3.1.7 In vivo models of EwS
As pediatric sarcomas are mainly driven by a fusion oncogene following chromosomal transloca-
tion, possibly early in the developmental stages, it can be assumed that conditional expression
of the translocation under the control of a specific promoter and at a specific timepoint will
produce accurate transgenic mouse models. Successful models have thus been developed for
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rhabdomyosarcoma, myxoid liposarcoma, clear cell sarcoma, and synovial sarcoma (Minas et al.,
2017). In EwS, however, the generation of transgenic mice remains a fundamental challenge.
This is partly due to the toxicity of EWS-FLI1 in various tissues, as mentioned earlier, with
rapid induction of apoptosis, despite addition of the previously reported mutations in p53 or
p19ARF (Ordóñez et al., 2009; Minas et al., 2017).
To avoid embryonic lethality, using Prx1-Cre mouse would allow conditional expression of
EWS-FLI1 in MSCs, as the Prx1 gene is expressed specifically in MSC progenitors in limb
buds, thereby sparing vital central organs. Nonetheless, the model was associated with high
developmental defects of the limbs, as EWS-FLI1 expression blocked differentiation of cells into
skeletal muscle and maturation of the bone was impaired. The number of tumors, however,
increased with loss of p53, which is consistent with previously reported observations. Nonetheless,
this is not representative of the majority of primary EwS, in which this pathway is not affected
(Lin et al., 2008).
This study illustrates only one of many attempts at generating an EwS mouse model. Other
various complications encountered when creating transgenic EwS models included early devel-
opment of leukemia and promoter leakiness, all challenged by the absence of additional genetic
alterations and the overall high rate of embryonic lethality. Even inducible models remained
unsuccessful and lacked progeny (Minas et al., 2017). Furthermore, based on studies from our
laboratory, changes in the transcriptional program following EWS-FLI1 expression toward an
EwS signature are more important in human MSCs than in mouse cells. Therefore, the inherent
permissiveness of cells varies between species, which can also explain the challenges in generating
genetically engineered mouse models of EwS. Indeed, regulatory mechanisms and microsatellites
are not conserved between humans and mice. As a result, the repertoire of activated and re-
pressed genes upon expression of EWS-FLI1 in mice differs from that in humans, and murine
models therefore fail to mimic the epigenetic changes seen in human tumors.
Thus, to date, in vivo studies rely exclusively on the use of xenografts, either from cell lines
or from primary EwS samples.
3.2 LIN28 and IMP RNA-binding proteins in EwS
As mentioned previously, 25% of the tumors that express LIN28 are childhood malignancies,
which is disproportionate in relation to their representation of only 1% of all cancers (Carmel-
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Gross et al., 2015). Of the two paralogs, LIN28B appears to be most frequently reactivated
in cancer, and can be expressed either alone or in combination with LIN28A (Viswanathan
et al., 2009; Carmel-Gross et al., 2015). Because both paralogs are capable of inhibiting the
let-7 pathway, albeit by distinct mechanisms, increased prevalence of LIN28B expressing tumors
may be explained by LIN28B-specific let-7 independent pathways, consistent with the fact that
LIN28B, but not LIN28A, contains a nucleus localizing signal.
In EwS particularly, we recently observed that LIN28B is uniformly re-expressed in a subset
of EwS that constitute 10% of cases, and that are associated with a particularly unfavorable
prognosis. Essentially, knockdown of LIN28B in LIN28B-expressing (LIN28B+) primary EwS
organoid cultures, enriched in CSCs, successfully reduced their clonogenic potential and propen-
sity to form tumors in vivo. LIN28B+ cells displayed decreased let-7 maturation, which could
be restored upon testing with the compound 1632, that inhibits LIN28B binding to the terminal
loops of pri-let-7 (Roos et al., 2016). Furthermore, we found that the half-life of EWS-FLI1
transcripts is prolonged through direct binding of LIN28B. Importantly, treatment of organoids
with the 1632 compound and subsequent injection of treated cells into immunocompromised
mice led to inhibition of tumor growth, suggesting a potential approach for clinical application.
Therefore, in this particularly aggressive subset of EwS, we showed that LIN28B is essential to
stabilize EWS-FLI1 transcripts and maintain the expression of target genes, and is important for
establishing the oncogenic program in EwS cells (paper accepted for publication, Figure 3.6A).
Strikingly, however, let-7 target transcripts were not over-represented among the mRNAs up-
regulated following LIN28B depletion. This suggests that other let-7 independent mechanisms
may be equally important in the maintenance of a stem-like state. Additionally, stabilization
of EWS-FLI1 transcripts by LIN28B did not result in higher EWS-FLI1 protein levels. Indeed,
the fusion protein remains stable in LIN28B+ and LIN28B– cells. Based on these observations,
increased aggressiveness of LIN28B+ cells is not due to increased EWS-FLI1 expression, al-
though the chimeric protein constitutes the main tumor drive in EwS. As reported previously,
a significant body of data has recently shown that LIN28B regulates target expression at the
translational level. We therefore hypothesize that LIN28B orchestrates a series of events that
are EWS-FLI1 independent and confer increased malignant potential to CSCs, and still remain
to be explored.
Whereas GSCs express IMP2 but not LIN28B (Degrauwe et al., 2016a), EwS can express both
families of RBPs. Consistent with this, co-expression of LIN28 and IMPs has been reported in
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various cancers (Busch et al., 2016). Through distinct mechanisms, both can negatively regulate
the let-7 pathway, giving rise to an elaborate regulatory network in which LIN28 and IMPs
sustain the expression of one another and further promote the maintenance of a CSC phenotype
(Busch et al., 2016). Additionally, adult hematopoietic progenitor cells can be reprogrammed
to acquire fetal-like features following LIN28B induction (Yuan et al., 2012), a process that
directly involves interaction of LIN28B and IMP3 independently of let-7 miRNAs, providing
supplementary evidence that both RBPs can participate in stemness maintenance (Wang et al.,
2019). Interestingly, however, the cellular environment may strongly influence the interplay
between IMPs and LIN28B in cancer contexts, as IMP1 expression was shown to result in the
negative regulation of LIN28B expression in the intestinal epithelium (Chatterji et al., 2018). In
EwS, the role of IMPs has not yet been reported. It remains unclear whether all IMPs or only
individual members of the IMP family are involved in CSC maintenance, and we speculate that
they may act in a synergistic or complementary manner alongside LIN28B.
Furthermore, our cohort analyses found that 90% of EwS lack the expression of endogenous
LIN28B. Therefore, in this subset of EwS, it may be postulated that IMPs participate in CSC
maintenance and regulate the let-7 pathway. Of note, the trend seems to be reverted in estab-
lished EwS cell lines. Indeed, we found that 90% of cell lines are LIN28B+, whereas only the
remaining 10% are LIN28B–. This can either result from de novo LIN28B expression, which
confers a newly acquired proliferative advantage in vitro, or result from the fact that LIN28B+
cells are inherently more aggressive and thereby intrinsically fitter and more prone to surviving
and proliferating following sustained passaging in in vitro cultures. Most likely, both mechanisms
may be jointly involved and explain the high proportion of LIN28B+ EwS cell lines. Regardless,
the discrepant frequency of LIN28B expression in primary cells compared to cell lines further
supports LIN28B as a key player in cell tumorigenicity and aggressiveness. Nonetheless, because
LIN28B– primary models are particularly challenging to work with in culture conditions with
remarkably low proliferation rates, LIN28B– cell lines represent good models to explore the role
of IMPs in the absence of LIN28B in EwS.
Therefore, we chose to investigate the biological relevance of IMP expression in EwS and
explore a possible interaction with LIN28B in CSC maintenance that may contribute to increased
aggressiveness in LIN28B+ EwS, using both primary EwS organoids and established EwS cell
lines. Subsequently, we questioned which are the EWS-FLI1-independent mechanisms employed
by LIN28B to promote cell aggressiveness (Figure 3.6B).
3.3. RESULTS 101
Figure 3.6: The roles of LIN28 and IMPs in EwS CSCs. (A) Schematic depiction of the role of LIN28 in
aggressive EwS. LIN28B represses let-7 maturation and stabilizes EWS-FLI1 transcripts, and loss of LIN28B contributes to
tumor shrinkage (paper accepted for publication). (B) The first aim of this work is to explore whether IMPs participate in
tumorigenesis in LIN28B+ EwS and whether they interact with LIN28B. Secondly, we explored LIN28B regulated pathways
that promote CSC survival independently of let-7 miRNAs and EWS-FLI1.
3.3 Results
IMP3 expression correlates with poor outcome
To evaluate the putative role of IMPs in promoting EwS progression, we questioned available
databases and correlated expression of each IMP paralog with patient survival. We found that
IMP3, but neither IMP1 nor IMP2, strongly correlated with poor prognosis when expressed
(Figure 3.7A). Additionally, based on public patient datasets from the R2 genomics analysis
and visualization platform (http://r2.amc.nl), higher IMP3 levels were found in metastatic and
relapsed cases compared to newly diagnosed EwS (Figure 3.7B), a trend that was not found
for IMP1 and IMP2 (data not shown). Next, based on our previous report that LIN28B is
expressed in more aggressive EwS, we looked for a correlation between the expression levels of
IMPs. Strikingly, we found that, of the three paralogs, only IMP3 is significantly co-expressed in
LIN28B+ tumors (Figure 3.7B). Based on these results, it appears that IMP3 may be involved
in the tumorigenesis of EwS.
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Figure 3.7: IMP3 correlates with poor prognosis and high LIN28B expression. (A) Kaplan-Meier plot of event-
free survival where the patients have been divided into high (red) and low (blue) IMP3-expressing based on the median
expression of the probe. P-value was calculated using log-rank test. (B) Box-plot showing IMP3 expression in patient
samples with newly diagnosed primary EwS with no evidence of previous disease (blue), relapsed EwS (green), or with EwS
metastases (red), based on a total of 37 samples. The value in brackets indicates the number of samples in each group.
Data generated from the R2 genomics platform. One-way ANOVA was used for statistical analysis. *P < .05. (C) The
boxplots compare the logarithmic normalized expression of IMP1 (left panel), IMP2 (middle panel) and IMP3 (right panel)
in the respective dataset in LIN28B+ vs LIN28B– samples, based on the data from 65 primary tumors. Samples were
defined as LIN28B+ if LIN28B expression was higher than the median expression of all genes over all samples. P-values
were calculated used Mann-Whitney U test.
Effect of IMP knockdown in EwS primary cells and cell lines
Next, we assessed the levels of expression of IMPs and LIN28B in two primary samples, namely
EwS1 and EwS2, grown as organoid spheres, as well as in three established EwS cell lines,
namely A673, SKNMC, and MHHES1, grown as adherent cells. Some of the characteristics of
the samples used are listed in Supplementary Table S2.1. Our samples uniformly express all
three IMP paralogs. Both primary spheres used are LIN28B. LIN28B is similarly expressed
in A673 and SKNMC but is not detected in MHHES1, constituting our only LIN28B– sample
(Figure 3.8A). This is in line with the observation that most EwS cell lines are LIN28B+,
suggesting reactivation of LIN28B expression may confer a proliferative advantage to the cells
when maintained in culture conditions. Thus, throughout this project, we regularly checked
expression of LIN28B in MHHES1 cells to ensure that LIN28B remained silenced. Of note,
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IMP3 is relatively lower in MHHES1 than in other samples. We compared the mRNA levels of
IMPs across samples comparing them to hpMSCs, as they are believed to be the cell of origin
of EwS. We found that hpMSCs express very low levels of all IMP paralogs, whereas levels are
similar in cell lines and primary EwS. Of note, IMP3 was more highly expressed in primary
samples than in cell lines (Figure 3.8B).
We used the CRISPR/Cas9 technology targeting IMP1, IMP2 and IMP3 to deplete these
proteins in our samples (Supplementary Table S2.2). A CRISPR vector encoding the Cas9
sequence but lacking a guide RNA was used as a control (Cas9), and the guide RNA displaying
the strongest knockdowns were chosen to target IMP1, IMP2 or IMP3 and are subsequently
referred to as sg IMP1, sg IMP2 and sg IMP3, respectively. Following IMP knockdown, cells
displayed no significantly visible morphological change (Figure 3.8C). Based on Western blot
analysis, individual knockdown of a member of the IMP family does not affect the expression
of other IMPs. Furthermore, we found no remarkable change in LIN28B expression following
depletion of IMP, apart from a discrete reduction of LIN28B after knockdown of IMP1 and
IMP3 in EwS1 (Figure 3.8D). Transcript levels of IMPs were strongly reduced following their
respective CRISPR-Cas9-mediated knockdown, and were specific to the targeted IMP paralog.
However, here we detected upregulation of LIN28B in IMP2 and IMP3 knockdown, in EwS2 only
(Figure 3.8E). In particular, EWS-FLI1 levels remain stable in all samples.
Based on these first results, it is possible that there is some redundancy between IMPs, as
downregulation of either one of the paralogs does not seem to affect let-7 target transcripts.
Effects of IMP knockdown on cell viability and proliferation in vitro
To assess whether IMP knockdown may affect cell viability, we proceeded to proliferation and
metabolic activity assays after knockdown of IMP1, IMP2 or IMP3. We first compared A673 and
MHHES1, as the latter lacks LIN28B expression and may therefore display distinct responses
to IMP knockdown. However, downregulation of either IMP paralogs resulted in no change of
metabolic activity, although discrete reduction of cell proliferation was detected in MHHES1
IMP3 knockdown, as measured by incorporation of BrdU (Figure 3.9A). Clonogenic assays on
these cell lines, in contrast, showed a striking increase in clonogenicity of cells lacking IMP2
(Figure 3.9B).
In primary EwS organoids, clonogenic assays showed a distinct response to IMP knockdown,
as sg IMP2 and sg IMP3 seemed to generally decrease the cell clonogenicity and, in the case of
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Figure 3.8: IMP expression and CRISPR-mediated knockdown. (A) Western blot showing the levels of IMPs,
LIN28B and EWS-FLI1 in cell lines A673, SKNMC and MHHES1, and primary EwS samples (EwS1 and EwS2). MHHES1
is the only sample without LIN28B expression. GAPDH was used as loading control. (B) mRNA expression levels of
IMPs in A673, EwS1 and EwS2, compared to hpMSCs, measured by qRT-PCR. Results are shown as mean± SD. Two-
way ANOVA was used for statistical analysis. (C) Representative micrography images of control (Cas9) or IMP-depleted
EwS2 organoids. The scale bar represents 100 μm. (D) Western blot showing CRISPR-Cas9 mediated knockdown of IMPs.
GAPDH was used as loading control. (E) mRNA expression levels of IMPs, LIN28B, EWS-FLI1 and the known let-7 target
HMGA2, following CRISPR-Cas9 mediated knockdown of IMPs, measured by qRT-PCR. Results are shown as mean± SD.
Two-way ANOVA was used for statistical analysis. *P < .05, **P < .01, ***P < .001, ****P < .0001.
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Figure 3.9: Effect of IMP downregulation on proliferation. (A) Top, metabolic activity of A673 (left) and
MHHES1 (right) following IMP knockdown. Bottom, cell proliferation as measured by BrdU incorporation in A673 (left)
and MHHES1 (right) following IMP knockdown. The results from two separate experiments on two different cell batches
are shown. Results are displayed as mean± SD. Two-tailed t-test was used for statistical analysis. (B) Clonogenic assay
performed on A673 and MHHES1 infected with control vector or IMP knockdown. Colonies were colored with crystal violet.
(C) Left panels, single-cell clonogenic assay performed with EwS1 and EwS2 following IMP knockdown. Results are shown
as the number of cells counted per 96-well plates. Single values from different experiments are shown. Two-tailed t-test
was used for statistical analysis. Right panel, metabolic activity of EwS2 following IMP knockdown. The results from two
separate experiments on two separate cell batches are shown and displayed as mean± SD. Two-tailed t-test was used for
statistical analysis. *P < .05, **P < .01, ***P < .001, ****P < .0001.
EwS2, decreased ATP content (Figure 3.9C).
Taken together, our observations indicate that mainly IMP2 and IMP3 may have a putative
role in CSC maintenance, although the clonogenic assay performed on A673 and MHHES1 is
contradictory to this hypothesis.
Effect of IMP knockdown in vivo
Following in vitro experiments, we completed our observations by proceeding to in vivo injection
of cells into immunodeficient mice. For A673 or MHHES1, 106 cells were injected bilaterally in
the subcutaneous tissue behind the scapula (n =5 mice per group). For EwS1 and EwS2, 104
and 2× 104 cells respectively were injected in the subcapsular compartment of the left kidney,
according to usual laboratory practice (n =4 mice per group for EwS1, n =5 mice per group
for EwS2). All mice from an experiment were sacrificed at the same timepoint, once the largest
tumors had grown to the maximum volume allowed by our experimental license.
The tumorigenic potential of A673 and MHHES1 remained stable in control and IMP depleted
cells, as the tumors formed were overall equally large (Figure 3.10A, left panels). We noted that
tumorigenicity of EwS1 organoids was slightly impaired with sg IMP2. However, there was no
change in the capacity of EwS2 organoids to form tumors following knockdown of either IMPs
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(Figure 3.10A, right panels). Importantly, we found no significant decrease in the capacity
of cells to initiate tumor across our samples following IMP knockdown, as seen by the final
proportion of tumors obtained (Figure 3.10B). Furthermore, for each cell line and primary sample
we performed Western blot analyses on cells from dissociated xenografts to confirm that the
knockdown remained stable in vivo (Supplementary Figure S2.1).
Nevertheless, a trend in IMP3-depleted MHHES1 cells to form less tumors warranted further
exploration, as these cells lack LIN28B expression, and represented the most suitable model to
explore the role of IMPs independent of LIN28B. Therefore, we repeated MHHES1 injections with
105 cells, to see if the trend may become more pronounced when starting with a smaller inoculum
(n =4 mice per group). Tumors grew more slowly, as the first ones appeared after six weeks (three
weeks when 106 cells were injected), and others were only visible after three months. As a result,
we decided to assess tumorigenicity of IMP-depleted MHHES1 using a survival curve to measure
the duration required for the injected cells to develop a tumor reaching a volume of about 1 cm3,
at which time the mouse was sacrificed (Figure 3.10C). The median duration for tumor formation
was 62, 52, 83 and 48 days for mice injected with control (Cas9), sg IMP1, sg IMP2 and sg IMP3
cells, respectively. Notably, one mouse injected with IMP2-depleted MHHES1 still had no tumor
after nine months. However, the differences were not statistically significant. Therefore, even in
cells lacking LIN28B expression, knockdown of individual IMPs is not sufficient to abrogate the
tumor-initiating potential of CSCs.
Effect of simultaneous IMP2 and IMP3 knockdown
From our results so far, the knockdown of a member of the IMP family alone failed to affect the
cell phenotype in our samples. Nonetheless, we found discrete changes in cell proliferation when
IMP2 or IMP3 were depleted. As these two paralogs may share some redundancy, we questioned
whether the simultaneous loss of IMP2 and IMP3 could impair CSC proliferation and tumor-
initiating capacity. To test this, we infected EwS1 cells with sg IMP2- or sg IMP3-expressing
CRISPR vectors alone (sg IMP2 and sg IMP3), or in combination (sg IMP2+3). From qRT-PCR
results, levels of LIN28B, EWS-FLI1 and the let-7 target HMGA2 remained stable following si-
multaneous knockdown of IMP2 and IMP3. In addition, Western blot analyses show no changes
in the expression levels of either LIN28B or the fusion protein EWS-FLI1 (Figure 3.11A). More-
over, simultaneous knockdown of IMP2 and IMP3 did not reduce clonogenicity of EwS1 organoid
spheres (Figure 3.11B). Of note, the slight decrease in tumorigenicity suggested from previous
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Figure 3.10: IMP knockdown does not impair tumorigenicity in vivo. (A) Tumor volume (top panels) and weight
(lower panels). The individual values are plotted and the lines show mean± SD. Two-tailed t-test was used for statistical
analysis. (B) Proportion of tumors formed across the EwS samples injected. The fractions indicate the number of tumors
obtained out of the total number of injections. (C) Kaplan-Meier plot showing the time required for tumors to grow to
a size of approximately 1 cm3 following injection of 105 MHHES1 cells in the subcutaneous tissue of mice (n =4 mice per
group). P-values were calculated using log-rank test. *P < .05. ns, not significant.
experiments (Figure 3.8C, left panel) was not replicated here.
Thus, taken together, our observations reject a putative role of IMPs in EwS tumorigenesis,
but further support the role of LIN28B as a key driver of CSC maintenance in EwS in LIN28B+
tumors.
EWS-FLI1 stability in LIN28B+ EwS
Based on the results from tumorigenicity assays, we focused on characterizing the biological
functions of LIN28B in EwS. Recent findings from our lab showed that primary LIN28B+ EwS
have a poorer prognosis (paper accepted for publication). In line with this, based on public
patient datasets from R2 genomics analysis and visualization platform (http://r2.amc.nl), we found
that LIN28B expression is more frequent in relapse (Figure 3.12A). Additionally, we reported
that LIN28B can bind and stabilize EWS-FLI1 transcripts in EwS1 and EwS2. However, EWS-
108 CHAPTER 3. EWING SARCOMA
Figure 3.11: Combined knockdown of IMP2 and IMP3 in EwS1 organoids. (A) Left, mRNA levels of IMPs,
LIN28B, EWS-FLI1 and HMGA2 in EwS1 infected with a control vector (Cas9), depleted from IMP2 (sg IMP2) or IMP3
(sg IMP3) alone or in combination (sg IMP2+3), measured by qRT-PCR. Results are displayed as mean± SD. Two-way
ANOVA was used for statistical analysis. Right, Western blot analysis of samples, showing specific knockdown of the
targeted IMP proteins. (B) Single-cell clonogenic assay of EwS1 infected with a control vector (Cas9), depleted from IMP2
(sg IMP2) or IMP3 (sg IMP3) alone or in combination (sg IMP2+3), displaying the total number of organoid spheres in a
96-well plate. Two-tailed t-test was used for statistical analysis. *P < .05, **P < .01, ***P < .001. ns, not significant.
FLI1 protein levels are stable in both LIN28B+ and LIN28B– tumors. Furthermore, transcription
of EWS-FLI1 was unchanged following depletion of LIN28B, as reported from nuclear run-on
assay performed on EwS1, whereas we detected lower levels of nascent transcripts among known
EWS-FLI1 targets (paper accepted for publication, Figure 3.12B). Hence, other mechanisms
may be in play that promote an aggressive phenotype in CSCs independently of EWS-FLI1. To
explore these, we first determined whether the stabilization of EWS-FLI1 transcripts by LIN28B
was common to other LIN28B+ cells.
In order to identify other stable or unstable EwS samples, we decided to base our study
on other immortalized EwS cell lines. To select the cell lines with the highest dependency
to LIN28B, we used the Dependency Map generated by the Broad Institute (Tsherniak et al.,
2017). By comparing the expression level of LIN28B and the dependency value (increasing
negative values translate a higher degree of dependency), we observed that EwS cell lines follow
a trend along which a higher expression of LIN28B appears to correlate with a higher degree of
dependency (Figure 3.12C). While A673 is moderately sensitive to LIN28B knockdown, SKNMC,
which expresses the highest LIN28B transcript levels in the corresponding screening, is among
the most sensitive cell lines, along with SKNEP1. Thus, we investigated the effect of LIN28B
knockdown on EWS-FLI1 stability on A673, SKNMC, and SKNEP1, as well as in SKES1, as it
also expresses higher levels of LIN28B.
We then proceeded to LIN28B knockdown using the CRISPR-Cas9 genome editing system.
Surprisingly, EWS-FLI1 expression was not reduced upon LIN28B knockdown (Figure 3.12D and
E). Thus, in these cells, LIN28B may not be essential for stabilization of the EWS-FLI1 tran-
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scripts. Nonetheless, LIN28B knockdown significantly impaired cellular growth (Figure 3.12F).
In light of recent evidence showing that LIN28B can affect transcription and translation of sev-
eral targets, we suggest that LIN28B may participate in differential transcription or translation
of key pathways that support tumor aggressiveness possibly linked to CSC maintenance.
3.4 Discussion and future perspectives
Despite being rare diseases, childhood cancers are currently the second cause of death in chil-
dren. Although the emergence of chemotherapy and radiation therapy has significantly improved
patient survival, the prognosis remains dismal for some malignancies, particularly in the case of
relapse or metastatic disease. Among these, EwS remains a therapeutic challenge. The spe-
cific translocation t(11;22)(q12;q24) detected in about 85% of cases leads to the formation of
the aberrant chimeric protein EWS-FLI1, whose expression was found to be sufficient to trans-
form hpMSCs (Delattre et al., 1994; Riggi et al., 2008). Indeed, EWS-FLI1 directly binds the
DNA, recruits partners and changes the chromatin conformation, resulting in the activation or
repression of target transcription. Thus, substantial epigenetic changes in EwS CSCs dictated
by EWS-FLI1 further support the maintenance of an aggressive tumor-driving phenotype, and
understanding the key epigenetic pathways affected in these cells is needed to identify putative
targets.
Our laboratory previously reported that silencing of miRNAs, including the let-7 family, is
essential for CSC maintenance (Riggi et al., 2010; De Vito et al., 2012; Cornaz-Buros et al.,
2014). Particularly, we recently reported that LIN28B, capable of repressing let-7 maturation,
is reactivated in a subset of highly aggressive EwS. In parallel, IMP2 has been demonstrated
to support a CSC phenotype in GBM, in which LIN28B is not expressed, by protecting let-7
target transcripts from degradation (Degrauwe et al., 2016a). Therefore, as LIN28B and IMPs
are co-expressed in EwS, we explored whether these RBPs share redundancy in EwS to sustain
the growth of the CSC population.
Here, we used the CRISPR-Cas9 gene editing technology to knockdown each IMP paralog in
primary EwS and in cell lines. We found that IMP expression is not crucial for CSC proliferation
in vitro or for tumor growth in vivo. Our strategy focused on depleting each IMP paralog
separately, and then two paralogs together, based on the hypothesis that IMPs may share some
redundancy. We prioritized downregulation of IMP2 and IMP3 over that of IMP1, given that
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Figure 3.12: LIN28B expression and knockdown in EwS cell lines. (A) Box-plot showing LIN28B expression in
patient samples with newly diagnosed primary EwS with no evidence of previous disease (blue), relapsed EwS (green), or
with EwS metastases (red), based on a total of 37 samples. The value in brackets indicates the number of samples in each
group. Data generated from the R2 genomics platform. One-way ANOVA was used for statistical analysis. (B) Relative
nascent RNA levels following LIN28B knockdown using a validated shRNA in EwS1. Results are displayed as mean± SD.
Multiple t-tests were used for statistical analysis. (C) Dependency map of LIN28B. LIN28B expression is plotted in the x
axis (TPM, transcripts per million) and the dependency score is plotted in the y axis. The tags indicate the name of the EwS
cell line. The star indicates punctual mutations of LIN28B found in SKPNDW. The cell lines used in this study are indicated
in green. (D) Relative levels of mRNA of LIN28B (top panel) and EWS-FLI1 (lower panel) measured by qRT-PCR in
different cell lines following CRISPR-mediated knockdown of LIN28B. Results are displayed as mean± SD. Multiple t-tests
were used for statistical analysis. (E) Western blot analyses of EwS cell lines following CRISPR-mediated knockdown of
LIN28B, showing protein expression of LIN28B and EWS-FLI1. Tubulin was used as loading control. (F) Micrography of
SKES1 cells infected with a control CRISPR vector (Cas9, left panel) or with LIN28B knockdown (sg LIN28B, right panel).
The scale bar represents 50 μm. *P < .05, **P < .01, ***P < .001. ns, not significant.
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IMP2 strongly affects CSC survival GBM and initial bioinformatic results pointed to a possible
role of IMP3. Additionally, our initial in vitro results suggested that these two paralogs discretely
reduced clonogenicity in EwS organoid spheres (Figure 3.9A and C). Nonetheless, loss of IMP2
and IMP3 did not further impair cell clonogenicity (Figure 3.11B). It may have been of interest
to see if the absence of all three IMP paralogs successfully impaired cell growth and tumor
formation, especially in organoids, as they more adequately mirror the behavior of the original
tumors. However, we chose not to proceed to the simultaneous depletion of all three paralogs.
Indeed, patient-derived organoids are particularly challenging to work with and are very sensitive
to the stress generated during lentiviral infection. Performing three series of infection on these
cells would have hardly appropriately reflected the biological changes due the knockdowns only.
Furthermore, co-depletion of IMP2 and IMP3 did not affect expression of IMP1, which would
have been expected to increase in order to compensate for the lack of the two other paralogs and
thereby maintain cell survival and stabilize the cell phenotype. Thus, our observations reinforce
the position of LIN28B as a major player in sustaining CSC growth in LIN28B+ tumors.
Strikingly, knockdown of each IMP paralog in the MHHES1 cell line, which lacks LIN28B
expression, did not impair tumorigenicity in vivo and did not affect the expression of let-7 target
mRNAs, excluding the hypothesis that IMPs regulate let-7 target expression in the absence of
LIN28B in EwS. Thus, it appears that other mechanisms are in place in these cells to promote
CSC maintenance through the let-7 pathway. Therefore, the maintained expression of let-7
targets, such as HMGA2 and IMPs themselves, may be controlled by other processes in these
cells. As a possible explanation, it was reported that let-7a is a direct EWS-FLI1 target (De Vito
et al., 2011). Whether EWS-FLI1-mediated repression of let-7a alone is sufficient to maintain
expression of let-7 targets in LIN28B– tumors remains to be explored.
The IMP family of RBPs is known to significantly stabilize transcripts, as evidenced by their
ability to increase the half life of mRNPs to more than two hours (Nielsen et al., 2004). Thus, in
the LIN28B– MHHES1 cell line, IMPs represented potential candidates involved in EWS-FLI1
mRNA stability. However, our previous study had shown that EWS-FLI1 in LIN28B– organoids
had a shorter half-life than in LIN28B+ organoids (paper accepted for publication). Here, we
found that knockdown of IMPs in MHHES1 indeed failed to affect EWS-FLI1 transcript and
protein levels, further rejecting a role of IMP in stabilizing EWS-FLI1 mRNAs.
Furthermore, although bioinformatic data from EwS patient survival and IMP3 levels in
tumors indicate a putative role in promoting cancer progression, we did not find that IMP3
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directly supports tumorigenicity. On the other hand, of the three paralogs only IMP3 correlated
with expression LIN28B. Possibly, the poor outcome observed in high IMP3-expressing tumors
results from expression of LIN28B rather than IMP3 itself. Moreover, this is in line with the
known effect of LIN28B on the let-7 pathway, which decreases let-7-mediated silencing of IMP3
and other target mRNAs.
Altogether, our results provide additional data to support that LIN28B plays an essential
role in EwS CSC maintenance. In addition to stabilizing EWS-FLI1 transcripts, the ability of
LIN28B to alter the translational program could also contribute to the aggressive phenotype
typical of LIN28B+ cancer cells. To explore the effects of LIN28B on the cellular transcriptome
and proteome, we first want to compare quantitative proteomic variations in EwS cell lines upon
LIN28B knockdown and cross this data with RNA-seq and LIN28B RIP-seq data in the same
cells. This will allow us to identify the genes whose protein levels vary while their corresponding
transcript levels remain stable. We will then compare the whole cell proteomic and RNA-seq data
obtained to the data of primary cells, in which EWS-FLI1 expression was decreased following
LIN28B downregulation. By crossing the data together, our goal is to identify specific pathways
that are most dependent on LIN28B expression, in an EWS-FLI1-independent manner, and that
could mediate an aggressive CSC phenotype (Figure 3.13).
Finally, based on these results, these pathways should be further characterized in EwS. Also,
it may be relevant to explore their implication in other pediatric tumors, as many harbor LIN28B
reactivation. In conclusion, our results may describe an additional mechanism necessary for CSC
maintenance in EwS, and help identify a new potential therapeutic approach for this aggressive
tumor. Furthermore, as LIN28B appears to be a central player in many pediatric tumors, this
work may help identify a mechanism through which LIN28B increases CSC aggressiveness that
may be common to other childhood cancers. Particularly, the potential involvement of LIN28B
should be investigated in other childhood sarcomas and cancers that carry specific translocations.
Moreover, the existence of a small molecule that prevents LIN28B inhibition of let-7 biogenesis
puts this oncofetal RBP in a privileged position as a potential therapeutic target.
It is unclear why or how LIN28B is reactivated in a subset of tumors only. It was first
suggested that LIN28B+ and LIN28B– tumors may originate from distinct cells, the former orig-
inating from NCSCs instead of MSCs. Indeed, whereas normal MSCs lack LIN28B expression,
the oncofetal RBP is detected in NCSCs. However, LIN28B appears to be more expressed in
relapsed and metastatic disease than in newly diagnosed EwS (Figure 3.12A). Whether the
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Figure 3.13: Identifying EWS-FLI1 independent genes regulated by LIN28B. Schematic Venn diagram represen-
tation of future steps of the project, with analysis of up- or down-regulated genes with knockdown of EWS-FLI1 or LIN28B.
Unstable models include EwS1 and EwS2, in which LIN28B knockdown negatively regulates EWS-FLI1 expression, and
stable models include A673 and SKNMC, in which EWS-FLI1 remains stable following loss of LIN28B. By excluding genes
whose regulation is dictated by EWS-FLI1 and finding genes whose expression changes with LIN28B knockdown only in
both models, we will identify a subset of genes whose expression is modulated by LIN28B in both stable and unstable
models and in an EWS-FLI1 independent manner.
metastases were diagnosed in recurrent disease only is not specified in this cohort. Nevertheless,
we could postulate that LIN28B is secondarily activated in a cell subpopulation following expo-
sure to therapy, in which case LIN28B would constitute a secondary oncogene that appears as a
result of epigenetic changes in the CSCs, further contributing to increased tumor heterogeneity
and cell survival.
Loss of let-7-mediated repression of LIN28B mRNA by other proteins could activate the
negative loop by restoring LIN28B levels. As a result, LIN28B expression would become high
enough to continue repressing let-7, activating a positive feedback loop. Thus, we should not
exclude IMPs as potential candidates in the first line of lifting the let-7-mediated repression
of targets and creating a permissive environment for LIN28B reactivation. Alternatively, a
recent study showed that one isoform of the TF CCAAT/enhancer binding protein β (C/EBP-
β), namely liver-enriched inhibitory protein (LIP), can repress let-7 transcription (Ackermann
et al., 2019), thereby allowing LIN28B expression. Furthermore, a previous study had shown
that C/EBP-β transcription is directly activated by EWS-FLI1 (Gardiner et al., 2017). Thus,
C/EBP-β transcriptional activation by EWS-FLI1 may be beneficial for CSCs as it results in
LIN28B reactivation, a postulation that requires further investigation.
In line with this notion, LIN28B reactivation may result from differential access of EWS-FLI1
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to GGAA repeats in the chromatin, which activates or represses transcription of genes that may
in turn support expression of LIN28B, as may be the case with C/EBP-β. Among the thousands
of GGAA motifs in the genome, only a small fraction is actually open and accessible to EWS-FLI1
(Riggi et al., 2014; Johnson et al., 2017). Thus, each cell may exhibit a different constellation of
open GGAA repeats sites. Hence, upon an ideal conformation, reactivation of a gene may occur,
that will subsequently activate or repress downstream pathways and promote tumorigenesis.
Given the high plasticity CSCs, this process could explain different EWS-FLI1 stabilization
mechanisms and, in some cases, reactivation of LIN28B. Nonetheless, the mechanisms that govern
differential binding of EWS-FLI1 to DNA still remain to be described.
Of interest, LIN28B stabilizes EWS-FLI1 transcripts in LIN28B+ tumors. Still, the EWS-
FLI1 protein level is stable between LIN28B+ and LIN28B– tumors. Therefore, in the remaining
∼ 90% of EwS, EWS-FLI1 expression is preserved in the absence of LIN28B, either by increased
transcription rate, or by protein stability. A study reported that the IGF/PI3K/AKT pathway
stimulates EWS-FLI1 transcription (Giorgi et al., 2015), a feature that may be conserved in
both LIN28B+ and LIN28B– tumors. Alternatively, a study on protein turnover shows that
the fusion protein is degraded by the proteasome system upon ubiquitination of a lysine residue
at the position 380 (Gierisch et al., 2016). However, to our knowledge no study has identi-
fied protein partners that mediate EWS-FLI1 protein stabilization. Thus, in the majority of
tumors, EWS-FLI1 may recruit other binding partners to form protein complexes that ensure
its constant expression. It would be of interest to characterize these potentially distinct com-
plexes in LIN28B+ versus LIN28B– cells to gain a better insight into these mechanisms, by using
mass-spectrometry for protein stabilization, and ChIP-seq profiling to identify transcription fac-
tors that partner up with EWS-FLI1. This would help identify proteins that ensure EWS-FLI1
protein stabilization or increased EWS-FLI1 transcription in the majority of EwS.
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3.5 Materials and Methods
Cell culture
Primary EwS samples were obtained at surgery from Hospital Sant Joan de Déu, Barcelona
(EwS1) and from Massachusetts General Hospital, Boston (EwS2), following written informed
consent from patients before inclusion of samples in the tumor biobanks. The samples were
anonymized prior to analysis and were exempted from informed consent in accordance with the
law of the Canton de Vaud. Following mechanical and enzymatic digestion, cells were main-
tained in culture as organoid spheres in IMDM (Gibco) supplemented with 20% KO serum
(Gibco), human recombinant EGF and bFGF at final concentrations of 10 ng/mL (PROSPEC)
and 1% Penicillin-Streptomycin (PenStrep, Gibco) in ultra-low attachment flasks (Corning), as
previously described (Suvà et al., 2009).
The following EwS cell lines used were purchased from ATCC: A673 (RRID:CVCL_0080),
SKNMC (RRID:CVCL_0530), SKNEP1 (RRID:CVCL_0631), SKES1 (RRID:CVCL_0627).
The MHHES1 cell line (RRID:CVCL_1411) was purchased from DSMZ. The A673, SKNMC
and MHHES1 cell lines were cultured in RPMI (Gibco) supplemented with 10% FBS (PAN
BIOTECH) and 1% PenStrep (Gibco). The SKES1 and SKNEP1 cell lines were cultured in
McCoy’s 5A Modified Medium (Gibco) supplemented with 15% FBS (PAN BIOTECH) and 1%
PenStrep (Gibco).
The LentiX-293T cell line was purchased from Clontech (Cat#632180) and grown in DMEM
(Gibco) supplemented with 10% FBS (PAN BIOTECH), 1% NeAA (Gibco) and 1% PenStrep
(Gibco).
Cell cultures were maintained at 37 ◦C and 5% CO2 in humidified culture incubators. Cells
were regularly tested to exclude mycoplasma contamination.
Lentiviral infection
LentiX-293T (Clontech) packaging cells were transfected using FuGENE R© 6 Transfection reagent
(Promega) for lentivirus production. The envelop and packaging vectors used were pMD2G
(Addgene, plasmid #12259) and pCMVΔR8.74 (Addgene, plasmid #12263), respectively. After
72 h, the supernatant was collected and filtered (0.45 μm). To transduce primary EwS organoid
cells, the supernatant containing the virus suspension was ultracentrifuged at 4 ◦C for 2 h at
26’000RPM with a SW28 rotor. The supernatant was discarded and the harvested virus was
allowed to resuspend overnight at 4 ◦C. On the following day, 106 cells were incubated for 8 h with
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viral suspension from two LentiX-293T 15 cm dishes, with Polybrene (Sigma-Aldrich) at a final
concentration of 6 μg/mL. To transduce EwS cell lines, 10mL of viral suspension was added to a
60% confluent dish of receiver cells and incubated overnight with Polybrene (Sigma-Aldrich) at a
final concentration of 6 μg/mL. The next morning, the medium was changed and completed with
8mL of the remaining viral suspension and incubated for 8 h with Polybrene (Sigma-Aldrich,
6 μg/mL). Prior to further analysis, antibiotic selection was initiated three days after infection
with puromycin at a final concentration of 2 μg/mL and maintained for 48 h.
Knockdown of IMP1-3 and LIN28B
For stable CRSIPR-mediated knockdown of IMP1-3, we chose gRNA sequences based on the
Broad Institute algorithm (https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design).
For a given gene sequence, the program browses through all possible gRNA sequences adjacent to
a PAM sequence. We selected the four top sequences, ranked from 1 to 4 according to specificity
and limited off-target effects. As a general rule, we ensured that the gRNAs target the gene of
interest between 5-66% of the target length. The sequences listed in Supplementery Table S2.2
were cloned into the CRISPRv2 plasmid (Addgene, plasmid #52961).
For stable CRISPR-mediated LIN28B knockdown, we used a previously described gRNA that
targets exon 2 of LIN28B (Powers et al., 2016). The oligos (Fwd 5’- CACCGCATCGACTGGAAT-
ATCCAAG -3’; Rev 5’- AAACCTTGGATATTCCAGTCGATGC -3’) were cloned into CRISPRv2
plasmid (Addgene, plasmid #52961). For CRISPR control conditions, we used a CRISPRv2 vec-
tor without a gRNA.
For nascent RNA experiment, shRNA was used for LIN28B silencing. The shRNA inserted
in a pLKO.1_puro vector was chosen from the RNAi Consortium and targets the 3’-UTR of
LIN28B (TRCN0000122191). In this experiment, we used pLKO.1 shGFP targeting the sequence
5’-GCAAGCTGACCCTGAAGTTCAT -3’ as control (Addgene, plasmid #30323).
CRISPR cloning
The CRISPRv2 plasmid was obtained from Zhang Lab (Addgene plasmid #52961) (Sanjana
et al., 2014). CRISPRv2 was digested with FastDigest Esp3I (ThermoFisher Scientific) at 37 ◦C
for 1 h. The sample was then run on an agarose gel and the 12 kb fragment was extracted with
the Monarch DNA Gel Extraction kit (NEB) according to manufacturer’s instructions. The
forward and reverse oligos were annealed by incubation for five minutes at 95 ◦C in annealing
buffer (10mM Tris pH7.5, 1mM EDTA, 50mMNaCl) and left to cool down to room temperature.
3.5. MATERIALS AND METHODS 117
Ligation of the vector with the annealed oligos was performed with T4 DNA ligase (ThermoFisher
Scientific) at 16 ◦C for 16 h, and the enzyme was inactivated at 65 ◦C for 10 minutes. After
butanol precipitation, we electroporated STBL3 bacteria with the ligation reaction product, and
subsequently screened and sequenced the resulting clones. For control conditions, we used a
CRISPRv2 vector without a gRNA.
Proliferation assays
For single-cell clonogenic assays, primary EwS organoids were manually dissociated into a single-
cell suspension. Cells were counted and diluted to a final concentration of 100 cells in 10mL of
culture medium. Cells were then plated at single-cell density in low-attachment 96-well plates
(Corning) with 100 μL medium per well. After one week, 100 μL of fresh medium was added to
each well. After a total incubation time of three weeks, the number of organoid spheres was
assessed by micrography imaging.
For metabolic activity assays, CellTiter Glo reagent (Promega) was used according to the
manufacturer’s instructions. Cells were seeded at a density of 5’000 cells per well in five replicates
into black opaque 96-well plates (ThermoFisher Scientific) and incubated for 72 h prior to reading.
Luminescence was measured with SynergyMx instrument (BioTek).
Cell proliferation was determined using Cell Proliferation ELISA BrdU colorimetric kit (Roche)
according to the manufacturer’s instructions. Cells were seeded at a density of 500 cells per well in
six replicates into 96-well plates (Corning) and were incubated with BrdU for 2 h 30. Absorbance
was measured with SynergyMx instrument (BioTek).
For colony formation assays, cells were seeded at a density of 200 cells per well in six replicates
into 24-well plates. After one week, wells were carefully washed with PBS and cells were fixed
with 100% methanol for 20 minutes. Methanol was removed, wells were washed again with PBS
and colonies were stained with a 0.5% crystal violet (Acros Organics) solution for five minutes
at room temperature. Plates were washed with water and allowed to dry overnight.
RNA extraction, cDNA synthesis and quantitative real-time PCR
RNA was extracted using the miRNeasy Mini Kit (Qiagen) according the manufacturer’s in-
struction. For cDNA synthesis, 500 ng of RNA template was reverse-transcribed using M-MLV
Reverse Transcriptase (Promega). qRT-PCR was performed using PowerUp SYBR Green (Ap-
plied Biosystems) with specific primers (Supplementary Table S2.3), and TaqMan Universal PCR
Master Mix (Applied Biosystems) with specific probes for NANOG, SOX2 and H19. qRT-PCR
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was run by QuantumStudio 5 instrument (ThermoFisher Scientific). Each reaction was per-
formed in triplicates and fold expression change was calculated using the comparative ΔΔCt
method, normalized to TBP and 36β4 endogenous controls.
Preparation of protein cell lysate and Western blot
For protein extraction, cells were harvested at +4 ◦C, washed in ice-cold PBS and lysed in SDS-
RIPA buffer (150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50mM Tris
pH8.0) containing protease inhibitor cocktail (Roche). The lysate was incubated on ice for
20 minutes, sonicated twice for 10 seconds at 35 kHz, and centrifuged at 4 ◦C for 10 minutes
at 13’000RPM. The supernatant was used for protein sample preparation. Protein concentra-
tion was assessed using Bradford Protein Assay Dye (Bio-Rad). Western blot was subsequently
performed according to standard procedures. Primary antibodies included: anti-IMP1 (Cell Sig-
nalling Technologies, Cat#2852), anti-IMP2 (MBL International, Cat#RN008P1), anti-IMP3
(MBL International, Cat#RN009P), anti-LIN28B (Cell Signalling Technologies, Cat#4196),
anti-HMGA2 (Cell Signalling Technologies, Cat#5269), anti-FLI1 (Abcam, Cat#ab15289),
anti-GAPDH-HRP (Abcam, Cat#ab9482), and anti-Tubulin (Millipore, Cat#CP06). Sec-
ondary antibodies included: HRP-conjugated sheep anti-mouse (GE Healthcare, Cat#NA931)
and goat anti-rabbit (Agilent, Cat#P0448). Bands were visualized and analyzed using Western
Bright Sirius (Wiltec AG) detection reagents, according to the manufacturer’s instructions, with
Fusion Fx software (Vilber Lourmat).
RNA-immunoprecipitation of LIN28B
RIP on EwS cells was performed using the EZ-Magna RIPTM RNA-Binding Protein Immunopre-
cipitation Kit (MerckMillipore) according to the manufacturer’s instructions. Briefly, following
lysis of cells at−80 ◦C, total lysate was incubated overnight with anti-LIN28B (final concentration
1:50, Cell Signalling Technologies, Cat#4196) pre-bound to magnetic beads provided with the
kit. The beads were then washed and the protein-RNA complexes were dissociated by proteinase
K digestion for 30 minutes at 55 ◦C. RNA was subsequently purified using the NucleoSpin R© RNA
isolation kit (Macherey-Nagel). The presence of LIN28B in LIN28B-immunoprecipitated lysate
was assessed by Western blot. Isolated RNA was subsequently processed for RNA-seq.
Nascent RNA capture and cDNA synthesis
Nascent RNA capture was performed with a Click-iTTM Nascent RNA Capture Kit (Life Tech-
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nologies) according to the manufacturer’s instructions. Briefly, cells were incubated with 5-EU
at a concentration of 0.5mM for 30 minutes. Total RNA was isolated using the NucleoSpin R©
RNA isolation kit (Macherey-Nagel) and biotinylated. Following RNA precipitation, Dynabeads
provided with the kit were used to isolate the nascent RNA with incorporated 5-EU. For RNA-
seq, the samples were immediately processed for library preparation. For cDNA synthesis from
the bound nascent RNA, the bead suspension was heated at 70 ◦C for five minutes. Random
primers (Promega) and dNTP (MP Biomedicals) were immediately added to the mixture. The
suspension was left to cool down to room temperature for 30 minutes under constant rotation.
M-MLV Reverse Transcriptase (Promega) and RNasin Ribonuclease inhibitor (Promega) were
subsequently added to the suspension, which was then warmed to 42 ◦C for 1 h with gentle
vortexing. Finally, the cDNA was collected after heating the solution for five minutes at 85 ◦C.
In vivo mouse injections and tumor dissociation
NOD-SCID gamma mice were given Paracetamol one day prior to surgery. Anaesthesia was
obtained by intraperitoneal injection of a solution containing 100mg/kg Ketamine (Ketasol-100,
Graueb AG) and 16mg/kg Xylazine (Rompun 2%, Provet AG), diluted in PBS. For EwS cell
lines, cells were injected bilaterally in the subcutaneous tissue behind the scapula. For EwS1 and
EwS2, cells were injected in the subcapsular compartment of the left kidney. Cells were allowed
to engraft for four weeks for the cell lines or eight weeks for the primary cells. Mice from the
experiments shown in Figure 3.10A and B were all sacrificed when a first tumor had reached
a volume of about 1 cm3. The tumor volume was calculated as V =
4
3
pi × h× l × s
8
, where
h indicates the tumor height, and l and s the dimensions of the tumor on the long and short
axes, respectively. Mice from the experiment shown in Figure 3.10C were sacrificed when their
respective tumor reached a size of approximately 1 cm3. Statistical analyses were performed using
GraphPad Prism 8 software. Animal experimental protocols were approved by the Veterinary
Service of the Canton of Vaud under authorization numbers VD2488 and VD3021.
To assess gene and protein expression in xenografts, tumors were dissociated using the human
Tumor Dissociation kit (Miltenyi Biotec) and the gentleMACSTM dissociator (Miltenyi Biotec)
according to the manufacturer’s instructions. To remove red blood cells, the cell suspension was
incubated in ACK buffer (150mM NH4Cl, 100mM KHCO3, 0.1mM EDTA-NA2, pH 7.2) for five
minutes on ice. The cells from the xenografts were subsequently cultured in normal conditions
until further processing.
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Analysis of RNA-sequencing data
RNA-seq library preparation was performed following the Illumina TruSeq or Smarter protocols
by the genomics platform at the Institute of Genetics and Genomics of Geneva. Sequencing was
performed using HiSeq 4000 Illumina.
Survival and gene expression data
The data presented in Figure 3.7A was collected from Savola et al. (2011), available as GSE17618,
to determine association of IMP expression with survival in EwS. We performed Cox univariate
analysis on the 8 probesets of the array associated to the IMP2, thus associating to each gene two
z -scores and P -values, for event-free and overall survival. For the data presented in Figure 3.7C,
as LIN28B is not represented in the array used by Savola et al. (2011), we turned to the RNA-seq
dataset of Brohl et al. (2014). We retrieved the gene-level normalized data (log2(RPKM)) from
Oncogenomicsdb and limited the analysis to 65 primary tumors (samples with IDs beginning
with “EWS” or “NCI”). After defining an expression detection threshold equal to the median
expression of all genes across all samples we classified the samples into LIN28B positive (6
samples) and negative (59 samples). We then compared the expression of the IMP paralogs
between positive and negative samples, using a Mann-Whitney U-test.
Statistical analyses
GraphPad Prism software 8 was used to generate graphs and to perform the corresponding
statistical tests, as indicated in the figure legends.
Chapter 4
Conclusion
Although the cancer hallmarks unify the essential properties of tumor cells across all cancer
types, there is extensive heterogeneity not only between different tumors, but also among the
cells within a single tumor bulk. Intratumoral heterogeneity is additionally fueled by CSCs, whose
discovery in different tumor types suggested that their presence may also constitute a hallmark
of cancer. These cells can be isolated by a similar set of markers across multiple tumor types,
but maintain distinct profiles. Therefore, it is crucial to identify key regulatory mechanisms that
are disrupted in CSCs in different cancers and that contribute to these cells acquiring the same
functional phenotype. Despite the fact that CSCs are generated following an array of different
biological alterations, it appears that some pathways are almost uniformly altered in several
cancers, such as dysregulation of miRNAs expression and reactivation of oncofetal RBPs.
Thus, in this work, we addressed various mechanisms that had been successfully shown to be
essential for CSC survival in other tumor types. Ultimately, strategies that we thought would
work based on previous results turned out not to be applicable in a different context. Therefore,
this work illustrates the challenges in accurately predicting the central cellular mechanisms in
cancer and the approaches to use in order to counteract them. Mainly, we noticed that obser-
vations in an adult cancer, here GBM, are hardly applicable to the pediatric tumor EwS, and
vice-versa. Yet, the initial goal was exactly the opposite, with the idea that enhancing miRNA
maturation in GBM would reproduce the phenotype observed in EwS, or that IMPs may be as
important for CSCs in EwS as they were in GSCs. This leads us to ask, why did we observe
such distinct responses in our models? Much of the answer lies in the complexity and possible
redundancies of the mechanisms that govern epigenetic modifications, and their impact in cancer
pathogenesis.
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In normal cells, epigenetic processes help coordinate the expression of the genes required
for development and homeostatic maintenance. Under such control, from the same genome, a
population of stem cells within a tissue is maintained and their replication is monitored to gen-
erate progenitor and lineage-committed cells, which will in turn be programmed by epigenetic
cues to differentiate in an organized fashion. However, this balance can be lost following ge-
netic mutations and/or genomic instability that can lead to aberrant epigenetic control. The
resulting deregulated and distorted epigenetic landscape participates in promoting unrestricted
cell proliferation, the first step toward tumor initiation and progression. Indeed, changes in
the epigenome can result from mutations in genes encoding epigenetic regulators, or in genes
with the power to affect downstream transcription of targets. Consequently, cancer cells display
modified chromatin conformation, DNA methylation, and/or ncRNA repertoires, leading to an
altered transcriptome. As epigenetic modifications are heritable, they participate in selecting
subpopulations of cells in the tumor that have proliferative and survival advantage in addition
to possibly increased invasive behavior (Tam and Weinberg, 2013; Easwaran et al., 2014). Thus,
epigenetic mechanisms have the capacity to orchestrate entire biological networks and rewire
the cell entirely, thereby mediating cancer cell plasticity, as exemplified by the successful repro-
gramming of somatic cells upon de novo expression of certain TFs (Yu et al., 2007). Ultimately,
these mechanisms can reprogram the cell, reverting its state completely to that of a CSC, dis-
playing a pluripotent and quiescent stem-like state with the capacity to promote local and/or
distant invasion. Through its ability to enable altered transcriptional programs to reprogram
cells, epigenetics can promote tumorigenesis through the emergence of CSCs and sustain tumor
heterogeneity (Mazor et al., 2016).
The cellular context, including the epigenetic state and the surrounding microenvironment, is
particularly determinant for cellular transformation. For example, in hereditary retinoblastoma,
a first Rb allele mutation occurs in the germ line, followed by mutation of the second allele in
the fast growing cells of the retina. This leads to bilateral development retinoblastoma before
one year of age in most cases. Following treatment, long-term survivors are at high-risk of
developing osteosarcoma, as well as soft tissue sarcoma. However, Rb is altered in numerous
cancers, including ovary, breast, bladder, CML, oesophageal and liver cancers (Burkhart and
Sage, 2008; Campbell et al., 2020). In fact, some will argue that the Rb pathway is affected
in the majority of adult cancers. In contrast, hereditary Rb mutations lead almost solely to
retinoblastoma as a primary cancer, and does not predispose to all these cancer types equally,
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but rather mainly to a restricted panel of tumors (Kleinerman et al., 2007; Dommering et al.,
2012). Indeed, the effects of Rb loss depend on whether it affects a stem cell, a progenitor cell or
a differentiated cell, and on the affected tissue (Burkhart and Sage, 2008). In line with this, we
mentioned previously that expression of EWS-FLI1 alone is sufficient to drive tumor formation
when expressed in hpMSCs in particular, but not all cells can support its expression, as EWS-
FLI1 can be cytotoxic and most cells will undergo apoptosis. Thus, activity of an oncogene is
dependent on a permissive environment. Interestingly, such oncogenes can completely rewire the
cells so that they become dependent on their expression to survive and proliferate, a phenomenon
coined as “oncogene addiction” (Weinstein, 2002). It is particularly striking that, despite genetic
instability, the expression of an oncogene can remain crucial for a cell to survive. The importance
of a single driver oncogene is best appreciated in cancer cell lines, which can maintain strong
oncogene addiction despite undergoing significant genetic drift upon successive passaging and
exposure to non-physiological conditions. Thus, identifying such oncogenes is a primary goal in
cancer research.
Coming back to the example of EwS, evidence that EWS-FLI1 silencing abrogates cell tu-
morigenicity strongly suggests that CSCs are “addicted” to this fusion protein. Thus, by targeting
EWS-FLI1 directly, a protein that is found only in tumor cells, we could effectively annihilate
the cancer cells and cure the patient. It is however unfortunate that such a strategy may not be
applied in the case of EwS. This is partly due to the biochemical instability of the molecule and
lack of a unique stable conformation of the protein, a result from its low hydrophobicity (Üren
et al., 2004). Consequently, lack of a high-resolution 3D structure of EWS-FLI1 challenges the
design of specific inhibitors using computer-assisted approaches. Moreover, large-scale screenings
and laboratory testing of the molecule alone is hindered, as instability of EWS-FLI1 poses ob-
stacles for its synthesis and purification (Üren and Toretsky, 2005). Currently, screenings mainly
focus on testing cells directly. Due to the small size of the patient population and scarcity
of tumor samples, such methods require strong collaborations between institutes, and between
academia and the industry to efficiently deliver results. Also, delivery of siRNA or antisense
oligonucleotides is not yet efficient in humans, but may still bear promises in the future. There-
fore, current strategies are focusing on disrupting key protein interactions that affect EWS-FLI1
expression and/or activity. So far, inhibition of RHA, which directly pairs with EWS-FLI1, with
the small molecule YK-4-279 successfully disrupted growth of tumor xenografts (Erkizan et al.,
2009). The clinical applicability of this approach still remains to be determined. Exploiting the
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IGF pathway that is essential for EwS has shown limited results, with only few patients respond-
ing well (Olmos et al., 2011). Additionally, epigenetic therapies inhibiting histone deacetylases
are also under clinical investigation (Arnaldez and Helman, 2014).
We found that LIN28B may be a secondarily activated oncogene acting as an epigenetic
mediator (Feinberg et al., 2016) and participating in the reprogramming of the cell in a subset of
highly aggressive EwS. As pediatric tumors generally present a low mutational burden, epigenetic
changes play a particularly crucial role in sustaining tumor growth in these cancers. In line with
this, re-expression of the oncofetal binding protein LIN28B participates in increasing ITH and
CSC maintenance. However, only a minority of EwS appear to express LIN28B, suggesting
that other such developmental factors could be involved in EwS tumorigenesis. Because IMP2
is crucial for GSC survival in GBM, and IMPs are involved in normal embryogenesis, we were
prompted to assess their possible role in EwS, as they are also expressed in this tumor type and
may be equally central in regulating the let-7 pathway. It was striking to find that IMP depletion
had no effect on the capacity of EwS CSCs to form tumors. Hence, while a cancer type may be
strongly addicted to a gene, as GSCs require IMP2 expression for survival, the same gene may
have no role in another tumor type, as EwS cells do not respond to IMP depletion. Intriguingly,
GBM is an adult cancer and accordingly has a particularly high mutational load, whereas,
in contrast, EwS is a cancer whose emergence and maintenance largely relies on epigenetic
mechanisms. Thus, given that the cellular context is highly divergent between these tumors, the
specific genetic and epigenetic landscapes of each tumor are indeed determinant for the expression
and function of their defined oncogenes, and generate distinct regulatory networks that promote
tumor formation and propagation.
In EwS, the chromatin at GGAA repeat motifs is generally tightly packaged, ensuring a
closed chromatin conformation, but can become opened when, upon binding to DNA, EWS-
FLI1 recruits chromatin remodelling partners, allowing chromatin opening and transcription
activation. The mechanisms that allow the initial binding of EWS-FLI1 to occur at these sites
are still unknown. Nevertheless, the specific constellation of sites where EWS-FLI1 binds and
opens chromatin to modulate gene transcription leads to an altered transcriptome, enabling
transformation and tumorigenesis. As a result, secondary oncogenes may appear, as may be the
case of LIN28B. Still, as the majority of EwS are LIN28B–, and in light of the extensive plasticity
of CSCs, other RBPs or other molecules may be recruited by EWS-FLI1. Much investigation is
still required to identify putative proteins whose participation with the fusion protein is crucial
125
for CSC maintenance. By doing so, we may come closer to identifying targetable partners whose
downregulation may specifically eradicate CSCs and possibly lead to cure.

Chapter 5
Supplementary Material
5.1 Glioblastoma
Table S1.1: Properties of primary GBM samples.
Tumor sample Age (years) Subtype Stem cell surface markers IDH MGMT promoter
MGH4S N/A PN low expression N/A methylated
MGH8S N/A PN high expression N/A methylated
MGH26S 61 PN N/A WT methylated
MGH28S 60 Mes nestin +++ WT unmethylated
MGH31S 70 Mes/N N/A WT unmethylated
List of characteristics of the primary GBM samples used in this work (Wakimoto et al., 2011; Patel
et al., 2014). PN, proneural; Mes, mesenchymal; N, neural; WT, wild-type; N/A, not applicable.
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Table S1.2: List of upregulated let-7 target genes in high H19 expression GBM.
Gene Correlation
NID2* 0.381066545
BZW2* 0.379652356
IMP2* 0.378782099
CCND1* 0.358244581
IGF2* 0.357797761
HMGA1* 0.342900201
HMGA2* 0.293640761
IMP3* 0.291511799
CCND2 0.239914434
IMP1 0.224505925
* Genes among the 500 top
upregulated genes.
Figure S1.1: H19 overexpression in GBM cell lines. (A) Kaplan-Meier overall survival curves for lower-grade glioma
patients with low (blue) or high (red) H19 expression. Data was obtained from the TCGA database and the curve used
RNA-sequencing data from 486 brain tumors. P-value was calculated using log-rank test. (B) Expression levels of IMPs,
H19 and HMGA2 in MGH26 (adherent, A, and spheres, S) and in two GBM cell lines, U-251 and U-87. Two-way ANOVA
was used for statistical analysis. (C) Expression of H19 in U-251 and U-87 with the empty control vector (pLIV empty)
or H19 overexpression (pLIV H19). Student’s t-test was used for statistical analysis. (D) Kaplan-Meier survival curves of
mice following orthotopic injection of 50’000 U-251 or U-87 cells, infected with an empty vector (control, grey) or with H19
induction (H19, green). n =5 mice per group. P-value was calculated using log-rank test. (E) Expression of H19 in U-87
xenografts following dissociation of brain tumors with (pLIV H19) or without (pLIV empty) H19 overexpression. Student’s
t-test was used for statistical analysis. * p≤ .05, ** p≤ .01, *** p≤ .001, **** p≤ .0001. ns, not significant.
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Table S1.3: List of oligos used for CRISPRi genome editing.
Target gene Sequence
H19 Fwd 5’- CACCGGGGAACCGAGGGGCAACCAG -3’
CRISPRi 1 Rev 5’-AAACCTGGTTGCCCCTCGGTTCCCC -3’
H19 Fwd 5’- CACCGGGGAACCGAGGGGCAACCAG -3’
CRISPRi 2 Rev 5’- CACCGGAGATGTCCAAGGTGCTCCT -3’
H19 Fwd 5’- CACCGGGGAACCGAGGGGCAACCAG -3’
CRISPRi 3 Rev 5’-AAACAGGAGCACCTTGGACATCTCC -3’
H19 Fwd 5’- CACCGGGGAACCGAGGGGCAACCAG -3’
CRISPRi 4 Rev 5’-AAACCTGGTTGCCCCTCGGTTCCCC -3’
The oligo sequences were chosen from the datasets from CRiNCL (Liu
et al., 2017) and based on predicted scores following the hCRISPRi-v2.1
algorithm (Horlbeck et al., 2016).
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5.2 Ewing Sarcoma
Figure S2.1: Western blot of EwS2 xenografts. GAPDH was used as loading control.
Table S2.1: Characteristics of Ewing sarcoma samples.
Sample Age (years) Sex Site Staging EWS-FLI1 LIN28B
EwS1 pediatric female scapula primary type 1 +
EwS2 pediatric male lung metastatic type 2 +
A673 15 female skeletal muscle primary type 1 +
SKNMC 14 female brain metastatic type 1 +
MHHES1 12 male ascites metastatic type 2 –
SKES1 18 male bone primary type 2 +
SKNEP1 25 female pleural effusion metastatic type 2 +
List of characteristics of the EwS primary samples (EwS1 and EwS2) and cell lines used in
this work.
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Table S2.2: List of oligos used for CRISPR-Cas9 genome editing.
Target gene Sequence Exon Product size (%)
IMP1 Fwd 5’- CACCGCAAGATCATCTTACAAGCGG -3’ 7 767
CRISPR1 Rev 5’-AAACCCGCTTGTAAGATGATCTTGC -3’ (44.2)
IMP1 Fwd 5’- CACCGATTCGGTGCCCAAAAAACAA -3’ 2 232
CRISPR2 Rev 5’-AAACTTGTTTTTTGGGCACCGAATC -3’ (13.4)
IMP1 Fwd 5’- CACCGGGCCATCGAGAATTGTTGCA -3’ 9 1010
CRISPR3 * Rev 5’-AAACTGCAACAATTCTCGATGGCCC -3’ (58.2)
IMP1 Fwd 5’- CACCGGAATGTCACCTATTCCAACC -3’ 5 383
CRISPR4 Rev 5’-AAACGGTTGGAATAGGTGACATTCC -3’ (22.1)
IMP2 Fwd 5’- CACCGTGCATATGTGACGTTGACAA -3’ 5 366
CRISPR1 Rev 5’-AAACTTGTCAACGTCACATATGCAC -3’ (20.3)
IMP2 Fwd 5’- CACCGAAAAGATGCCAAGTGCGCTG -3’ 10 1105
CRISPR2 Rev 5’-AAACCAGCGCACTTGGCATCTTTTC -3’ (61.4)
IMP2 Fwd 5’- CACCGGTGGGGACCAGGATCCGCAG -3’ 6 587
CRISPR3 * Rev 5’-AAACCTGCGGATCCTGGTCCCCACC -3’ (32.6)
IMP2 Fwd 5’- CACCGTGCATATGTGACGTTGACAA -3’ 5 366
CRISPR4 Rev 5’-AAACTTGTCAACGTCACATATGCAC -3’ (20.3)
IMP3 Fwd 5’- CACCGTATCCCGCCTCATTTACAGT -3’ 3 276
CRISPR1 * Rev 5’-AAACACTGTAAATGAGGCGGGATAC -3’ (15.9)
IMP3 Fwd 5’- CACCGCCATCGAGGCGCTTTCAGGT -3’ 6 173
CRISPR2 Rev 5’-AACACCTGAAAGCGCCTCGATGGC -3’ (9.9)
IMP3 Fwd 5’- CACCGCCACCGTAAAGAAAATGCGG -3’ 5 366
CRISPR3 Rev 5’-AACCCGCATTTTCTTTACGGTGGC -3’ (20.3)
IMP3 Fwd 5’- CACCGAGGCGCAGAGGCAAATCACA -3’ 10 1105
CRISPR4 Rev 5’-AAACTGTGATTTGCCTCTGCGCCTC -3’ (61.4)
The oligo sequences were chosen for application of the Zhang Lab protocol using CRISPRv2 according
to Shalem et al. (2014). The last two columns indicate the number of the targeted exon, and the
expected transcript length following cleavage by Cas9 in bp, and as the percentage length relative to
the original transcript (in brackets). * indicates the sequences that were associated with the strongest
knockdown and that were subsequently used in described experiments, unless specified otherwise.
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Table S2.3: List of primers used for qRT-PCR.
Gene Forward primer Reverse primer
IMP1 5’-GGCCATCGACAATTGTTGCAG -3’ 5’- CCAGGGATCAGGTGAGACTG -3’
IMP2 5’- AGCTAAGCGGGCATCAGTTTG -3’ 5’- CCGCAGCGGGAAATCAATCT -3’
IMP3 5’- TATATCGGAAACCTCAGCGAGA -3’ 5’-GGACCGAGTGCTCAACTTCT -3’
LIN28B 5’- CCTGTTTAGGAAGTGAAAGAAGAC -3’ 5’- CACTTCTTTGGCTGAGGAGGTAG -3’
EWS-FLI1 5’- AGCAGCCTCCCACTAGTTAC -3’ 5’- CCAAGCTCCTCTTCTGACTG -3’
HMGA1 5’- CGAAGTGCCAACTAAGAG -3’ 5’- TGGTGGTTTTCCGGGTCTTG -3’
HMGA2 5’-GCGCCTCAGAAGAGAGGAC -3’ 5’-GTCTTCCCCTGGGTCTCTTAG -3’
RRM2 5’- CACGGAGCCGAAAACTAAAGC -3’ 5’- TCTGCCTTCTTATACATCTGCCA -3’
CCND1 5’-GCTGCGAAGTGGAAACCATC -3’ 5’- CCTCCTTCTGCACACATTTGAA -3’
NTRK1 5’-GGGCCTCTCCTTACAGGAAC -3’ 5’- AGCTTCTGTTCAGGCACTCC -3’
CD79A 5’- CAAGAACCGAATCATCACAGC -3’ 5’- CGTTCTGCCATCGTTTCC -3’
FCGRT 5’- TGGCGATGAGCACCACTAC -3’ 5’-GATTCCCACCACGAGCAC -3’
CCK 5’-GCCCTGCTGGCAAGATAC -3’ 5’-GCAGGTTCTTAACGATGGACA -3’
IGF2 5’- CGATGCTGGTGCTTCTCACC -3’ 5’-GTCACAGCTGCGGAAACAGC -3’
TBP 5’- CGGCTGTTTAACTTCGCTTC -3’ 5’- CACACGCCAAGAAACAGTGA -3’
36β4 5’-GCAATGTTGCCAGTGTCTGT -3’ 5’-GCCTTGACCTTTTCAGCAAG -3’
GAPDH 5’-GGTCTCCTCTGACTTCAACA -3’ 5’-GTGAGGGTCTCTCTCTTCCT -3’
Chapter 6
Publications
1 Manuscript I: LIN28B control of EWS-FLI1 stability
The core of the work presented in the thesis manuscript is based on the results collected in our
laboratory, showing that LIN28B was re-expressed in a subset of highly aggressive EwS, and
that LIN28B binding prolonged the half-life of EWS-FLI1. Furthermore, the putative role of
LIN28B could be targeted using the 1632 compound, which reduced the tumor size in vivo. My
contributions include nascent RNA isolation (Figure 6B), several Western blots (Figure S3D and
Figure S5C) and survival assays (Figure S5B). I analyzed and interpreted the data, reviewed the
paper and contributed to its intellectual content. The paper has been accepted for publication
in the journal Cell Reports.
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Abstract
Ewing sarcoma (EwS) is associated with poor prognosis despite current multimodal therapy. Targeting of EWS-
FLI1, the fusion protein responsible for its pathogenesis, and its principal downstream targets has not yet produced
satisfactory therapeutic options, fuelling the search for alternative approaches. Here, we show that the oncofetal
RNA-binding protein LIN28B regulates the stability of EWS-FLI1 mRNA in about 10% of EwS. LIN28B depletion
in these tumours leads to a decrease in expression of EWS-FLI1 and its direct transcriptional network, abrogating
EwS cell self-renewal and tumorigenicity. Moreover, pharmacological inhibition of LIN28B mimics the effect of
LIN28B depletion, suggesting that LIN28B sustains the emergence of a subset of EwS in which it also serves as
an effective therapeutic target.
Significance
We show that a subset (∼ 10%) of Ewing sarcoma (EwS) express the RNA-binding protein LIN28B. Depletion
of LIN28B in cells derived from these tumours reduces EWS-FLI1 expression, alters the transcriptional program
associated with EwS and decreases their tumorigenic properties. Using a compound that blocks LIN28 function,
we demonstrate that inhibition of LIN28B leads to a decrease in EWS-FLI1 expression and the ensuing disruption
of its core oncogenic regulatory program, abrogating EwS cell self-renewal and tumour initiation. Our results
suggest that LIN28B warrants further investigation as a regulator of the expression of the fusion transcript and
as a potential therapeutic target in the tumours that express this oncofetal protein.
Cell Reports, Published March 31, 2020. DOI: 10.1016/j.celrep.2019.12.053
2. MANUSCRIPT II: TARGETING HASPIN FOR CANCER THERAPY 135
2 Manuscript II: Targeting Haspin for cancer therapy
During my PhD, I was given the opportunity to collaborate on a project led by Johannes C.
Melms and Benjamin Izar, from the Dana-Farber Cancer Institute, Boston, focusing on new
ways to target RAF/MEK-inhibitor resistant melanoma. A screening of small molecules that
inhibit the JAK/STAT pathway revealed that melanoma cells were most sensitive to the drug
CX-6258, both in vitro and in vivo, exhibiting impaired tumor growth upon drug delivery.
Among the kinases that bind CX-6258, HASPIN was identified as the main inhibited target
and mediator of the drug effect, by induction of type-I interferon (IFN-1). Next, available public
data was interrogated to determine whether other neoplasms may respond to HASPIN inhibition.
Strikingly, multiple myeloma and EwS expressed high levels of the HASPIN kinase, and cell lines
for these two cancers were particularly sensitive to knockdown based on data from the Broad
Institute Dependency Map (Tsherniak et al., 2017). Thus, my contribution to this collaboration
consisted in exploring the effects of CX-6258 on three EwS cell lines, namely SK-ES-1, SK-NEP-1
and RDES. In vitro testing of all three cell lines revealed sensitivity to the drug, as cells treated
with CX-6258 displayed a marked reduction of proliferation. Moreover, IFN-1 expression was
induced in a dose-dependent fashion in treated EwS cell lines, suggesting that the mechanisms
following HASPIN inhibition in EwS are similar to those described in melanoma (Melms et al.,
2019). Based on the accumulated results, HASPIN inhibition appears as an interesting approach
for melanoma treatment, and could also be extended to other tumor types, such as EwS and
multiple myeloma.
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Abstract
Melanoma patients resistant to RAF/MEK-inhibitors (RMi) are frequently resistant to other therapies, such as
immune checkpoint inhibitors (ICI), and individuals succumb to their disease. New drugs that control tumor
growth and favorably modulate the immune environment are therefore needed. We report that the small molecule
CX-6258 has potent activity against both RMi sensitive (RMS) and resistant (RMR) melanoma cell lines. Haspin
Kinase (HASPIN) was identified as a target of CX-6258. HASPIN inhibition resulted in reduced proliferation,
frequent formation of micronuclei (MN), recruitment of cGAS and activation of the cGAS-STING-pathway. In
murine models, CX-6258 induced a potent cGAS-dependent type-I-interferon response in tumor cells, increased
IFNγ-producing CD8+ T-cells and reduced Treg frequency in vivo. HASPIN was more strongly expressed in
malignant compared to healthy tissue and its inhibition by CX-6258 had minimal toxicity in ex vivo expanded
human tumor-infiltrating lymphocytes (TILs), proliferating TILs and in vitro differentiated neurons, suggesting
a potential therapeutic index for anti-cancer therapy. Furthermore, the activity of CX-6258 was validated in
several Ewing sarcoma and multiple myeloma cell lines. Thus, HASPIN inhibition may overcome drug resistance
in melanoma, modulate the immune environment and target a vulnerability in different cancer lineages.
Significance
Haspin Kinase inhibition by CX-6258 is a novel and potent strategy for RAF/MEK-inhibitor resistant melanoma
and potentially other tumor types. HASPIN inhibition has direct anti-tumor activity and induces a favorable
immune-microenvironment.
Cancer Research, Published OnlineFirst December 27 2019. DOI: 10.1158/0008-5472.CAN-19-2330
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